U.S. patent application number 11/177324 was filed with the patent office on 2007-06-28 for oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors.
Invention is credited to Jose Aquino, Barbara Jagodzinska, Varghese John, Michel Maillard, Gary Probst, Jay Tung.
Application Number | 20070149584 11/177324 |
Document ID | / |
Family ID | 35462378 |
Filed Date | 2007-06-28 |
United States Patent
Application |
20070149584 |
Kind Code |
A9 |
John; Varghese ; et
al. |
June 28, 2007 |
Oxime derivative substituted hydroxyethylamine aspartyl protease
inhibitors
Abstract
The invention relates to novel compounds and methods of treating
diseases, disorders, and conditions associated with amyloidosis.
Amyloidosis refers to a collection of diseases, disorders, and
conditions associated with abnormal deposition of A-beta
protein.
Inventors: |
John; Varghese; (San
Francisco, CA) ; Maillard; Michel; (Redwood City,
CA) ; Jagodzinska; Barbara; (Redwood City, CA)
; Aquino; Jose; (Daly City, CA) ; Probst;
Gary; (San Francisco, CA) ; Tung; Jay;
(Belmont, CA) |
Correspondence
Address: |
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER;LLP
901 NEW YORK AVENUE, NW
WASHINGTON
DC
20001-4413
US
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20060135581 A1 |
June 22, 2006 |
|
|
Family ID: |
35462378 |
Appl. No.: |
11/177324 |
Filed: |
July 11, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60586207 |
Jul 9, 2004 |
|
|
|
60608143 |
Sep 9, 2004 |
|
|
|
60656873 |
Mar 1, 2005 |
|
|
|
60681138 |
May 16, 2005 |
|
|
|
Current U.S.
Class: |
514/378 ;
514/406; 514/616; 548/247; 548/361.1; 564/147; 564/152 |
Current CPC
Class: |
C07C 233/36 20130101;
C07D 335/06 20130101; C07C 255/58 20130101; C07D 231/12 20130101;
C07D 285/08 20130101; C07C 255/42 20130101; A61P 43/00 20180101;
C07C 237/20 20130101; C07C 251/84 20130101; C07D 271/10 20130101;
C07D 261/20 20130101; C07C 251/44 20130101; C07C 2601/04 20170501;
C07D 213/40 20130101; A61P 25/28 20180101; C07D 257/04 20130101;
C07C 251/54 20130101; C07D 233/64 20130101; C07C 2601/14 20170501;
C07D 231/56 20130101; C07D 405/10 20130101 |
Class at
Publication: |
514/378 ;
514/406; 514/616; 548/247; 548/361.1; 564/152; 564/147 |
International
Class: |
A61K 31/42 20060101
A61K031/42; A61K 31/416 20060101 A61K031/416; A61K 31/165 20060101
A61K031/165 |
Claims
1. A compound of formula (I), ##STR107## or at least one
pharmaceutically acceptable salt thereof, wherein R.sub.1 is
##STR108## wherein n is 0 or 1; q is 0 or 1; r is 0, 1, or 2; K is
selected from --(CR.sub.3aR.sub.3b)--, --O--, --SO.sub.2--,
--C(O)--, and --CH(NR.sub.55R.sub.60)--; R.sub.55 and R.sub.60 are
each independently selected from hydrogen and alkyl; R.sub.3a and
R.sub.3b are independently selected from -hydrogen, -halogen,
--O-alkyl, and -alkyl optionally substituted with at least one
group independently selected from halogen, --CN, --CF.sub.3, and
--OH; W is selected from --(CH.sub.2).sub.1-4--, --O--,
--S(O).sub.0-2--, --N(R.sub.55)--, and --C(O)--; E is a bond or
alkyl; A is selected from -aryl optionally substituted with at
least one group independently selected from R.sub.50, -cycloalkyl
optionally substituted with at least one group independently
selected from R.sub.50, -heteroaryl optionally substituted with at
least one group independently selected from R.sub.50, and
-heterocycle optionally substituted with at least one group
independently selected from R.sub.50, wherein at least one atom of
the heterocycle is optionally replaced with --C(O)-- and
--S(O).sub.0-2--; wherein at least one heteroatom of the heteroaryl
or heterocycle is optionally substituted with a group independently
selected from --(CO).sub.0-1R.sub.215, --(CO).sub.0-1R.sub.220,
--S(O).sub.0-2R.sub.200, and --N(R.sub.200)--S(O).sub.0-2R.sub.200;
R.sub.50 is independently selected from --OH, -halogen,
--OCF.sub.3, --NO.sub.2, --CN, --N(R)C(O)R, --CO.sub.2--R,
--NH--CO.sub.2--R, --O-(alkyl)-CO.sub.2H, --NRR', --SR,
--CH.sub.2OH, --C(O)--R.sub.25, --C(O)NRR', --SO.sub.2NRR',
--S(O).sub.1-2R.sub.25, -alkyl optionally substituted with at least
one group independently selected from --CF.sub.3, halogen,
--O-alkyl, --OCF.sub.3, --NRR', --OH, and --CN, -cycloalkyl
optionally substituted with at least one group independently
selected from --CF.sub.3, halogen, --O-alkyl, --OCF.sub.3, NRR',
--OH, and --CN, --O-alkyl optionally substituted with at least one
group independently selected from --CF.sub.3, halogen, --O-alkyl,
--OCF.sub.3, --NRR', --OH, and --CN, --O-benzyl optionally
substituted with at least one group independently selected from
--H, --OH, halogen, and alkyl,
--O--(CH.sub.2).sub.0-2--O--(CH.sub.2).sub.1-2--O-alkyl, and
--(CH.sub.2).sub.0-2--O--(CH.sub.2).sub.1-2--OH; R and R' are each
independently selected from hydrogen, alkyl,
--(CH.sub.2).sub.0-2-aryl and --(CH.sub.2).sub.0-2-cycloalkyl,
wherein each aryl or cycloalkyl is optionally substituted with at
least one group independently selected from halogen, hydroxy,
alkyl, --O-alkyl, amino, monoalkylamino, and dialkylamino; R.sub.25
is selected from alkyl, --(CH.sub.2).sub.0-2-aryl and
--(CH.sub.2).sub.0-2-cycloalkyl, wherein each aryl or cycloalkyl is
optionally substituted with at least one group independently
selected from halogen, hydroxy, alkyl, --O-alkyl, amino,
monoalkylamino, and dialkylamino; L is selected from a bond,
--C(O)--, --S(O).sub.1-2--, --O--, --C(R.sub.110)(R.sub.112)O--,
--OC(R.sub.110)(R.sub.112)--, --N(R.sub.110)--,
--C(O)N(R.sub.110)--, --N(R.sub.110)C(O)--, --C(R.sub.110)(R')--,
--C(OH)R.sub.110--, --SO.sub.2NR.sub.110--,
--N(R.sub.110)SO.sub.2--, --N(R.sub.110)C(O)N(R.sub.112)--,
--N(R.sub.110)C(S)N(R.sub.112)--, --OCO.sub.2--, --NCO.sub.2--, and
--OC(O)N(R.sub.110)--; R.sub.110 and R.sub.112 are each
independently selected from -hydrogen and -alkyl optionally
substituted with at least one group independently selected from
--OH, --O-alkyl, and halogen; G is selected from -alkyl (optionally
substituted with at least one group independently selected from
--CO.sub.2H, --CO.sub.2(alkyl), --O-alkyl, --OH, --NRR', alkyl,
-haloalkyl, -alkyl-O-alkyl), aryl (optionally substituted with at
least one group independently selected from R.sub.50), and
heteroaryl (optionally substituted with at least one group
independently selected from R.sub.50);
--(CH.sub.2).sub.0-3-cycloalkyl wherein cycloalkyl is optionally
substituted with at least one group independently selected from
--CO.sub.2H, --CO.sub.2-- (alkyl), --O-alkyl, --OH, --NH.sub.2,
haloalkyl, alkyl, -alkyl-O-alkyl, mono(alkyl)amino, di(alkyl)
amino, aryl (optionally substituted with at least one group
independently selected from R.sub.50), and heteroaryl (optionally
substituted with at least one group independently selected from
R.sub.50); --(CRR).sub.1-4-aryl wherein the aryl is optionally
substituted with at least one group independently selected from
R.sub.50, --(CH.sub.2).sub.1-4-heteroaryl wherein the heteroaryl is
optionally substituted with at least one group independently
selected from R.sub.50, --(CH.sub.2).sub.0-4-heterocycle, wherein
the heterocycle is optionally substituted with at least one group
independently selected from R.sub.50, and
--C(R.sub.10)(R.sub.12)--C(O)--NH--R.sub.14; R.sub.10 and R.sub.12
are each independently selected from --H, -alkyl,
-(alkyl).sub.0-1-aryl, -(alkyl).sub.0-1-heteroaryl,
-(alkyl).sub.0-1-heterocycle, -aryl, -heteroaryl, -heterocycle,
--(CH.sub.2).sub.1-4--OH,
--(CH.sub.2).sub.1-4-Z-(CH.sub.2).sub.1-4-aryl, and
--(CH.sub.2).sub.1-4-Z-(CH.sub.2).sub.1-4-heteroaryl, wherein the
heterocycle, aryl, and heteroaryl groups included within R.sub.10
and R.sub.12 are optionally substituted with at least one group
independently selected from R.sub.50; Z is selected from --O--,
--S--, and --NR.sub.16--; R.sub.14 is: --H, alkyl, -aryl,
-heteroaryl, -heterocycle, -(alkyl)-aryl, -(alkyl)-heteroaryl,
-(alkyl)-, and --(CH.sub.2).sub.0-2--O--(CH.sub.2).sub.0-2--OH;
wherein the heterocycle, aryl, and heteroaryl groups included
within R.sub.14 are optionally substituted with at least one group
independently selected from R.sub.50; R.sub.16 is selected from
hydrogen and alkyl; or R.sub.1 is selected from ##STR109## alkyl;
wherein X, Y, and Z are independently selected from
--C(H).sub.0-2--, --O--, --C(O)--, --NH--, and --N--; wherein at
least one bond of the (IIf) ring may optionally be a double bond;
R.sub.50, R.sub.50a, and R.sub.50b are independently selected from
--H, halogen, --OH, --SH, --CN, --C(O)-alkyl, --NR.sub.7R.sub.8,
--NO.sub.2, --S(O).sub.0-2-alkyl, alkyl, alkoxy, --O-benzyl
(optionally substituted with at least one group independently
selected from --H, --OH, and alkyl), --C(O)--NR.sub.7R.sub.8,
alkyloxy, alkoxyalkoxyalkoxy, and cycloalkyl; wherein the alkyl,
alkoxy, and cycloalkyl groups within R.sub.50, R.sub.50a, and
R.sub.50b are optionally substituted with at least one group
independently selected from alkyl, halogen, OH, NR.sub.5R.sub.6,
CN, haloalkoxy, NR.sub.7R.sub.8, and alkoxy; R.sub.5 and R.sub.6
are independently selected from --H and alkyl, or R.sub.5 and
R.sub.6, and the nitrogen to which they are attached, form a 5 or 6
membered heterocycloalkyl ring; and R.sub.7 and R.sub.8 are
independently selected from --H, alkyl optionally substituted with
at least one group independently selected from --OH, --NH.sub.2,
and halogen, -cycloalkyl, and -alkyl-O-alkyl; R.sub.2 is selected
from --H, -alkyl optionally substituted with at least one group
independently selected from R.sub.200, --OH, --O-alkyl optionally
substituted with at least one group independently selected from
R.sub.200, --O-aryl optionally substituted with at least one group
independently selected from R.sub.200, --NH-alkyl optionally
substituted with at least one group independently selected from
R.sub.200, -heterocycloalkyl, (wherein at least one carbon is
optionally replaced with a group independently selected from
--(CR.sub.245R.sub.250)--, --O--, --C(O)--, --C(O)C(O)--,
--N(R.sub.200).sub.0-2--, and --S(O).sub.0-2--, and wherein the
heterocycloalkyl is optionally substituted with at least one group
independently selected from R.sub.200), --NH-heterocycloalkyl,
wherein at least one carbon is optionally replaced with a group
independently selected from --(CR.sub.245R.sub.250)--, --O--,
--C(O)--, --C(O)C(O)--, --N(R.sub.200).sub.0-2--, and
--S(O).sub.0-2--, and wherein the heterocycloalkyl is optionally
substituted with at least one group independently selected from
R.sub.200, --C(O)--N(R.sub.315)(R.sub.320), wherein R.sub.315 and
R.sub.320 are each independently selected from --H, alkyl, and
aryl, --NH--R.sub.400, --R.sub.400, --NH--R.sub.500, --R.sub.500,
--NH--R.sub.600, --R.sub.600, and --R.sub.700; R.sub.400 is
##STR110## wherein R.sub.405 is selected from --H,
--N(R.sub.515).sub.2 and O-alkyl; R.sub.500 is a heteroaryl
selected from (IIa) and (IIb) ##STR111## wherein M.sub.1 and
M.sub.4 are independently selected from --C(R.sub.505)--, --N--,
--N(R.sub.515)--, --S--, and --O--; M.sub.2 and M.sub.3 are
independently selected from --C(R.sub.510)--,
--N(R.sub.520).sub.0-1--, --S--, and --O--; M.sub.5 is selected
from --C-- and --N--; R.sub.505 is independently selected from --H,
-alkyl, -halogen, --NO.sub.2, --CN, R.sub.200, and -aryl; R.sub.510
is independently selected from --H, -alkyl, -halogen, -amino,
--CF.sub.3, R.sub.200, and -aryl; R.sub.515 is independently
selected from --H, -alkyl, and -aryl; R.sub.520 is independently
selected from --H, -alkyl, --(CH.sub.2).sub.0-2-aryl, and
--C(Ph).sub.3; R.sub.600 is a monocyclic, bicyclic, or tricyclic
heteroaryl ring system of 6, 7, 8, 9, 10, 11, 12, 13, or 14 atoms,
optionally substituted with at least one group independently
selected from --R.sub.605; R.sub.605 is selected from --H,
-halogen, -alkyl, -aryl, --CO.sub.2-alkyl, --NO.sub.2, --CN,
--NH.sub.2, --NR.sub.220R.sub.225, -thioalkyl, --CF.sub.3, --OH,
--O-alkyl, and -heterocycloalkyl; R.sub.700 is aryl optionally
substituted with at least one --R.sub.205; R.sub.C is selected from
formula (IIIa), (IIIb), (IIIc), (IIId), (IIIe), and (IIIf)
##STR112## wherein, A.sub.1 and A.sub.2 are independently selected
from --(CH.sub.2).sub.0-2--, --CH(R.sub.200)--,
--C(R.sub.200).sub.2--, --NH--, --NR.sub.220--,
--C(.dbd.N--R.sub.230)--, --C(.dbd.CH--R.sub.230)--,
--C(.dbd.N--C(O)--R.sub.230)--, and
--C(.dbd.CH--C(O)--R.sub.230)--; A.sub.3, A.sub.4, A.sub.5, and
A.sub.6 are independently selected from --CH.sub.2--,
--CH(R.sub.200)--, --C(R.sub.200).sub.2--, --O--, --C(O)--,
--S(O).sub.0-2--, --NH--, --NR.sub.220--, --N(CO)O
.sub.1R.sub.200--, --N(S(O.sub.2)alkyl)-, --C(.dbd.N--R.sub.230)--,
--C(.dbd.N--NH(alkyl))-, --C(.dbd.N--N(alkyl)(alkyl))-,
--C(.dbd.N--O--(CH.sub.2).sub.1-4--OH)--,
--C(.dbd.CH--R.sub.230)--, --C(.dbd.N--C(O)--R.sub.230)--, and
--C(.dbd.CH--C(O)--R.sub.230)--; R.sub.230 is independently
selected from --H, --OH, R.sub.215 (optionally substituted with
--OH, --NH.sub.2, --C(O)H, and --CN), alkyl, cycloalkyl, alkoxy,
-alkyl-OH, -alkyl-NH.sub.2, -alkyl-C(O)H, --O--R.sub.215
(optionally substituted with --OH, --NH.sub.2, --C(O)H, and --CN),
--O-alkyl, --O-alkyl-OH, --O-alkyl-NH.sub.2, --O-alkyl-C(O)H,
--NH.sub.2, --NHR.sub.215, --N(R.sub.215).sub.2,
--NR.sub.235R.sub.240, and --CN; wherein at least one carbon of the
alkyl or cycloalkyl within R.sub.230 is optionally independently
replaced with --C(O)-- or a heteroatom; wherein the cycloalkyl and
heterocylcoalkyl within formulae (IIIa), (IIIb), (IIIc), (IIId),
(IIIe), and (IIIf) may optionally contain at least one double bond;
wherein in formulae (IIIa), (IIIb), (IIIc), and (IIId), at least
one of A.sub.1, A.sub.2, A.sub.3, A.sub.4, or A.sub.5 is selected
from --C(.dbd.N--R.sub.230)--, --C(.dbd.N--NH(alkyl))-,
--C(.dbd.N--N(alkyl)(alkyl))-,
C(.dbd.N--O--(CH.sub.2).sub.1-4--OH)--, --C(.dbd.CH--R.sub.230)--,
--C(.dbd.N--C(O)--R.sub.230)--, and
--C(.dbd.CH--C(O)--R.sub.230)--; wherein in formulae (IIIe) and
(IIIf), when A.sub.1, A.sub.2, and A.sub.6 are selected from
--(CH.sub.2).sub.0-2--, --CH(R.sub.200)--, --C(R.sub.200).sub.2--,
--O--, --C(O)--, --S(O).sub.0-2--, --NH--, --NR.sub.220--,
--N(CO).sub.0-1R.sub.200--, and --N(S(O.sub.2)alkyl)-, at least one
carbon of the aryl ring group within (IIIe) and (IIIf) is
optionally independently replaced with a group selected from --N--,
--NH--, --O--, --C(O)--, and --S(O).sub.0-2--; wherein each aryl or
heteroaryl group attached directly or indirectly to R.sub.C is
optionally substituted with at least one group independently
selected from R.sub.200; wherein each cycloalkyl or
heterocycloalkyl attached directly or indirectly to R.sub.C is
optionally substituted with at least one group independently
selected from R.sub.210; and R.sub.X is selected from aryl,
heteroaryl, cycloalkyl, heterocycloalkyl, and --R.sub.xa--R.sub.xb,
wherein R.sub.xa and R.sub.xb are independently selected from aryl,
heteroaryl, cycloalkyl, and heterocycloalkyl; wherein each aryl or
heteroaryl group of R.sub.X is optionally substituted with at least
one group independently selected from R.sub.200; wherein each
cycloalkyl or heterocycloalkyl of R.sub.X is optionally substituted
with at least one group independently selected from R.sub.210; and
wherein at least one carbon of the heteroaryl or heterocycloalkyl
group of R.sub.X is independently optionally replaced with a group
independently selected from --NH--, --N--,
--N(CO).sub.0-1R.sub.215--, --N(CO).sub.0-1R.sub.220--, --O--,
--C(O)--, --S(O).sub.0-2--, and --NS(O).sub.0-2R.sub.200; R.sub.200
at each occurrence is independently selected from -alkyl optionally
substituted with at least one group independently selected from
R.sub.205, --OH, --NO.sub.2, -halogen, --CN,
--(CH.sub.2).sub.0-4--C(O)H, --(CO).sub.0-1R.sub.215,
--(CO).sub.0-1R.sub.220,
--(CH.sub.2).sub.0-4--(CO).sub.0-1--NR.sub.220R.sub.225,
--(CH.sub.2).sub.0-4--(CO).sub.0-1--NH(R.sub.215),
--(CH.sub.2).sub.0-4--C(O)-alkyl,
--(CH.sub.2).sub.0-4--(CO).sub.0-1-cycloalkyl,
--(CH.sub.2).sub.0-4--(CO).sub.0-1-heterocycloalkyl,
--(CH.sub.2).sub.0-4--(CO).sub.0-1-aryl,
--(CH.sub.2).sub.0-4--(CO).sub.0-1-heteroaryl,
--(CH.sub.2).sub.0-4--C(O)--O--R.sub.215,
--(CH.sub.2).sub.0-4--SO.sub.2--NR.sub.220R.sub.225,
--(CH.sub.2).sub.0-4--S(O).sub.0-2-alkyl,
--(CH.sub.2).sub.0-4--S(O).sub.0-2-cycloalkyl,
--(CH.sub.2).sub.0-4--N(H or R.sub.215)--C(O)--O--R.sub.215,
--(CH.sub.2).sub.0-4--N(H or R.sub.215)--SO.sub.2--R.sub.220,
--(CH.sub.2).sub.0-4--N(H or R.sub.215)--C(O)--N(R.sub.215).sub.2,
--(CH.sub.2).sub.0-4--N(H or R.sub.215)--C(O)--R.sub.220,
--(CH.sub.2).sub.0-4--O--C(O)-alkyl,
--(CH.sub.2).sub.0-4--O--(R.sub.215),
--(CH.sub.2).sub.0-4--S--(R.sub.215), --(CH.sub.2).sub.0-4--O-alkyl
optionally substituted with at least one halogen, and -adamantane;
wherein each aryl and heteroaryl group included within R.sub.200 is
optionally substituted with at least one group independently
selected from R.sub.205, R.sub.210, and alkyl (optionally
substituted with at least one group independently selected from
R.sub.205 and R.sub.210); wherein each cycloalkyl or
heterocycloalkyl group included within R.sub.200 is optionally
substituted with at least one group independently selected from
R
.sub.210; R.sub.205 at each occurrence is independently selected
from -alkyl, -haloalkoxy, --(CH.sub.2).sub.0-3-cycloalkyl,
-halogen, --(CH.sub.2).sub.1-6--OH, --O-aryl, --OH, --SH,
--(CH.sub.2).sub.0-4--C(O)H, --(CH.sub.2).sub.0-6--CN,
--(CH.sub.2).sub.0-6--C(O)--NR.sub.235R.sub.240,
--(CH.sub.2).sub.0-6--C(O)--R.sub.235, --(CH.sub.2).sub.0-4--N(H or
R.sub.215)--SO.sub.2--R.sub.235, --OCF.sub.3, --CF.sub.3, -alkoxy,
-alkoxycarbonyl, and --NR.sub.235R.sub.240;R.sub.210 at each
occurrence is independently selected from --(CH.sub.2).sub.0-4--OH,
--(CH.sub.2).sub.0-4--CN, --(CH.sub.2).sub.0-4--C(O)H, -alkyl
optionally substituted with at least one group independently
selected from R.sub.205, -alkanoyl, --S-alkyl; --S(O).sub.2-alkyl,
-halogen, -alkoxy, -haloalkoxy, --NR.sub.220R.sub.225, -cycloalkyl
optionally substituted with at least one group independently
selected from R.sub.205, -heterocycloalkyl, -heteroaryl,
--(CH.sub.2).sub.0-4--NR.sub.235R.sub.240,
--(CH.sub.2).sub.0-4--NR.sub.235(alkoxy),
--(CH.sub.2).sub.0-4--S--(R.sub.215),
--(CH.sub.2).sub.0-4--NR.sub.235--C(O)H,
--(CH.sub.2).sub.0-4--NR.sub.235--C(O)-(alkoxy),
--(CH.sub.2).sub.0-4--NR.sub.235--C(O)--R.sub.240,
--C(O)--NHR.sub.215, --C(O)-alkyl, --C(O)--NR.sub.235R.sub.240, and
--S(O).sub.2--NR.sub.235R.sub.240; R.sub.215 at each occurrence is
independently selected from -alkyl, --(CH.sub.2).sub.0-2-aryl,
--(CH.sub.2).sub.0-2-cycloalkyl, --(CH.sub.2).sub.0-2-heteroaryl,
--(CH.sub.2).sub.0-2-heterocycloalkyl, and
--CO.sub.2--CH.sub.2-aryl; wherein the aryl group included within
R.sub.215 is optionally substituted with at least one group
independently selected from R.sub.205 and R.sub.210, and wherein
the heterocycloalkyl and heteroaryl groups included within
R.sub.215 are optionally substituted with at least one group
independently selected from R.sub.210; R.sub.220 and R.sub.225 at
each occurrence are independently selected from --H, -alkyl,
--(CH.sub.2).sub.0-4--C(O)H, -alkylhydroxyl, -alkoxycarbonyl,
-alkylamino, --S(O).sub.2-alkyl, -alkanoyl optionally substituted
with at least one halogen, --C(O)--NH.sub.2, --C(O)--NH(alkyl),
--C(O)--N(alkyl)(alkyl), -haloalkyl,
--(CH.sub.2).sub.0-2-cycloalkyl, -(alkyl)-O-(alkyl), -aryl,
-heteroaryl, and -heterocycloalkyl; wherein the aryl, heteroaryl,
cycloalkyl, and heterocycloalkyl groups included within R.sub.220
and R.sub.225 are each optionally substituted with at least one
group independently selected from R.sub.270; R.sub.270 at each
occurrence is independently selected from --R.sub.205, -alkyl
optionally substituted with at least one group independently
selected from R.sub.205, -aryl, -halogen, -alkoxy, -haloalkoxy,
--NR.sub.235R.sub.240, --OH, --CN, -cycloalkyl optionally
substituted with at least one group independently selected from
R.sub.205, --C(O)-alkyl, --S(O).sub.2--NR.sub.235R.sub.240,
--C(O)--NR.sub.235R.sub.240, --S(O).sub.2-alkyl, and
--(CH.sub.2).sub.0-4--C(O)H; R.sub.235 and R.sub.240 at each
occurrence are independently selected from --H, --OH, --CF.sub.3,
--OCH.sub.3, --NHCH.sub.3, --N(CH.sub.3).sub.2,
--(CH.sub.2).sub.0-4--C(O)(H or alkyl), -alkyl, -alkanoyl,
--SO.sub.2-alkyl, and -aryl.
2. The compound according to claim 1, wherein R.sub.1 is selected
from --CH.sub.2-aryl, wherein the aryl ring is optionally
substituted with at least one group independently selected from
halogen, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 alkoxy, and
--OH.
3. The compound according to claim 1, wherein R.sub.1 is selected
from 3-allyloxy-5-fluoro-benzyl, 3-benzyloxy-5-fluoro-benzyl,
4-hydroxy-benzyl, 3-hydroxy-benzyl, 3-propyl-thiophen-2-yl-methyl,
3,5-difluoro-2-propylamino-benzyl,
2-ethylamino-3,5-difluoro-benzyl, 2-hydroxy-5-methyl-benzamide,
3-fluoro-5-[2-(2-methoxy-ethoxy)-ethoxy]-benzyl,
3-fluoro-5-heptyloxy-benzyl, and 3-fluoro-5-hexyloxy-benzyl,
4-hydroxy-benzyl, 3-hydroxy-benzyl, 5-chloro-thiophen-2-yl-methyl,
5-chloro-3-ethyl-thiophen-2-yl-methyl,
3,5-difluoro-2-hydroxy-benzyl, piperidin-4-yl-methyl,
2-oxo-piperidin-4-yl-methyl, 2-oxo-1,2-dihydro-pyridin-4-yl-methyl,
5-hydroxy-6-oxo-6H-pyran-2-yl-methyl,
3,5-difluoro-4-hydroxy-benzyl, 3,5-difluoro-benzyl,
3-fluoro-4-hydroxy-benzyl, 3-fluoro-5-hydroxy-benzyl, and
3-fluoro-benzyl.
4. The compound according to claim 1, wherein R.sub.2 is selected
from hydrogen, 3-Allyl-5-benzyl-2-oxo-imidazolidin-1-yl,
6-Benzyl-3,3-dimethyl-2-oxo-piperazin-1-yl,
3-Allyl-5-benzyl-2-oxo-pyrrolidin-1-yl,
5-Benzyl-3-isobutyl-2-oxo-imidazolidin-1-yl,
3-Benzyl-5-methyl-1,1-dioxo-1.lamda..sup.6-[1,2,5]thiadiazolidin-2-yl,
3-Benzyl-1,1-dioxo-1.lamda..sup.6-isothiazolidin-2-yl,
2-Benzyl-5-oxo-pyrrolidin-1-yl,
5-Benzyl-3-ethyl-2-oxo-pyrrolidin-1-yl,
3-Amino-5-benzyl-2-oxo-pyrrolidin-1-yl,
3-Acetylamino-5-benzyl-2-oxo-pyrrolidin-1-yl,
5-Benzyl-3-[1,3]dioxolan-4-ylmethyl-2-oxo-pyrrolidin-1-yl,
3-Benzyl-5-oxo-morpholin-4-yl, 2-Benzyl-6-oxo-piperazin-1-yl,
8-Benzyl-6-methyl-10-oxo-6,9-diaza-spiro[4.5]dec-9-yl,
5-Benzyl-3-furan-2-ylmethylene-2-oxo-pyrrolidin-1-yl,
3-acetylamino-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-acetylamino-3-(cyclopropylmethyl)-2-oxo-pyrrolidin-1-yl,
3-(2-amino-5-carboxypentanoylamino)-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-(2-methoxy-acetylamino)-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-ethoxycarbonylamino-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-ethylureido-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-hydroxypropionylamino-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-Bromo-[1,2,4]thiadiazol-5-ylamino, [1,2,4]thiadiazol-5-ylamino,
4-Chloro-[1,2,5]thiadiazol-3-ylamino, [1,2,5]thiadiazol-3-ylamino,
thiazol-2-ylamino, 5-Bromo-[1,3,4]thiadiazol-2-ylamino,
[1,3,4]thiadiazol-2-ylamino, 5-Amino-[1,3,4]thiadiazol-2-ylamino,
2-Bromo-thiazol-5-ylamino, thiazol-5-ylamino,
5-trifluoromethyl-[1,3,4]thiadiazol-2-ylamino,
5-trifluoromethyl-[1,3,4]oxadiazol-2-ylamino,
5-Amino-[1,3,4]oxadiazol-2-ylamino,
1-trityl-1H-[1,2,4]triazol-3-ylamino, 1H-[1,2,4]triazol-3-ylamino,
oxazol-2-ylamino, 5-Bromo-2-trityl-2H-[1,2,3]triazol-4-ylamino,
2-trityl-2H-[1,2,3]triazol-4-ylamino,
5-Bromo-2H-[1,2,3]triazol-4-ylamino, 2H-[1,2,3]triazol-4-ylamino,
thiophen-2-ylamino, 3-methyl-5-nitro-3H-imidazol-4-ylamino,
4-Cyano-5-phenyl-isothiazol-3-ylamino,
4-phenyl-[1,2,5]thiadiazol-3-ylamino,
3,4-dioxo-cyclobut-1-enylamino,
2-methoxy-3,4-dioxo-cyclobut-1-enylamino, and
2-methylamino-3,4-dioxo-cyclobut-1-enylamino.
5. The compound according to claim 1, wherein R.sub.C is selected
from ##STR113## wherein A.sub.5 is --C(.dbd.N--R.sub.230) and
A.sub.1, A.sub.2, A.sub.3, A.sub.4, R.sub.X and R.sub.230 are
defined as in claim 1.
6. The compound according to claim 5, wherein A.sub.5 is selected
from --C(.dbd.N--OH)--, --C(.dbd.N--O--CH.sub.3)--,
--C(.dbd.N--O--CH.sub.2CH.sub.3)--,
--C(.dbd.N--O--CH.sub.2CH.sub.2OH)--,
--C(.dbd.N--O--CH.sub.2CH.sub.2NH.sub.2)--,
--C(.dbd.N--NHCH.sub.3)--, and --C(.dbd.N--CN)--, and A.sub.1,
A.sub.2, A.sub.3, and A.sub.4 are --CH.sub.2--.
7. The compound according to claim 1, wherein R.sub.C is selected
from 1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexyl,
1-(3-tert-Butyl-phenyl)-4-methoxyimino-cyclohexyl,
1-(3-tert-Butyl-phenyl)-4-ethoxyimino-cyclohexyl,
1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethoxyimino)-cyclohexyl,
1-(3-tert-Butyl-phenyl)-4-(2-amino-ethoxyimino)-cyclohexyl,
5-(3-tert-Butyl-phenyl)-2-hydroxyimino-hexahydro-pyrimidin-5-yl,
1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-cyclohexyl,
1-(3-tert-Butyl-phenyl)-4-cyanoimino-cyclohexyl,
5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-yl,
5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-benzo[c]isoxazol-5-yl,
1-(Acrylic acid methyl
ester)-4-(tert-Butyl-phenyl)-cyclohexane-4-yl,
1-(Acrylamide)-4-(tert-Butyl-phenyl)-cyclohexane-4-yl,
1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethylidene)-cyclohex-1-yl,
1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-cyclohex-1-yl,
1-(3-tert-Butyl-phenyl)-4-(dimethyl-hydrazono)-cyclohex-1-yl,
4-methoxyimino-1-(3-thiophen-3-yl-phenyl)-cyclohexyl,
1-(3-furan-3-yl-phenyl)-4-methoxyimino-cyclohexyl,
4-methoxyimino-1-[3-(1H-pyrrol-2-yl)-phenyl]-cyclohexyl,
4-methoxyimino-1-(3-pyridin-4-yl-phenyl)-cyclohexyl,
4-methoxyimino-1-(3-pyrimidin-5-yl-phenyl)-cyclohexyl,
4-methoxyimino-1-(3-pyrazol-1-yl-phenyl)-cyclohexyl,
2-Acetyl-5-(3-tert-butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-yl,
1-(3-tert-Butyl-phenyl)-4-methylene-cyclohexyl, and ethyl
2-(4-(3-tert-butylphenyl)cyclohexylidene)acetate.
8. The compound according to claim 1, wherein R.sub.X is selected
from 3-(1,1-dimethyl-propyl)-phenyl, 3-(1-ethyl-propyl)-phenyl,
3-(1H-pyrrol-2-yl)-phenyl, 3-(1-hydroxy-1-methyl-ethyl)-phenyl,
3-(1-methyl-1H-imidazol-2-yl)-phenyl,
3-(1-methyl-cyclopropyl)-phenyl, 3-(2,2-dimethyl-propyl)-phenyl,
3-(2,5-dihydro-1H-pyrrol-2-yl)-phenyl,
3-(2-Chloro-thiophen-3-yl)-phenyl,
3-(2-Cyano-thiophen-3-yl)-phenyl, 3-(2-fluoro-benzyl)-phenyl,
3-(3,5-dimethyl-3H-pyrazol-4-yl)-phenyl,
3-(3,6-dimethyl-pyrazin-2-yl)-phenyl,
3-(3-Cyano-pyrazin-2-yl)-phenyl, 3-(3-formyl-furan-2-yl)-phenyl,
3-(3H-[1,2,3]triazol-4-yl)-phenyl, 3-(3H-imidazol-4-yl)-phenyl,
3-(3-methyl-butyl)-phenyl, 3-(3-methyl-pyridin-2-yl)-phenyl,
3-(3-methyl-thiophen-2-yl)-phenyl, 3-(4-Cyano-pyridin-2-yl)-phenyl,
3-(4-fluoro-benzyl)-phenyl, 3-(4H-[1,2,4]triazol-3-yl)-phenyl,
3-(4-methyl-thiophen-2-yl)-phenyl,
3-(5-Acetyl-thiophen-2-yl)-phenyl,
3-(5-Acetyl-thiophen-3-yl)-phenyl,
3-(5-formyl-thiophen-2-yl)-phenyl,
3-(5-oxo-pyrrolidin-2-yl)-phenyl,
3-(6-methyl-pyridazin-3-yl)-phenyl,
3-(6-methyl-pyridin-2-yl)-phenyl, 3-(Cyano-dimethyl-methyl)-phenyl,
3-[1-(2-tert-Butyl-pyrimidin-4-yl)-cyclohexylamino,
3-[1,2,3]triazol-1-yl-phenyl, 3-[1,2,4]oxadiazol-3-yl-phenyl,
3-[1,2,4]oxadiazol-5-yl-phenyl, 3-[1,2,4]thiadiazol-3-yl-phenyl,
3-[1,2,4]thiadiazol-5-yl-phenyl, 3-[1,2,4]triazol-4-yl-phenyl,
3-Acetyl-5-tert-butyl-phenyl, 3'-Acetylamino-biphenyl-3-yl,
3-Adamantan-2-yl-phenyl, 3-Bromo-[1,2,4]thiadiazol-5-yl)-phenyl,
3-Bromo-5-tert-butyl-phenyl, 3-Cyano-phenyl, 3-Cyclobutyl-phenyl,
3-Cyclopentyl-phenyl, 3-Cyclopropyl-phenyl, 3-ethyl-phenyl,
3-ethynyl-phenyl, 3-fluoro-5-(2-hydroxy-1,1-dimethyl-ethyl)-phenyl,
3-furan-3-yl-phenyl, 3-imidazol-1-yl-phenyl, 3-isobutyl-phenyl,
3-isopropyl-phenyl, 3-isoxazol-3-yl-phenyl, 3-isoxazol-4-yl-phenyl,
3-isoxazol-5-yl-phenyl, 3-pent-4-enyl-phenyl, 3-pentyl-phenyl,
3-Phenyl-propionic acid ethyl ester, 3-pyrazin-2-yl-phenyl,
3-pyridin-2-yl-phenyl, 3-pyrrolidin-2-yl-phenyl,
3-sec-Butyl-phenyl, 3-tert-Butyl-4-chloro-phenyl,
3-tert-Butyl-4-cyano-phenyl, 3-tert-Butyl-4-ethyl-phenyl,
3-tert-Butyl-4-methyl-phenyl,
3-tert-Butyl-4-trifluoromethyl-phenyl,
3-tert-Butyl-5-chloro-phenyl, 3-tert-Butyl-5-cyano-phenyl,
3-tert-Butyl-5-ethyl-phenyl, 3-tert-Butyl-5-fluoro-phenyl,
3-tert-Butyl-5-methyl-phenyl,
3-tert-Butyl-5-trifluoromethyl-phenyl, 3-tert-Butyl-phen-1-yl,
3-tert-Butyl-phenyl, 3-thiazol-2-yl-phenyl, 3-thiazol-4-yl-phenyl,
3-thiophen-3-yl-phenyl, 3-trifluoromethyl-phenyl,
4-Acetyl-3-tert-butyl-phenyl, 4-tert-Butyl-pyridin-2-yl,
4-tert-Butyl-pyrimidin-2-yl, 5-tert-Butyl-pyridazin-3-yl,
6-tert-Butyl-pyridazin-4-yl, 6-tert-Butyl-pyrimidin-4-yl,
3-pyridin-4-yl-phenyl, 3-pyrimidin-5-yl-phenyl, and
3-pyrazol-1-yl-phenyl.
9. The compound according to claim 1, wherein R.sub.X is
3-tert-Butyl-phen-1-yl.
10. The compound according to claim 1, wherein the formula (I)
compound is selected from
4-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexylamino]-2-(3,5-difluor-
o-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-methoxyimino-cyclohexylamino]-2-(3,5-difluor-
o-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-ethoxyimino-cyclohexylamino]-2-(3,5-difluoro-
-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethoxyimino)-cyclohexylamino]-2-(-
3,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[4-(2-Amino-ethoxyimino)-1-(3-tert-butyl-phenyl)-cyclohexylamino]-2-(3,-
5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-2-hydroxyimino-hexahydro-pyrimidin-5-ylamino]--
2-(3,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-cyclohexylamino]-2-(3,5-d-
ifluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(dimethyl-hydrazono)-cyclohexylamino]-2-(3,5-
-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-cyanoimino-cyclohexylamino]-2-(3,5-difluoro--
benzyl)-3-hydroxy-N-methyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamino]-2-(3,-
5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-benzo[c]isoxazol-5-ylamino]-
-2-(3,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-methylcarbamoylmethylene-cyclohexylamino]-2--
(3,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
{4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-methylcar-
bamoyl-butylamino]-cyclohexylidene}-acetic acid methyl ester,
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethylidene)-cyclohexylamino]-2-(3-
,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexylamino]-2-(3,5-difluor-
o-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-methoxyimino-cyclohexylamino]-2-(3,5-difluor-
o-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-ethoxyimino-cyclohexylamino]-2-(3,5-difluoro-
-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethoxyimino)-cyclohexylamino]-2-(-
3,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[4-(2-Amino-ethoxyimino)-1-(3-tert-butyl-phenyl)-cyclohexylamino]-2-(3,-
5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-2-hydroxyimino-hexahydro-pyrimidin-5-ylamino]--
2-(3,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-cyclohexylamino]-2-(3,5-d-
ifluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(dimethyl-hydrazono)-cyclohexylamino]-2-(3,5-
-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-cyanoimino-cyclohexylamino]-2-(3,5-difluoro--
benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamino]-2-(3,-
5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-benzo[c]isoxazol-5-ylamino]-
-2-(3,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-methylcarbamoylmethylene-cyclohexylamino]-2--
(3,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
{4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-phenylcar-
bamoyl-butylamino]-cyclohexylidene}-acetic acid methyl ester,
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethylidene)-cyclohexylamino]-2-(3-
,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-(1H-imidaz-
ol-2-yl)-butylamino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-butylamino]--
cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[3-(3,5-difluoro-phenoxy)-2-hydroxy-propylamino-
]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[3-(3,5-difluoro-benzenesulfonyl)-2-hydroxy-pro-
pylamino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-4-oxo-butyla-
mino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-pentylamino]-
-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-pentylamino]-
-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-tetrazol-1-
-yl-butylamino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-(5-trifluo-
romethyl-[1,3,4]oxadiazol-2-yl)-butylamino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-([1,2,4]th-
iadiazol-5-ylamino)-butylamino]-cyclohexanone oxime,
3-[3-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexylamino]-1-(3,5-difl-
uoro-benzyl)-2-hydroxy-propylamino]-4-methylamino-cyclobut-3-ene-1,2-dione-
,
3-[3-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexylamino]-1-(3,5-dif-
luoro-benzyl)-2-hydroxy-propylamino]-4-methoxy-cyclobut-3-ene-1,2-dione,
4-(3-tert-Butyl-phenyl)-4-[2-hydroxy-4-(3-propyl-thiophen-2-yl)-3-([1,2,4-
]thiadiazol-5-ylamino)-butylamino]-cyclohexanone oxime,
1-(5-(3-tert-butylphenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamino)-4-(3,5-
difluorophenyl)butan-2-ol and
1-(5-(3-tert-butylphenyl)-2-methyl-4,5,6,7-tetrahydro-2H-indazol-5-ylamin-
o)-4-(3,5-difluorophenyl)butan-2-ol.
11. A method of preventing or treating at least one condition that
benefits from inhibition of at least one aspartyl-protease,
comprising: administering to a host a composition comprising a
therapeutically effective amount of at least one compound of
formula (I), ##STR114## or pharmaceutically acceptable salts
thereof, wherein R.sub.1 is ##STR115## wherein n is 0 or 1; q is 0
or 1; r is 0, 1, or 2; K is selected from --(CR.sub.3aR.sub.3b)--,
--O--, --SO.sub.2--, --C(O)--, and --CH(NR.sub.55R.sub.60)--;
R.sub.55 and R.sub.60 are each independently selected from hydrogen
and alkyl; R.sub.3a and R.sub.3b are independently selected from
-hydrogen, -halogen, --O-alkyl, and -alkyl optionally substituted
with at least one group independently selected from halogen, --CN,
--CF.sub.3, and --OH; W is selected from --(CH.sub.2).sub.1-4--,
--O--, --S(O).sub.0-2--, --N(R.sub.55)--, and --C(O)--; E is a bond
or alkyl; A is selected from -aryl optionally substituted with at
least one group independently selected from R.sub.50, -cycloalkyl
optionally substituted with at least one group independently
selected from R.sub.50, -heteroaryl optionally substituted with at
least one group independently selected from R.sub.50, and
-heterocycle optionally substituted with at least one group
independently selected from R.sub.50, wherein at least one atom of
the heterocycle is optionally replaced with --C(O)-- and
--S(O).sub.0-2--; wherein at least one heteroatom of the heteroaryl
or heterocycle is optionally substituted with a group independently
selected from --(CO).sub.0-1R.sub.215, --(CO).sub.0-1R.sub.220,
--S(O).sub.0-2R.sub.200, and --N(R.sub.200)--S(O).sub.0-2R.sub.200;
R.sub.50 is independently selected from --OH, -halogen,
--OCF.sub.3, --NO.sub.2, --CN, --N(R)C(O)R, --CO.sub.2--R,
--NH--CO.sub.2--R, --O-(alkyl)-CO.sub.2H, --NRR', --SR,
--CH.sub.2OH, --C(O)--R.sub.25, --C(O)NRR', --SO.sub.2NRR',
--S(O).sub.1-2R.sub.25, -alkyl optionally substituted with at least
one group independently selected from --CF.sub.3, halogen,
--O-alkyl, --OCF.sub.3, --NRR', --OH, and --CN, -cycloalkyl
optionally substituted with at least one group independently
selected from --CF.sub.3, halogen, --O-alkyl, --OCF.sub.3, --NRR',
--OH, and --CN, --O-alkyl optionally substituted with at least one
group independently selected from --CF.sub.3, halogen, --O-alkyl,
--OCF.sub.3, --NRR', --OH, and --CN, --O-benzyl optionally
substituted with at least one group independently selected from
--H, --OH, halogen, and alkyl,
--O--(CH.sub.2).sub.0-2--O--(CH.sub.2).sub.1-2--O-alkyl, and
--(CH.sub.2).sub.0-2--O--(CH.sub.2).sub.1-2--OH; R and R' are each
independently selected from hydrogen, alkyl,
--(CH.sub.2).sub.0-2-aryl and --(CH.sub.2).sub.0-2-cycloalkyl,
wherein each aryl or cycloalkyl is optionally substituted with at
least one group independently selected from halogen, hydroxy,
alkyl, --O-alkyl, amino, monoalkylamino, and dialkylamino; R.sub.25
is selected from alkyl, --(CH.sub.2).sub.0-2-aryl and
--(CH.sub.2).sub.0-2-cycloalkyl, wherein each aryl or cycloalkyl is
optionally substituted with at least one group independently
selected from halogen, hydroxy, alkyl, --O-alkyl, amino,
monoalkylamino, and dialkylamino; L is selected from a bond,
--C(O)--, --S(O).sub.1-2--, --O--, --C(R.sub.110)(R.sub.112)O--,
--OC(R.sub.110)(R.sub.112)--, --N(R.sub.110)--,
--C(O)N(R.sub.110)--, --N(R.sub.110)C(O)--, --C(R.sub.110)(R')--,
--C(OH)R.sub.110--, --SO.sub.2NR.sub.110--,
--N(R.sub.110)SO.sub.2--, --N(R.sub.110)C(O)N(R.sub.112)--,
--N(R.sub.110)C(S)N(R.sub.112)--, --OCO.sub.2--, --NCO.sub.2--, and
--OC(O)N(R.sub.110)--; R.sub.110 and R.sub.112 are each
independently selected from -hydrogen and -alkyl optionally
substituted with at least one group independently selected from
--OH, --O-alkyl, and halogen; G is selected from -alkyl (optionally
substituted with at least one group independently selected from
--CO.sub.2H, --CO.sub.2(alkyl), --O-alkyl, --OH, --NRR', alkyl,
-haloalkyl, -alkyl-O-alkyl), aryl (optionally substituted with at
least one group independently selected from R.sub.50), and
heteroaryl (optionally substituted with at least one group
independently selected from R.sub.50);
--(CH.sub.2).sub.0-3-cycloalkyl wherein cycloalkyl is optionally
substituted with at least one group independently selected from
--CO.sub.2H, --CO.sub.2-- (alkyl), --O-alkyl, --OH, --NH.sub.2,
haloalkyl, alkyl, -alkyl-O-alkyl, mono(alkyl)amino, di(alkyl)
amino, aryl (optionally substituted with at least one group
independently selected from R.sub.50), and heteroaryl (optionally
substituted with at least one group independently selected from
R.sub.50); --(CRR).sub.1-4-aryl wherein the aryl is optionally
substituted with at least one group independently selected from
R.sub.50, --(CH.sub.2).sub.1-4-heteroaryl wherein the heteroaryl is
optionally substituted with at least one group independently
selected from R.sub.50, --(CH.sub.2).sub.0-4-heterocycle, wherein
the heterocycle is optionally substituted with at least one group
independently selected from R.sub.50, and
--C(R.sub.10)(R.sub.12)--C(O)--NH--R.sub.14; R.sub.10 and R.sub.12
are each independently selected from --H, -alkyl,
-(alkyl).sub.0-1-aryl, -(alkyl).sub.0-1-heteroaryl,
-(alkyl).sub.0-1-heterocycle, -aryl, -heteroaryl, -heterocycle,
--(CH.sub.2).sub.1-4--OH,
--(CH.sub.2).sub.1-4-Z-(CH.sub.2).sub.1-4-aryl, and
--(CH.sub.2).sub.1-4-Z-(CH.sub.2).sub.1-4-heteroaryl, wherein the
heterocycle, aryl, and heteroaryl groups included within R.sub.10
and R.sub.12 are optionally substituted with at least one group
independently selected from R.sub.50; Z is selected from --O--,
--S--, and --NR.sub.16--; R.sub.14 is: --H, -alkyl, -aryl,
-heteroaryl, -heterocycle, -(alkyl)-aryl, -(alkyl)-heteroaryl,
-(alkyl)-, and --(CH.sub.2).sub.0-2--O--(CH.sub.2).sub.0-2--OH;
wherein the heterocycle, aryl, and heteroaryl groups included
within R.sub.14 are optionally substituted with at least one group
independently selected from R.sub.50; R.sub.16 is selected from
hydrogen and alkyl; or R.sub.1 is selected from ##STR116## alkyl;
wherein X, Y, and Z are independently selected from
--C(H).sub.0-2--, --O--, --C(O)--, --NH--, and --N--; wherein at
least one bond of the (IIf) ring may optionally be a double bond;
R.sub.50, R.sub.50a, and R.sub.50b are independently selected from
--H, halogen, --OH, --SH, --CN, --C(O)-alkyl, --NR.sub.7R.sub.8,
--NO.sub.2, --S(O).sub.0-2-alkyl, alkyl, alkoxy, --O-benzyl
(optionally substituted with at least one group independently
selected from --H, --OH, and alkyl), --C(O)--NR.sub.7R.sub.8,
alkyloxy, alkoxyalkoxyalkoxy, and cycloalkyl; wherein the alkyl,
alkoxy, and cycloalkyl groups within R.sub.50, R.sub.50a, and
R.sub.50b are optionally substituted with at least one group
independently selected from alkyl, halogen, OH, NR.sub.5R.sub.6,
CN, haloalkoxy, NR.sub.7R.sub.8, and alkoxy; R.sub.5 and R.sub.6
are independently selected from --H and alkyl, or R.sub.5 and
R.sub.6, and the nitrogen to which they are attached, form a 5 or 6
membered heterocycloalkyl ring; and R.sub.7 and R.sub.8 are
independently selected from --H, alkyl optionally substituted with
at least one group independently selected from --OH, --NH.sub.2,
and halogen, -cycloalkyl, and -alkyl-O-alkyl; R.sub.2 is selected
from --H. -alkyl optionally substituted with at least one group
independently selected from R.sub.200] --OH, --O-alkyl optionally
substituted with at least one group independently selected from
R.sub.200, --O-aryl optionally substituted with at least one group
independently selected from R.sub.200, --NH-alkyl optionally
substituted with at least one group independently selected from
R.sub.200, -heterocycloalkyl, (wherein at least one carbon is
optionally replaced with a group independently selected from
--(CR.sub.245R.sub.250)--, --O--, --C(O)--, --C(O)C(O)--,
--N(R.sub.200).sub.0-2--, and --S(O).sub.0-2--, and wherein the
heterocycloalkyl is optionally substituted with at least one group
independently selected from R.sub.200), --NH-heterocycloalkyl,
wherein at least one carbon is optionally replaced with a group
independently selected from --(CR.sub.245R.sub.250)--, --O--,
--C(O)--, --C(O)C(O)--, --N(R.sub.200).sub.0-2--, and
--S(O).sub.0-2--, and wherein the heterocycloalkyl is optionally
substituted with at least one group independently selected from
R.sub.200, --C(O)--N(R.sub.315)(R.sub.320), wherein R.sub.315 and
R.sub.320 are each independently selected from --H, alkyl, and
aryl, --NH--R.sub.400, --R.sub.400, --NH--R.sub.500, --R.sub.500,
--NH--R.sub.600, --R.sub.600, and --R.sub.700; R.sub.400 is
##STR117## wherein R.sub.405 is selected from --H,
--N(R.sub.515).sub.2 and O-alkyl; R.sub.500 is a heteroaryl
selected from (IIa) and (IIb) ##STR118## wherein M.sub.1 and
M.sub.4 are independently selected from --C(R.sub.505)--, --N--,
--N(R.sub.515)--, --S--, and --O--; M.sub.2 and M.sub.3 are
independently selected from --C(R.sub.510)--,
--N(R.sub.520).sub.0-1--, --S--, and --O--; M.sub.5 is selected
from --C-- and --N--; R.sub.505 is independently selected from --H,
-alkyl, -halogen, --NO.sub.2, --CN, R.sub.200, and -aryl; R.sub.510
is independently selected from --H, -alkyl, -halogen, -amino,
--CF.sub.3, R.sub.200, and -aryl; R.sub.515 is independently
selected from --H, -alkyl, and -aryl; R.sub.520 is independently
selected from --H, -alkyl, --(CH.sub.2).sub.0-2-aryl, and
--C(Ph).sub.3; R.sub.600 is a monocyclic, bicyclic, or tricyclic
heteroaryl ring system of 6, 7, 8, 9, 10, 11, 12, 13, or 14 atoms,
optionally substituted with at least one group independently
selected from --R.sub.605; R.sub.605 is selected from --H,
-halogen, -alkyl, -aryl, --CO.sub.2-alkyl, --NO.sub.2, --CN,
--NH.sub.2, --NR.sub.220R.sub.225, -thioalkyl, --CF.sub.3, --OH,
--O-alkyl, and -heterocycloalkyl; R.sub.700 is aryl optionally
substituted with at least one --R.sub.205; R.sub.C is selected from
formula (IIIa), (IIIb), (IIIc), (IIId), (IIIe), and (IIIf)
##STR119## wherein, A.sub.1 and A.sub.2 are independently selected
from --(CH.sub.2).sub.0-2--, --CH(R.sub.200)--,
--C(R.sub.200).sub.2--, --NH--, --NR.sub.220--,
--C(.dbd.N--R.sub.230)--, --C(.dbd.CH--R.sub.230)--,
--C(.dbd.N--C(O)--R.sub.230)--, and
--C(.dbd.CH--C(O)--R.sub.230)--; A.sub.3, A.sub.4, A.sub.5, and
A.sub.6 are independently selected from --CH.sub.2--,
--CH(R.sub.200)--, --C(R.sub.200).sub.2--, --O--, --C(O)--,
--S(O).sub.0-2--, --NH--, --NR.sub.220--,
--N(CO).sub.0-1R.sub.200--, --N(S(O.sub.2)alkyl)-,
--C(.dbd.N--R.sub.230)--, --C(.dbd.N--NH(alkyl))-,
--C(.dbd.N--N(alkyl)(alkyl))-,
--C(.dbd.N--O--(CH.sub.2).sub.1-4--OH)--,
--C(.dbd.CH--R.sub.230)--, --C(.dbd.N--C(O)--R.sub.230)--, and
--C(.dbd.CH--C(O)--R.sub.230)--; R.sub.230 is independently
selected from --H, --OH, R.sub.215 (optionally substituted with
--OH, --NH.sub.2, --C(O)H, and --CN), alkyl, cycloalkyl, alkoxy,
-alkyl-OH, -alkyl-NH.sub.2, -alkyl-C(O)H, --O--R.sub.215
(optionally substituted with --OH, --NH.sub.2, --C(O)H, and --CN),
--O-alkyl, --O-alkyl-OH, --O-alkyl-NH.sub.2, --O-alkyl-C(O)H,
--NH.sub.2, --NHR.sub.215, --N(R.sub.215).sub.2,
--NR.sub.235R.sub.240, and --CN; wherein at least one carbon of the
alkyl or cycloalkyl within R.sub.230 is optionally independently
replaced with --C(O)-- or a heteroatom; wherein the cycloalkyl and
heterocylcoalkyl within formulae (IIIa), (IIIb), (IIIc), (IIId),
(IIIe), and (IIIf) may optionally contain at least one double bond;
wherein in formulae (IIIa), (IIIb), (IIIc), and (IIId), at least
one of A.sub.1, A.sub.2, A.sub.3, A.sub.4, or A.sub.5 is selected
from --C(.dbd.N--R.sub.230)--, --C(.dbd.N--NH(alkyl))-,
--C(.dbd.N--N(alkyl)(alkyl))-,
C(.dbd.N--O--(CH.sub.2).sub.1-4--OH)--, --C(.dbd.CH--R.sub.230)--,
--C(.dbd.N--C(O)--R.sub.230)--, and
--C(.dbd.CH--C(O)--R.sub.230)--; wherein in formulae (IIIe) and
(IIIf), when A.sub.1, A.sub.2, and A.sub.6 are selected from
--(CH.sub.2).sub.0-2--, --CH(R.sub.200)--, --C(R.sub.200).sub.2--,
--O--, --C(O)--, --S(O).sub.0-2--, --NH--, --NR.sub.220--,
--N(CO).sub.0-1R.sub.200--, and --N(S(O.sub.2)alkyl)-, at least one
carbon of the aryl ring group within (IIIe) and (IIIf) is
optionally independently replaced with a group selected from --N--,
--NH--, --O--, --C(O)--, and --S(O).sub.0-2--; wherein each aryl or
heteroaryl group attached directly or indirectly to R.sub.C is
optionally substituted with at least one group independently
selected from R.sub.200; wherein each cycloalkyl or
heterocycloalkyl attached directly or indirectly to R.sub.C is
optionally substituted with at least one group independently
selected from R.sub.210; and R.sub.X is selected from aryl,
heteroaryl, cycloalkyl, heterocycloalkyl, and --R.sub.xa--R.sub.xb,
wherein R.sub.xa and R.sub.xb are independently selected from aryl,
heteroaryl, cycloalkyl, and heterocycloalkyl; wherein each aryl or
heteroaryl group of R.sub.X is optionally substituted with at least
one group independently selected from R.sub.200; wherein each
cycloalkyl or heterocycloalkyl of R.sub.X is optionally substituted
with at least one group independently selected from R.sub.210; and
wherein at least one carbon of the heteroaryl or heterocycloalkyl
group of R.sub.X is independently optionally replaced with a group
independently selected from --NH--, --N--,
--N(CO).sub.0-1R.sub.215--, --N(CO).sub.0-1R.sub.220--, --O--,
--C(O)--, --S(O).sub.0-2--, and --NS(O).sub.0-2R.sub.200; R.sub.200
at each occurrence is independently selected from -alkyl optionally
substituted with at least one group independently selected from
R.sub.205, --OH, --NO.sub.2, -halogen, --CN,
--(CH.sub.2).sub.0-4--C(O)H, --(CO).sub.0-1R.sub.215,
--(CO).sub.0-1R.sub.220,
--(CH.sub.2).sub.0-4--(CO).sub.0-1--NR.sub.220R.sub.225,
--(CH.sub.2).sub.0-4--(CO).sub.0-1--NH(R.sub.215),
--(CH.sub.2).sub.0-4--C(O)-alkyl,
--(CH.sub.2).sub.0-4--(CO).sub.0-1-cycloalkyl,
--(CH.sub.2).sub.0-4--(CO).sub.0-1-heterocycloalkyl,
--(CH.sub.2).sub.0-4--(CO).sub.0-1-aryl,
--(CH.sub.2).sub.0-4--(CO).sub.0-1-heteroaryl,
--(CH.sub.2).sub.0-4--C(O)--O--R.sub.215,
--(CH.sub.2).sub.0-4--SO.sub.2--NR.sub.220R.sub.225,
--(CH.sub.2).sub.0-4--S(O).sub.0-2-alkyl,
--(CH.sub.2).sub.0-4--S(O).sub.0-2-cycloalkyl,
--(CH.sub.2).sub.0-4--N(H or R.sub.215)--C(O)--O--R.sub.215,
--(CH.sub.2).sub.0-4--N(H or R.sub.215)--SO.sub.2--R.sub.220,
--(CH.sub.2).sub.0-4--N(H or R.sub.215)--C(O)--N(R.sub.215).sub.2,
--(CH.sub.2).sub.0-4--N(H or R.sub.215)--C(O)--R.sub.220,
--(CH.sub.2).sub.0-4--O--C(O)-alkyl,
--(CH.sub.2).sub.0-4--O--(R.sub.215),
--(CH.sub.2).sub.0-4--S--(R.sub.215), --(CH.sub.2).sub.0-4--O-alkyl
optionally substituted with at least one halogen, and -adamantane;
wherein each aryl and heteroaryl group included within R.sub.200 is
optionally substituted with at least one group independently
selected from R
.sub.205, R.sub.210, and alkyl (optionally substituted with at
least one group independently selected from R.sub.205 and
R.sub.210); wherein each cycloalkyl or heterocycloalkyl group
included within R.sub.200 is optionally substituted with at least
one group independently selected from R.sub.210; R.sub.205 at each
occurrence is independently selected from -alkyl, -haloalkoxy,
--(CH.sub.2).sub.0-3-cycloalkyl, -halogen,
--(CH.sub.2).sub.1-6--OH, --O-aryl, --OH, --SH,
--(CH.sub.2).sub.0-4--C(O)H, --(CH.sub.2).sub.0-6--CN,
--(CH.sub.2).sub.0-6--C(O)--NR.sub.235R.sub.240,
--(CH.sub.2).sub.0-6--C(O)--R.sub.235, --(CH.sub.2).sub.0-4--N(H or
R.sub.215)--SO.sub.2--R.sub.235, --OCF.sub.3, --CF.sub.3, -alkoxy,
-alkoxycarbonyl, and --NR.sub.235R.sub.240;R.sub.210 at each
occurrence is independently selected from --(CH.sub.2).sub.0-4--OH,
--(CH.sub.2).sub.0-4--CN, --(CH.sub.2).sub.0-4--C(O)H, -alkyl
optionally substituted with at least one group independently
selected from R.sub.205, -alkanoyl, --S-alkyl; --S(O).sub.2-alkyl,
-halogen, -alkoxy, -haloalkoxy, --NR.sub.220R.sub.225, -cycloalkyl
optionally substituted with at least one group independently
selected from R.sub.205, -heterocycloalkyl, -heteroaryl,
--(CH.sub.2).sub.0-4--NR.sub.235R.sub.240,
--(CH.sub.2).sub.0-4--NR.sub.235(alkoxy),
--(CH.sub.2).sub.0-4--S--(R.sub.215),
--(CH.sub.2).sub.0-4--NR.sub.235--C(O)H,
--(CH.sub.2).sub.0-4--NR.sub.235--C(O)-(alkoxy),
--(CH.sub.2).sub.0-4--NR.sub.235--C(O)--R.sub.240,
--C(O)--NHR.sub.215, --C(O)-alkyl, --C(O)--NR.sub.235R.sub.240, and
--S(O).sub.2--NR.sub.235R.sub.240; R.sub.215 at each occurrence is
independently selected from -alkyl, --(CH.sub.2).sub.0-2-aryl,
--(CH.sub.2).sub.0-2-cycloalkyl, --(CH.sub.2).sub.0-2-heteroaryl,
--(CH.sub.2).sub.0-2-heterocycloalkyl, and
--CO.sub.2--CH.sub.2-aryl; wherein the aryl group included within
R.sub.215 is optionally substituted with at least one group
independently selected from R.sub.205 and R.sub.210, and wherein
the heterocycloalkyl and heteroaryl groups included within
R.sub.215 are optionally substituted with at least one group
independently selected from R.sub.210; R.sub.220 and R.sub.225 at
each occurrence are independently selected from --H, -alkyl,
--(CH.sub.2).sub.0-4--C(O)H, -alkylhydroxyl, -alkoxycarbonyl,
-alkylamino, --S(O).sub.2-alkyl, -alkanoyl optionally substituted
with at least one halogen, --C(O)--NH.sub.2, --C(O)--NH(alkyl),
--C(O)--N(alkyl)(alkyl), -haloalkyl,
--(CH.sub.2).sub.0-2-cycloalkyl, -(alkyl)-O-(alkyl), -aryl,
-heteroaryl, and -heterocycloalkyl; wherein the aryl, heteroaryl,
cycloalkyl, and heterocycloalkyl groups included within R.sub.220
and R.sub.225 are each optionally substituted with at least one
group independently selected from R.sub.270; R.sub.270 at each
occurrence is independently selected from --R.sub.205, -alkyl
optionally substituted with at least one group independently
selected from R.sub.205, -aryl, -halogen, -alkoxy, -haloalkoxy,
--NR.sub.235R.sub.240, --OH, --CN, -cycloalkyl optionally
substituted with at least one group independently selected from
R.sub.205, --C(O)-alkyl, --S(O).sub.2--NR.sub.235R.sub.240,
--C(O)--NR.sub.235R.sub.240, --S(O).sub.2-alkyl, and
--(CH.sub.2).sub.0-4--C(O)H; R.sub.235 and R.sub.240 at each
occurrence are independently selected from --H, --OH, --CF.sub.3,
--OCH.sub.3, --NHCH.sub.3, --N(CH.sub.3).sub.2,
--(CH.sub.2).sub.0-4--C(O)(H or alkyl), -alkyl, -alkanoyl,
--SO.sub.2-alkyl, and -aryl.
12. The method according to claim 11, wherein the at least one
compound of formula (I) is selected from
4-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexylamino]-2-(3,5-difluor-
o-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-methoxyimino-cyclohexylamino]-2-(3,5-difluor-
o-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-ethoxyimino-cyclohexylamino]-2-(3,5-difluoro-
-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethoxyimino)-cyclohexylamino]-2-(-
3, -difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[4-(2-Amino-ethoxyimino)-1-(3-tert-butyl-phenyl)-cyclohexylamino]-2-(3,-
5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-2-hydroxyimino-hexahydro-pyrimidin-5-ylamino]--
2-(3,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-cyclohexylamino]-2-(3,5-d-
ifluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(dimethyl-hydrazono)-cyclohexylamino]-2-(3,5-
-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-cyanoimino-cyclohexylamino]-2-(3,5-difluoro--
benzyl)-3-hydroxy-N-methyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamino]-2-(3,-
5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-benzo[c]isoxazol-5-ylamino]-
-2-(3,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-methylcarbamoylmethylene-cyclohexylamino]-2--
(3,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
{4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-methylcar-
bamoyl-butylamino]-cyclohexylidene}-acetic acid methyl ester,
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethylidene)-cyclohexylamino]-2-(3-
,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexylamino]-2-(3,5-difluor-
o-benzyl)-3hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-methoxyimino-cyclohexylamino]-2-(3,5-difluor-
o-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-ethoxyimino-cyclohexylamino]-2-(3,5-difluoro-
-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethoxyimino)-cyclohexylamino]-2-(-
3,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[4-(2-Amino-ethoxyimino)-1-(3-tert-butyl-phenyl)-cyclohexylamino]-2-(3,-
5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-2-hydroxyimino-hexahydro-pyrimidin-5-ylamino]--
2-(3,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-cyclohexylamino]-2-(3,5-d-
ifluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(dimethyl-hydrazono)-cyclohexylamino]-2-(3,5-
-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-cyanoimino-cyclohexylamino]-2-(3,5-difluoro--
benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamino]-2-(3,-
5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-benzo[c]isoxazol-5-ylamino]-
-2-(3,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-methylcarbamoylmethylene-cyclohexylamino]-2--
(3,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
{4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-phenylcar-
bamoyl-butylamino]-cyclohexylidene}-acetic acid methyl ester,
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethylidene)-cyclohexylamino]-2-(3-
,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-(1H-imidaz-
ol-2-yl)-butylamino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-butylamino]--
cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[3-(3,5-difluoro-phenoxy)-2-hydroxy-propylamino-
]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[3-(3,5-difluoro-benzenesulfonyl)-2-hydroxy-pro-
pylamino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-4-oxo-butyla-
mino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-pentylamino]-
-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-pentylamino]-
-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-tetrazol-1-
-yl-butylamino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-(5-trifluo-
romethyl-[1,3,4]oxadiazol-2-yl)-butylamino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-([1,2,4]th-
iadiazol-5-ylamino)-butylamino]-cyclohexanone oxime,
3-[3-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexylamino]-1-(3,5-difl-
uoro-benzyl)-2-hydroxy-propylamino]-4-methylamino-cyclobut-3-ene-1,2-dione-
,
3-[3-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexylamino]-1-(3,5-dif-
luoro-benzyl)-2-hydroxy-propylamino]-4-methoxy-cyclobut-3-ene-1,2-dione,
4-(3-tert-Butyl-phenyl)-4-[2-hydroxy-4-(3-propyl-thiophen-2-yl)-3-([1,2,4-
]thiadiazol-5-ylamino)-butylamino]-cyclohexanone oxime,
1-(5-(3-tert-butylphenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamino)-4-(3,5-
-difluorophenyl)butan-2-ol and
1-(5-(3-tert-butylphenyl)-2-methyl-4,5,6,7-tetrahydro-2H-indazol-5-ylamin-
o)-4-(3,5-difluorophenyl)butan-2-ol.
13. A method of preventing or treating at least one condition
associated with amyloidosis, comprising: administering to a host a
composition comprising a therapeutically effective amount of at
least one selective beta-secretase inhibitor of formula (I), or
pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2
and R.sub.C are as defined in claim 11.
14. The method according to claim 11, wherein the aspartyl protease
is beta-secretase and the condition is Alzheimer's disease.
15. The method according to claim 11, wherein the aspartyl protease
is beta-secretase and the condition is dementia.
16. A method of preventing or treating at least one condition
associated with amyloidosis, comprising: administering to a host a
composition comprising a therapeutically effective amount of at
least one selective beta-secretase inhibitor of formula (I),
further comprising a composition including beta-secretase complexed
with at least one compound of formula (I), or pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2 and R.sub.c are
as defined in claim 11.
17. A method of inhibiting beta-secretase activity in a host, the
method comprising the step of administering to the host an
effective amount of at least one compound of formula (I) or at
least one pharmaceutically acceptable salt thereof, wherein
R.sub.1, R.sub.2 and R.sub.c are as defined in claim 11.
18. A method of affecting beta-secretase-mediated cleavage of
amyloid precursor protein in a patient, comprising administering a
therapeutically effective amount of at least one compound of
formula (I), or at least one pharmaceutically acceptable salt
thereof, wherein R.sub.1, R.sub.2 and R.sub.c are as defined in
claim 11.
19. A method of inhibiting cleavage of amyloid precursor protein at
a site between Met596 and Asp597 (numbered for the APP-695 amino
acid isotype), or at a corresponding site of an isotype or mutant
thereof, comprising: administering a therapeutically effective
amount of at least one compound of formula (I), or at least one
pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2
and R.sub.c are as defined in claim 11.
20. A method of inhibiting cleavage of amyloid precursor protein or
mutant thereof at a site between amino acids, comprising:
administering a therapeutically effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2 and R.sub.c are
as defined in claim 11, and wherein the site between amino acids
corresponds to between Met652 and Asp653 (numbered for the APP-751
isotype); between Met671 and Asp672 (numbered for the APP-770
isotype); between Leu596 and Asp597 of the APP-695 Swedish
Mutation; between Leu652 and Asp653 of the APP-751 Swedish
Mutation; or between Leu671 and Asp672 of the APP-770 Swedish
Mutation.
21. A method of inhibiting production of A-beta, comprising:
administering to a patient a therapeutically effective amount of at
least one compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2 and R.sub.c are
as defined in claim 1.
22. A method of preventing, delaying, halting, or reversing a
disease characterized by A-beta deposits or plaques, comprising:
administering a therapeutically effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2 and R.sub.c are
as defined in claim 11.
23. The method in claim 22, wherein the A-beta deposits or plaques
are in a human brain.
24. A method of interacting an inhibitor with beta-secretase,
comprising: administering to a patient in need thereof a
therapeutically effective amount of at least one compound of
formula (I), or at least one pharmaceutically acceptable salt
thereof, wherein R.sub.1, R.sub.2 and R.sub.c are as defined in
claim 11, and wherein the at least one compound interacts with at
least one of the following beta-secretase subsites S1, S1', and
S2'.
25. A method of modifying the pharmacokinetic parameters of a
pharmaceutical composition comprising at least one compound of
formula (I) wherein R.sub.1, R.sub.2 and R.sub.C are as defined in
claim 11, further comprising increasing at least one parameter
selected from C.sub.max, T.sub.max, and half-life.
26. A method of treating a condition in a patient, comprising:
administering a therapeutically effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt, derivative or biologically active metabolite
thereof, to the patient, wherein R.sub.1, R.sub.2, and R.sub.c are
defined as in claim 11.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority under 35
U.S.C. .sctn. 119(e) to U.S. Provisional Application 60/586,207,
filed Jul. 9, 2004, U.S. Provisional Application 60/608,143, filed
Sep. 9, 2004, U.S. Provisional Application 60/656,873, filed Mar.
1, 2005, and U.S. Provisional Application 60/681,138, filed May 16,
2005, incorporated herein by reference in full.
FIELD OF THE PRESENT INVENTION
[0002] The present invention is directed to novel compounds and
also to methods of treating at least one condition, disorder, or
disease associated with amyloidosis using such compounds.
BACKGROUND OF THE PRESENT INVENTION
[0003] Amyloidosis refers to a collection of conditions, disorders,
and diseases associated with abnormal deposition of amyloidal
protein. For instance, Alzheimer's disease is believed to be caused
by abnormal deposition of amyloidal protein in the brain. Thus,
these amyloidal protein deposits, otherwise known as amyloid-beta
peptide, A-beta, or betaA4, are the result of proteolytic cleavage
of the amyloid precursor protein (APP).
[0004] The majority of APP molecules that undergo proteolytic
cleavage are cleaved by the aspartyl protease alpha-secretase.
Alpha-secretase cleaves APP between Lys687 and Leu688 producing a
large, soluble fragment, alpha-sAPP, which is a secreted form of
APP that does not result in beta-amyloid plaque formation. The
alpha-secretase cleavage pathway precludes the formation of A-beta,
thus providing an alternate target for preventing or treating
amyloidosis.
[0005] Some APP molecules, however, are cleaved by a different
aspartyl protease known as beta-secretase which is also referred to
in the literature as BACE, BACE1, Asp2, and Memapsin2.
Beta-secretase cleaves APP after Met671, creating a C-terminal
fragment. See, for example, Sinha et al., Nature, (1999),
402:537-554 and published PCT application WO 00/17369. After
cleavage of APP by beta-secretase, an additional aspartyl protease,
gamma-secretase, may then cleave the C-terminus of this fragment,
at either Val711 or Ile713, (found within the APP transmembrane
domain), generating an A-beta peptide. The A-beta peptide may then
proceed to form beta-amyloid plaques. A detailed description of the
proteolytic processing of APP fragments is found, for example, in
U.S. Pat. Nos. 5,441,870, 5,721,130, and 5,942,400.
[0006] The amyloidal disease Alzheimer's is a progressive
degenerative disease that is characterized by two major pathologic
observations in the brain which are (1) neurofibrillary tangles,
and (2) beta-amyloid (or neuritic) plaques. A major factor in the
development of Alzheimer's disease is A-beta deposits in regions of
the brain responsible for cognitive activities. These regions
include, for example, the hippocampus and cerebral cortex. A-beta
is a neurotoxin that may be causally related to neuronal death
observed in Alzheimer's disease patients. See, for example, Selkoe,
Neuron, 6 (1991) 487. Since A-beta peptide accumulates as a result
of APP processing by beta-secretase, inhibiting beta-secretase's
activity is desirable for the treatment of Alzheimer's disease.
[0007] Dementia-characterized disorders also arise from A-beta
accumulation in the brain including accumulation in cerebral blood
vessels (known as vasculary amyloid angiopathy) such as in the
walls of meningeal and parenchymal arterioles, small arteries,
capillaries, and venules. A-beta may also be found in cerebrospinal
fluid of both individuals with and without Alzheimer's disease.
Additionally, neurofibrillary tangles similar to the ones observed
in Alzheimer's patients can also be found in individuals without
Alzheimer's disease. In this regard, a patient exhibiting symptoms
of Alzheimer's due to A-beta deposits and neurofibrillary tangles
in their cerebrospinal fluid may in fact be suffering from some
other form of dementia. See, for example, Seubert et al., Nature,
359 (1992) 325-327. Examples of other forms of dementia where
A-beta accumulation generates amyloidogenic plaques or results in
vascular amyloid angiopathy include Trisomy 21 (Down's Syndrome),
Hereditary Cerebral Hemorrhage with amyloidosis of the Dutch-Type
(HCHWA-D), and other neurodegenerative disorders. Consequently,
inhibiting beta-secretase is not only desirable for the treatment
of Alzheimer's, but also for the treatment of other conditions
associated with amyloidosis.
[0008] Amyloidosis is also implicated in the pathophysiology of
stroke. Cerebral amyloid angiopathy is a common feature of the
brains of stroke patients exhibiting symptoms of dementia, focal
neurological syndromes, or other signs of brain damage. See, for
example, Corio et al., Neuropath Appl. Neurobiol., 22 (1996)
216-227. This suggests that production and deposition of A-beta may
contribute to the pathology of Alzheimer's disease, stroke, and
other diseases and conditions associated with amyloidosis.
Accordingly, the inhibition of A-beta production is desirable for
the treatment of Alzheimer's disease, stroke, and other diseases
and conditions associated with amyloidosis.
[0009] Presently there are no known effective treatments for
preventing, delaying, halting, or reversing the progression of
Alzheimer's disease and other conditions associated with
amyloidosis. Consequently, there is an urgent need for methods of
treatment capable of preventing and treating conditions associated
with amyloidosis including Alzheimer's disease.
[0010] Likewise, there is a need for methods of treatment using
compounds that inhibit beta-secretase-mediated cleavage of APP.
There is also a need for methods of treatment using compounds that
are effective inhibitors of A-beta production, and/or are effective
at reducing A-beta deposits or plaques, as well as methods of
treatment capable of combating diseases and conditions
characterized by amyloidosis, or A-beta deposits, or plaques.
[0011] There is also a need for methods of treating conditions
associated with amyloidosis using compounds that are efficacious,
bioavailable and/or selective for beta-secretase. An increase in
efficacy, selectivity, and/or oral bioavailability may result in
preferred, safer, less expensive products that are easier for
patients to use.
[0012] There is also a need for methods of treating at least one
condition associated with amyloidosis using compounds with
characteristics that would allow them to cross the
blood-brain-barrier. Desirable characteristics include a low
molecular weight and a high log P (increased log P=increased
lipophilicity).
[0013] Generally, known aspartyl protease inhibitors are either
incapable of crossing the blood-brain barrier or do so with great
difficulty. These compounds are unsuitable for the treatment of the
conditions described herein. Accordingly, there is a need for
methods of treating at least one condition associated with
amyloidosis using compounds that can readily cross the blood-brain
barrier and inhibit beta-secretase.
[0014] There is also a need for a method of finding suitable
compounds for inhibiting beta-secretase activity, inhibiting
cleavage of APP, inhibiting production of A-beta, and/or reducing
A-beta deposits or plaques.
[0015] The present invention is directed to novel compounds and
also to methods of treating at least one condition, disorder, or
disease associated with amyloidosis using such compounds. An
embodiment of the present invention is compounds of formula (I) or
at least one pharmaceutically acceptable salt thereof, wherein
R.sub.1, R.sub.2, and R.sub.C are defined below. Another embodiment
of the present invention is a method of administering at least one
compound of formula (I) or at least one pharmaceutically acceptable
salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are defined
below, in treating at least one condition, disorder, or disease
associated with amyloidosis. Another embodiment is directed to
methods of treatment comprising administering at least one compound
of formula (I) or at least one pharmaceutically acceptable salt
thereof, wherein R.sub.1, R.sub.2, and R.sub.C are defined below,
useful in preventing, delaying, halting, or reversing the
progression of Alzheimer's disease.
[0016] Another embodiment of the present invention is directed to
uses of beta-secretase inhibitors of at least one compound of
formula (I) or at least one pharmaceutically acceptable salt
thereof, wherein R.sub.1, R.sub.2, and R.sub.C are defined below,
in treating or preventing at least one condition, disorder, or
disease associated with amyloidosis.
[0017] Another embodiment of the present invention is the
administration of beta-secretase inhibitors of at least one
compound of formula (I) or at least one pharmaceutically acceptable
salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are defined
below, exhibiting at least one property chosen from improved
efficacy, bioavailability, selectivity, and blood-brain barrier
penetrating properties. The present invention accomplishes one or
more of these objectives and provides further related
advantages.
BRIEF SUMMARY OF THE PRESENT INVENTION
[0018] The present invention is directed to novel compounds and
also to methods of treating at least one condition, disorder, or
disease associated with amyloidosis using such compounds. The
present invention is directed to compounds of formula (I) or at
least one pharmaceutically acceptable salt thereof, wherein
R.sub.1, R.sub.2, and R.sub.C are defined below, and methods of
treating at least one condition, disorder, or disease associated
with amyloidosis. As previously noted, amyloidosis refers to a
collection of diseases, disorders, and conditions associated with
abnormal deposition of A-beta protein.
[0019] An embodiment of the present invention is to provide
compounds having properties contributing to viable pharmaceutical
compositions. These properties include improved efficacy,
bioavailability, selectivity, and/or blood-brain barrier
penetrating properties. They can be inter-related, though an
increase in any one of them correlates to a benefit for the
compound and its corresponding method of treatment. For example, an
increase in any one of these properties may result in preferred,
safer, less expensive products that are easier for patients to
use.
[0020] Accordingly, an embodiment of the present invention is to
provide compounds of formula (I), ##STR1## or pharmaceutically
acceptable salts thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
defined below.
[0021] Another embodiment of the present invention is a method of
preventing or treating at least one condition that benefits from
inhibition of at least one aspartyl-protease, comprising
administering to a host a composition comprising a therapeutically
effective amount of at least one compound of formula (I), ##STR2##
or at least one pharmaceutically acceptable salt thereof, wherein
R.sub.1, R.sub.2, and R.sub.C are defined below.
[0022] Another embodiment is to provide selective compounds of
formula (I), ##STR3## or pharmaceutically acceptable salts thereof,
wherein R.sub.1, R.sub.2, and R.sub.C are defined below.
[0023] Another embodiment is to provide efficacious compounds of
formula (I), ##STR4## or pharmaceutically acceptable salts thereof,
wherein the inhibition is at least 10% for a dose of about 100
mg/kg or less, and wherein R.sub.1, R.sub.2, and R.sub.C are
defined below.
[0024] Another embodiment is to provide orally bioavailable
compounds of formula (I), ##STR5## or pharmaceutically acceptable
salts thereof, wherein said compound has an F value of at least
10%, and wherein R.sub.1, R.sub.2, and R.sub.C are defined
below.
[0025] Another embodiment of the present invention provides a
method for preventing or treating at least one condition that
benefits from inhibition of at least one aspartyl-protease,
comprising administering to a host at least one compound of formula
(I), or pharmaceutically acceptable salts thereof, wherein the
inhibition is at least 10% for a dose of 100 mg/kg or less, and
wherein R.sub.1, R.sub.2, and R.sub.C are defined below.
[0026] Another embodiment of the present invention provides a
method for preventing or treating at least one condition that
benefits from inhibition of at least one aspartyl-protease,
comprising administering to a host a composition comprising a
therapeutically effective amount of at least one compound of
formula (I), or pharmaceutically acceptable salts thereof, wherein
R.sub.1, R.sub.2, and R.sub.C are as defined below.
[0027] Another embodiment of the present invention provides a
method of preventing or treating at least one condition that
benefits from inhibition of at least one aspartyl-protease,
comprising administering to a host a composition comprising a
therapeutically effective amount of at least one compound of
formula (I), or pharmaceutically acceptable salts thereof, wherein
the inhibition is at least 10% for a dose of 100 mg/kg or less, and
wherein R.sub.1, R.sub.2, and R.sub.C are as defined below.
[0028] Another embodiment provides a method of preventing or
treating at least one condition that benefits from inhibition of
beta-secretase, comprising administering to a host a composition
comprising a therapeutically effective amount of at least one
compound of formula (I), or pharmaceutically acceptable salts
thereof, wherein the inhibition is at least 10% for a dose of 100
mg/kg or less, and wherein R.sub.1, R.sub.2, and R.sub.C are as
defined below.
[0029] In another embodiment, the present invention provides a
method for preventing or treating at least one condition associated
with amyloidosis, comprising administering to a patient in need
thereof a therapeutically effective amount of at least one compound
of formula (I), or at least one pharmaceutically acceptable salt
thereof, the compound having an F value of at least 10%, wherein
R.sub.1, R.sub.2, and R.sub.C are as defined below.
[0030] In another embodiment, the present invention provides a
method of preventing or treating at least one condition associated
with amyloidosis, comprising administering to a host a composition
comprising a therapeutically effective amount of at least one
selective beta-secretase inhibitor of formula (I), or
pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2,
and R.sub.C are as defined below.
[0031] In another embodiment, the present invention provides a
method of preventing or treating Alzheimer's disease by
administering to a host an effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as defined below.
[0032] In another embodiment, the present invention provides a
method of preventing or treating dementia by administering to a
host an effective amount of at least one compound of formula (I),
or pharmaceutically acceptable salt thereof, wherein R.sub.1,
R.sub.2, and R.sub.C are as defined below.
[0033] In another embodiment, the present invention provides a
method of inhibiting beta-secretase activity in a host, the method
comprising administering to the host an effective amount of at
least one compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as defined below.
[0034] In another embodiment, the present invention provides a
method of inhibiting beta-secretase activity in a cell, the method
comprising administering to the cell an effective amount of at
least one compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as defined below.
[0035] In another embodiment, the present invention provides a
method of inhibiting beta-secretase activity in a host, the method
comprising administering to the host an effective amount of at
least one compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein the host is a human, and wherein
R.sub.1, R.sub.2, and R.sub.C are as defined below.
[0036] In another embodiment, the present invention provides a
method of affecting beta-secretase-mediated cleavage of amyloid
precursor protein in a patient, comprising administering a
therapeutically effective amount of at least one compound of
formula (I), or at least one pharmaceutically acceptable salt
thereof, wherein R.sub.1, R.sub.2, and R.sub.C are as defined
below.
[0037] In another embodiment, the present invention provides a
method of inhibiting cleavage of amyloid precursor protein at a
site between Met596 and Asp597 (numbered for the APP-695 amino acid
isotype), or at a corresponding site of an isotype or mutant
thereof, comprising administering a therapeutically effective
amount of at least one compound of formula (I), or at least one
pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2,
and R.sub.C are as defined below.
[0038] In another embodiment, the present invention provides a
method of inhibiting production of A-beta, comprising administering
to a patient a therapeutically effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as defined below.
[0039] In another embodiment, the present invention provides a
method of preventing or treating deposition of A-beta, comprising
administering a therapeutically effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as defined below.
[0040] In another embodiment, the present invention provides a
method of preventing, delaying, halting, or reversing a disease
characterized by A-beta deposits or plaques, comprising
administering a therapeutically effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as defined below.
[0041] In another embodiment, the A-beta deposits or plaques are in
a human brain.
[0042] In another embodiment, the present invention provides a
method of inhibiting the activity of at least one aspartyl protease
in a patient in need thereof, comprising administering a
therapeutically effective amount of at least one compound of
formula (I), or at least one pharmaceutically acceptable salt
thereof, wherein R.sub.1, R.sub.2, and R.sub.C are as defined
below.
[0043] In another embodiment, the at least one aspartyl protease is
beta-secretase.
[0044] In another embodiment, the present invention provides a
method of interacting an inhibitor with beta-secretase, comprising
administering to a patient in need thereof a therapeutically
effective amount of at least one compound of formula (I), or at
least one pharmaceutically acceptable salt thereof, wherein
R.sub.1, R.sub.2, and R.sub.C are as defined below, wherein the at
least one compound interacts with at least one beta-secretase
subsite such as S1, S1', or S2'.
[0045] In another embodiment, the present invention provides an
article of manufacture, comprising (a) at least one dosage form of
at least one compound of formula (I), or pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
defined below, (b) a package insert providing that a dosage form
comprising a compound of formula (I) should be administered to a
patient in need of therapy for at least one disorder, condition or
disease associated with amyloidosis, and (c) at least one container
in which at least one dosage form of at least one compound of
formula (I) is stored.
[0046] In another embodiment, the present invention provides a
packaged pharmaceutical composition for treating at least one
condition related to amyloidosis, comprising (a) a container which
holds an effective amount of at least one compound of formula (I),
or at least one pharmaceutically acceptable salt thereof, wherein
R.sub.1, R.sub.2, and R.sub.C are as defined below, and (b)
instructions for using the pharmaceutical composition.
Definitions
[0047] Throughout the specification and claims, including the
detailed description below, the following definitions apply.
[0048] It should be noted that, as used in this specification and
the appended claims, the singular forms "a," "an," and "the"
include plural referents unless the content clearly dictates
otherwise. Thus, for example, reference to a composition containing
"a compound" includes a mixture of two or more compounds. It should
also be noted that the term "or" is generally employed in its sense
including "and/or" unless the content clearly dictates
otherwise.
[0049] Where multiple substituents are indicated as being attached
to a structure, it is to be understood that the substituents can be
the same or different.
[0050] APP, amyloid precursor protein, is defined as any APP
polypeptide, including APP variants, mutations, and isoforms, for
example, as disclosed in U.S. Pat. No. 5,766,846.
[0051] Beta-amyloid peptide (A-beta peptide) is defined as any
peptide resulting from beta-secretase mediated cleavage of APP,
including, for example, peptides of 39, 40, 41, 42, and 43 amino
acids, and extending from the beta-secretase cleavage site to amino
acids 39, 40, 41, 42, or 43.
[0052] Beta-secretase is an aspartyl protease that mediates
cleavage of APP at the N-terminus edge of A-beta. Human
beta-secretase is described, for example, in WO 00/17369.
[0053] The term "complex" as used herein refers to an
inhibitor-enzyme complex, wherein the inhibitor is a compound of
formula (I) described herein and wherein the enzyme is
beta-secretase or a fragment thereof.
[0054] The term "host" as used herein refers to a cell or tissue,
in vitro or in vivo, an animal, or a human.
[0055] The term "treating" refers to administering a compound or a
composition of formula (I) to a host having at least a tentative
diagnosis of disease or condition. The methods of treatment and
compounds of the present invention will delay, halt, or reverse the
progression of the disease or condition thereby giving the host a
longer and/or more functional life span.
[0056] The term "preventing" refers to administering a compound or
a composition of formula (I) to a host who has not been diagnosed
as having the disease or condition at the time of administration,
but who could be expected to develop the disease or condition or be
at increased risk for the disease or condition. The methods of
treatment and compounds of the present invention may slow the
development of disease symptoms, delay the onset of the disease or
condition, halt the progression of disease development, or prevent
the host from developing the disease or condition at all.
Preventing also includes administration of at least one compound or
a composition of the present invention to those hosts thought to be
predisposed to the disease or condition due to age, familial
history, genetic or chromosomal abnormalities, due to the presence
of one or more biological markers for the disease or condition,
such as a known genetic mutation of APP or APP cleavage products in
brain tissues or fluids, and/or due to environmental factors.
[0057] The term "halogen" in the present invention refers to
fluorine, bromine, chlorine, or iodine.
[0058] The term "alkyl" in the present invention refers to straight
or branched chain alkyl groups having 1 to 20 carbon atoms. An
alkyl group may optionally comprise at least one double bond and/or
at least one triple bond. The alkyl groups herein are unsubstituted
or substituted in one or more positions with various groups. For
example, such alkyl groups may be optionally substituted with at
least one group independently selected from alkyl, alkoxy, --C(O)H,
carboxy, alkoxycarbonyl, cycloalkyl, heterocycloalkyl, aryl,
heteroaryl, amido, alkanoylamino, amidino, alkoxycarbonylamino,
N-alkyl amidino, N-alkyl amido, N,N'-dialkylamido,
aralkoxycarbonylamino, halogen, alkyl thio, alkylsulfinyl,
alkylsulfonyl, hydroxy, cyano, nitro, amino, monoalkylamino,
dialkylamino, haloalkyl, haloalkoxy, aminoalkyl,
monoalkylaminoalkyl, dialkylaminoalkyl, and the like. Additionally,
at least one carbon within any such alkyl may be optionally
replaced with --C(O)--.
[0059] Examples of alkyls include methyl, ethyl, ethenyl, ethynyl,
propyl, 1-ethyl-propyl, propenyl, propynyl, isopropyl, n-butyl,
isobutyl, sec-butyl, tert-butyl, 2-methylbutyl, 3-methyl-butyl,
1-but-3-enyl, butynyl, pentyl, 2-pentyl, isopentyl, neopentyl,
3-methylpentyl, 1-pent-3-enyl, 1-pent-4-enyl, pentyn-2-yl, hexyl,
2-hexyl, 3-hexyl, 1-hex-5-enyl, formyl, acetyl, acetylamino,
trifluoromethyl, propionic acid ethyl ester, trifluoroacetyl,
methylsulfonyl, ethylsulfonyl, 1-hydroxy-1-methylethyl,
2-hydroxy-1,1-dimethyl-ethyl, 1,1-dimethyl-propyl,
cyano-dimethyl-methyl, propylamino, and the like.
[0060] In an embodiment, alkyls may be selected from sec-butyl,
isobutyl, ethynyl, 1-ethyl-propyl, pentyl, 3-methyl-butyl,
pent-4-enyl, isopropyl, tert-butyl, 2-methylbutane, and the
like.
[0061] In another embodiment, alkyls may be selected from formyl,
acetyl, acetylamino, trifluoromethyl, propionic acid ethyl ester,
trifluoroacetyl, methylsulfonyl, ethylsulfonyl,
1-hydroxy-1-methylethyl, 2-hydroxy-1,1,-dimethyl-ethyl,
1,1-dimethyl-propyl, cyano-dimethyl-methyl, propylamino, and the
like.
[0062] The term "alkoxy" in the present invention refers to
straight or branched chain alkyl groups, wherein an alkyl group is
as defined above, and having 1 to 20 carbon atoms, attached through
at least one divalent oxygen atom, such as, for example, methoxy,
ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy,
pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, allyloxy,
2-(2-methoxy-ethoxy)-ethoxy, benzyloxy, 3-methylpentoxy, and the
like.
[0063] In an embodiment, alkoxy groups may be selected from
allyloxy, hexyloxy, heptyloxy, 2-(2-methoxy-ethoxy)-ethoxy,
benzyloxy, and the like.
[0064] The term "--C(O)-alkyl" or "alkanoyl" refers to an acyl
group derived from an alkylcarboxylic acid, a cycloalkylcarboxylic
acid, a heterocycloalkylcarboxylic acid, an arylcarboxylic acid, an
arylalkylcarboxylic acid, a heteroarylcarboxylic acid, or a
heteroarylalkylcarboxylic acid, examples of which include formyl,
acetyl, 2,2,2-trifluoroacetyl, propionyl, butyryl, valeryl,
4-methylvaleryl, and the like.
[0065] The term "cycloalkyl" refers to an optionally substituted
carbocyclic ring system of one or more 3, 4, 5, 6, 7, or 8 membered
rings, including 9, 10, 11, 12, 13, and 14 membered fused ring
systems, all of which can be saturated or partially unsaturated.
The cycloalkyl may be monocyclic, bicyclic, tricyclic, and the
like. Bicyclic and tricyclic as used herein are intended to include
both fused ring systems, such as adamantyl, octahydroindenyl,
decahydro-naphthyl, and the like, substituted ring systems, such as
cyclopentylcyclohexyl, and spirocycloalkyls such as
spiro[2.5]octane, spiro[4.5]decane, 1,4-dioxa-spiro[4.5]decane, and
the like. A cycloalkyl may optionally be a benzo fused ring system,
which is optionally substituted as defined herein with respect to
the definition of aryl. At least one --CH.sub.2-- group within any
such cycloalkyl ring system may be optionally replaced with
--C(O)--, --C(S)--, --C(.dbd.N--H)--, --C(.dbd.N--OH)--,
--C(.dbd.N-alkyl)- (optionally substituted as defined herein with
respect to the definition of alkyl), or --C(.dbd.N--O-alkyl)-
(optionally substituted as defined herein with respect to the
definition of alkyl).
[0066] Further examples of cycloalkyl groups include cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, octahydronaphthyl,
2,3-dihydro-1H-indenyl, and the like.
[0067] In an embodiment, a cycloalkyl may be selected from
cyclopentyl, cyclohexyl, cycloheptyl, adamantenyl,
bicyclo[2.2.1]heptyl, and the like.
[0068] The cycloalkyl groups herein are unsubstituted or
substituted in at least one position with various groups. For
example, such cycloalkyl groups may be optionally substituted with
alkyl, alkoxy, --C(O)H, carboxy, alkoxycarbonyl, cycloalkyl,
heterocycloalkyl, aryl, heteroaryl, amido, alkanoylamino, amidino,
alkoxycarbonylamino, N-alkyl amidino, N-alkyl amido,
N,N'-dialkylamido, aralkoxycarbonylamino, halogen, alkylthio,
alkylsulfinyl, alkylsulfonyl, hydroxy, cyano, nitro, amino,
monoalkylamino, dialkylamino, haloalkyl, haloalkoxy, aminoalkyl,
monoalkylaminoalkyl, dialkylaminoalkyl, and the like.
[0069] The term "cycloalkylcarbonyl" refers to an acyl group of the
formula cycloalkyl-C(O)-- in which the term "cycloalkyl" has the
significance given above, such as cyclopropylcarbonyl,
cyclohexylcarbonyl, adamantylcarbonyl,
1,2,3,4-tetrahydro-2-naphthoyl,
2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl,
1-hydroxy-1,2,3,4-tetrahydro-6-naphthoyl, and the like.
[0070] The term "heterocycloalkyl," "heterocycle," or
"heterocyclyl," refers to a monocyclic, bicyclic or tricyclic
heterocycle group, containing at least one nitrogen, oxygen or
sulfur atom ring member and having 3 to 8 ring members in each
ring, wherein at least one ring in the heterocycloalkyl ring system
may optionally contain at least one double bond. At least one
--CH.sub.2-- group within any such heterocycloalkyl ring system may
be optionally replaced with --C(O)--, --C(S)--, --C(N)--,
--C(.dbd.N--H)--, --C(.dbd.N--OH)--, --C(.dbd.N-alkyl)- (optionally
substituted as defined herein with respect to the definition of
alkyl), or --C(.dbd.N--O-alkyl)- (optionally substituted as defined
herein with respect to the definition of alkyl).
[0071] The terms "bicyclic" and "tricyclic" as used herein are
intended to include both fused ring systems, such as
2,3-dihydro-1H-indole, and substituted ring systems, such as
bicyclohexyl. At least one --CH.sub.2-- group within any such
heterocycloalkyl ring system may be optionally replaced with
--C(O)--, --C(N)-- or --C(S)--. Heterocycloalkyl is intended to
include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring
members, and carbocyclic fused and benzo fused ring systems wherein
the benzo fused ring system is optionally substituted as defined
herein with respect to the definition of aryl. Such
heterocycloalkyl groups may be optionally substituted on one or
more carbon atoms by halogen, alkyl, alkoxy, cyano, nitro, amino,
alkylamino, dialkylamino, monoalkylaminoalkyl, dialkylaminoalkyl,
haloalkyl, haloalkoxy, aminohydroxy, oxo, aryl, aralkyl,
heteroaryl, heteroaralkyl, amidino, N-alkylamidino,
alkoxycarbonylamino, alkylsulfonylamino, and the like, and/or on a
secondary nitrogen atom (i.e., --NH--) by hydroxy, alkyl,
aralkoxycarbonyl, alkanoyl, heteroaralkyl, phenyl, phenylalkyl, and
the like.
[0072] Examples of a heterocycloalkyl include morpholinyl,
thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl
S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl,
pyrrolinyl, 2,5-dihydro-pyrrolyl, tetrahydropyranyl, pyranyl,
thiopyranyl, piperidinyl, tetrahydrofuranyl, tetrahydrothienyl,
imidazolidinyl, homopiperidinyl, 1,2-dihydro-pyridinyl,
homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl
S,S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl,
1,4-dioxa-spiro[4.5]decyl, dihydropyrazinyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl
S-oxide, tetrahydrothienyl S,S-dioxide, homothiomorpholinyl
S-oxide, 2-oxo-piperidinyl, 5-oxo-pyrrolidinyl,
2-oxo-1,2-dihydro-pyridinyl, 6-oxo-6H-pyranyl,
1,1-dioxo-hexahydro-thiopyranyl, 1-acetyl-piperidinyl,
1-methanesulfonylpiperidinyl, 1-ethanesulfonylpiperidinyl,
1-oxo-hexahydro-thiopyranyl, 1-(2,2,2-trifluoroacetyl)-piperidinyl,
1-formyl-piperidinyl, and the like.
[0073] In an embodiment, a heterocycloalkyl may be selected from
pyrrolidinyl, 2,5-dihydro-pyrrolyl, piperidinyl,
1,2-dihydro-pyridinyl, pyranyl, piperazinyl, imidazolidinyl,
thiopyranyl, tetrahydropyranyl, 1,4-dioxa-spiro[4.5]decyl, and the
like.
[0074] In another embodiment, a heterocycloalkyl may be selected
from 2-oxo-piperidinyl, 5-oxo-pyrrolidinyl,
2-oxo-1,2-dihydro-pyridinyl, 6-oxo-6H-pyranyl,
1,1-dioxo-hexahydro-thiopyranyl, 1-acetyl-piperidinyl,
1-methanesulfonyl piperidinyl, 1-ethanesulfonylpiperidinyl,
1-oxo-hexahydro-thiopyranyl, 1-(2,2,2-trifluoroacetyl)-piperidinyl;
1-formyl-piperidinyl, and the like.
[0075] The term "aryl" refers to an aromatic carbocyclic group
having a single ring (e.g., phenyl) or multiple condensed rings in
which at least one ring is aromatic. The aryl may be monocyclic,
bicyclic, tricyclic, etc. Bicyclic and tricyclic as used herein are
intended to include both fused ring systems, such as naphthyl and
.beta.-carbolinyl, and substituted ring systems, such as biphenyl,
phenylpyridyl, diphenylpiperazinyl, tetrahydronaphthyl, and the
like. Preferred aryl groups of the present invention are phenyl,
1-naphthyl, 2-naphthyl, indanyl, indenyl, dihydronaphthyl,
fluorenyl, tetralinyl or
6,7,8,9-tetrahydro-5H-benzo[a]cycloheptenyl. The aryl groups herein
are unsubstituted or substituted in one or more positions with
various groups. For example, such aryl groups may be optionally
substituted with alkyl, alkoxy, C(O)H, carboxy, alkoxycarbonyl,
aryl, heteroaryl, cycloalkyl, heterocycloalkyl, amido,
alkanoylamino, amidino, alkoxycarbonylamino, N-alkyl amidino,
N-alkyl amido, N,N'-dialkylamido, aralkoxycarbonylamino, halogen,
alkyl thio, alkylsulfinyl, alkylsulfonyl, hydroxy, cyano, nitro,
amino, monoalkylamino, dialkylamino, aralkoxycarbonylamino,
haloalkyl, haloalkoxy, aminoalkyl, monoalkylaminoalkyl,
dialkylaminoalkyl, and the like.
[0076] Examples of aryl groups are phenyl, p-tolyl,
4-methoxyphenyl, 4-(tert-butoxy)phenyl, 3-methyl-4-methoxyphenyl,
4-CF.sub.3-phenyl, 4-fluorophenyl, 4-chlorophenyl, 3-nitrophenyl,
3-aminophenyl, 3-acetamidophenyl, 4-acetamidophenyl,
2-methyl-3-acetamidophenyl, 2-methyl-3-aminophenyl,
3-methyl-4-aminophenyl, 2-amino-3-methylphenyl,
2,4-dimethyl-3-aminophenyl, 4-hydroxyphenyl,
3-methyl-4-hydroxyphenyl, 1-naphthyl, 2-naphthyl,
3-amino-1-naphthyl, 2-methyl-3-amino-1naphthyl, 6-amino-2-naphthyl,
4,6-dimethoxy-2-naphthyl, piperazinylphenyl, and the like.
[0077] Further examples of aryl groups include
3-tert-butyl-1-fluoro-phenyl, 1,3-difluoro-phenyl,
(1-hydroxy-1-methyl-ethyl)-phenyl,
1-fluoro-3-(2-hydroxy-1,1-dimethyl-ethyl)-phenyl,
(1,1-dimethyl-propyl)-phenyl, cyclobutyl-phenyl,
pyrrolidin-2-yl-phenyl, (5-oxo-pyrrolidin-2-yl)-phenyl,
(2,5-dihydro-1H-pyrrol-2-yl)-phenyl, (1H-pyrrol-2-yl)-phenyl,
(cyano-dimethyl-methyl)-phenyl, tert-butyl-phenyl,
1-fluoro-2-hydroxy-phenyl, 1,3-difluoro-4-propylamino-phenyl,
1,3-difluoro-4-hydroxy-phenyl, 1,3-difluoro-4-ethylamino-phenyl,
3-isopropyl-phenyl, (3H-[1,2,3]triazol-4-yl)-phenyl,
[1,2,3]triazol-1-yl-phenyl, [1,2,4]thiadiazol-3-yl-phenyl,
[1,2,4]thiadiazol-5-yl-phenyl, (4H-[1,2,4]triazol-3-yl)-phenyl,
[1,2,4]oxadiazol-3-yl-phenyl, imidazol-1-yl-phenyl,
(3H-imidazol-4-yl)-phenyl, [1,2,4]triazol-4-yl-phenyl,
[1,2,4]oxadiazol-5-yl-phenyl, isoxazol-3-yl-phenyl,
(1-methyl-cyclopropyl)-phenyl, isoxazol-4-yl-phenyl,
isoxazol-5-yl-phenyl, 1-cyano-2-tert-butyl-phenyl,
1-trifluoromethyl-2-tert-butyl-phenyl,
1-chloro-2-tert-butyl-phenyl, 1-acetyl-2-tert-butyl-phenyl,
1-tert-butyl-2-methyl-phenyl, 1-tert-butyl-2-ethyl-phenyl,
1-cyano-3-tert-butyl-phenyl, 1-trifluoromethyl-3-tert-butyl-phenyl,
1-chloro-3-tert-butyl-phenyl, 1-acetyl-3-tert-butyl-phenyl,
1-tert-butyl-3-methyl-phenyl 1-tert-butyl-3-ethyl-phenyl,
4-tert-butyl-1-imidazol-1-yl-phenyl, ethylphenyl, isobutylphenyl,
isopropylphenyl, 3-allyloxy-1-fluoro-phenyl,
(2,2-dimethyl-propyl)-phenyl, ethynylphenyl,
1-fluoro-3-heptyloxy-phenyl,
1-fluoro-3-[2-(2-methoxy-ethoxy)-ethoxy]-phenyl,
1-benzyloxy-3-fluoro-phenyl, 1-fluoro-3-hydroxy-phenyl,
1-fluoro-3-hexyloxy-phenyl, (4-methyl-thiophen-2-yl)-phenyl,
(5-acetyl-thiophen-2-yl)-phenyl, furan-3-yl-phenyl,
thiophen-3-yl-phenyl, (5-formyl-thiophen-2-yl)-phenyl,
(3-formyl-furan-2-yl)-phenyl, acetylamino-phenyl,
trifluoromethylphenyl, sec-butyl-phenyl, pentylphenyl,
(3-methyl-butyl)-phenyl, (1-ethyl-propyl)-phenyl,
cyclopentyl-phenyl, 3-pent-4-enyl-phenyl, phenyl propionic acid
ethyl ester, pyridin-2-yl-phenyl, (3-methyl-pyridin-2-yl)-phenyl,
thiazol-2-yl-phenyl, (3-methyl-thiophen-2-yl)-phenyl,
fluoro-phenyl, adamantan-2-yl-phenyl,
1,3-difluoro-2-hydroxy-phenyl, cyclopropyl-phenyl,
1-bromo-3-tert-butyl-phenyl,
(3-bromo-[1,2,4]thiadiazol-5-yl)-phenyl,
(1-methyl-1H-imidazol-2-yl)-phenyl,
3,5-dimethyl-3H-pyrazol-4-yl)-phenyl,
(3,6-dimethyl-pyrazin-2-yl)-phenyl, (3-cyano-pyrazin-2-yl)-phenyl,
thiazol-4-yl-phenyl, (4-cyano-pyridin-2-yl)-phenyl,
pyrazin-2-yl-phenyl, (6-methyl-pyridazin-3-yl)-phenyl,
(2-cyano-thiophen-3-yl)-phenyl, (2-chloro-thiophen-3-yl)-phenyl,
(5-acetyl-thiophen-3-yl)-phenyl, cyano-phenyl, and the like.
[0078] The term "heteroaryl" refers to an aromatic heterocycloalkyl
group as defined above. The heteroaryl groups herein are
unsubstituted or substituted in at least one position with various
groups. For example, such heteroaryl groups may be optionally
substituted with, for example, alkyl, alkoxy, halogen, hydroxy,
cyano, nitro, amino, monoalkylamino, dialkylamino, haloalkyl,
haloalkoxy, C(O)H, carboxy, alkoxycarbonyl, cycloalkyl,
heterocycloalkyl, aryl, heteroaryl, amido, alkanoylamino, amidino,
alkoxycarbonylamino, N-alkyl amidino, N-alkyl amido,
N,N'-dialkylamido, alkyl thio, alkylsulfinyl, alkylsulfonyl,
aralkoxycarbonylamino, aminoalkyl, monoalkylaminoalkyl,
dialkylaminoalkyl, and the like.
[0079] Examples of heteroaryl groups include pyridyl, pyrimidyl,
furanyl, imidazolyl, thienyl, oxazolyl, thiazolyl, pyrazinyl,
3-methyl-thienyl, 4-methyl-thienyl, 3-propyl-thienyl,
2-chloro-thienyl, 2-chloro-4-ethyl-thienyl, 2-cyano-thienyl,
5-acetyl-thienyl, 5-formyl-thienyl, 3-formyl-furanyl,
3-methyl-pyridinyl, 3-bromo-[1,2,4]thiadiazolyl,
1-methyl-1H-imidazole, 3,5-dimethyl-3H-pyrazolyl,
3,6-dimethyl-pyrazinyl, 3-cyano-pyrazinyl, 4-tert-butyl-pyridinyl,
4-cyano-pyridinyl, 6-methyl-pyridazinyl, 2-tert-butyl-pyrimidinyl,
4-tert-butyl-pyrimidinyl, 6-tert-butyl-pyrimidinyl,
5-tert-butyl-pyridazinyl, 6-tert-butyl-pyridazinyl, quinolinyl,
benzothienyl, indolyl, indolinyl, pyridazinyl, isoindolyl,
isoquinolyl, quinazolinyl, quinoxalinyl, phthalazinyl, imidazolyl,
isoxazolyl, pyrazolyl, indolizinyl, indazolyl, benzothiazolyl,
benzimidazolyl, benzofuranyl, thienyl, pyrrolyl, oxadiazolyl,
thiadiazolyl, triazolyl, tetrazolyl, oxazolopyridinyl,
imidazopyridinyl, isothiazolyl, naphthyridinyl, cinnolinyl,
carbazolyl, beta-carbolinyl, isochromanyl, chromanyl,
tetrahydroisoquinolinyl, isoindolinyl, isobenzotetrahydrofuranyl,
isobenzotetrahydrothienyl, isobenzothienyl, benzoxazolyl,
pyridopyridinyl, benzotetrahydrofuranyl, benzotetrahydrothienyl,
purinyl, benzodioxolyl, triazinyl, phenoxazinyl, phenothiazinyl,
pteridinyl, benzothiazolyl, imidazopyridinyl, imidazothiazolyl,
dihydrobenzisoxazinyl, benzisoxazinyl, benzoxazinyl,
dihydrobenzisothiazinyl, benzopyranyl, benzothiopyranyl,
coumarinyl, isocoumarinyl, chromonyl, chromanonyl,
pyridinyl-N-oxide, tetrahydroquinolinyl, dihydroquinolinyl,
dihydroquinolinonyl, dihydroisoquinolinonyl, dihydrocoumarinyl,
dihydroisocoumarinyl, isoindolinonyl, benzodioxanyl,
benzoxazolinonyl, pyrrolyl N-oxide, pyrimidinyl N-oxide,
pyridazinyl N-oxide, pyrazinyl N-oxide, quinolinyl N-oxide, indolyl
N-oxide, indolinyl N-oxide, isoquinolyl N-oxide, quinazolinyl
N-oxide, quinoxalinyl N-oxide, phthalazinyl N-oxide, imidazolyl
N-oxide, isoxazolyl N-oxide, oxazolyl N-oxide, thiazolyl N-oxide,
indolizinyl N-oxide, indazolyl N-oxide, benzothiazolyl N-oxide,
benzimidazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide,
thiadiazolyl N-oxide, triazolyl N-oxide, tetrazolyl N-oxide,
benzothiopyranyl S-oxide, benzothiopyranyl S,S-dioxide,
tetrahydrocarbazole, tetrahydrobetacarboline, and the like.
[0080] In an embodiment, a heteroaryl group may be selected from
pyridyl, pyrimidyl, furanyl, imidazolyl, thienyl, oxazolyl,
thiazolyl, pyrazinyl, and the like.
[0081] In another embodiment, a heteroaryl group may be selected
from 3-methyl-thienyl, 4-methyl-thienyl, 3-propyl-thienyl,
2-chloro-thienyl, 2-chloro-4-ethyl-thienyl, 2-cyano-thienyl,
5-acetyl-thienyl, 5-formyl-thienyl, 3-formyl-furanyl,
3-methyl-pyridinyl, 3-bromo-[1,2,4]thiadiazolyl,
1-methyl-1H-imidazole, 3,5-dimethyl-3H-pyrazolyl,
3,6-dimethyl-pyrazinyl, 3-cyano-pyrazinyl, 4-tert-butyl-pyridinyl,
4-cyano-pyridinyl, 6-methyl-pyridazinyl, 2-tert-butyl-pyrimidinyl,
4-tert-butyl-pyrimidinyl, 6-tert-butyl-pyrimidinyl,
5-tert-butyl-pyridazinyl, 6-tert-butyl-pyridazinyl, and the
like.
[0082] Further examples of heterocycloalkyls and heteroaryls may be
found in Katritzky, A. R. et al., Comprehensive Heterocyclic
Chemistry: The Structure, Reactions, Synthesis and Use of
Heterocyclic Compounds, Vol. 1-8, New York: Pergamon Press,
1984.
[0083] The term "aralkoxycarbonyl" refers to a group of the formula
aralkyl-O--C(O)-- in which the term "aralkyl" is encompassed by the
definitions above for aryl and alkyl. Examples of an
aralkoxycarbonyl group include benzyloxycarbonyl
4-methoxyphenylmethoxycarbonyl, and the like.
[0084] The term "aryloxy" refers to a group of the formula --O-aryl
in which the term aryl is as defined above.
[0085] The term "aralkanoyl" refers to an acyl group derived from
an aryl-substituted alkanecarboxylic acid such as phenylacetyl,
3-phenylpropionyl(hydrocinnamoyl), 4-phenylbutyryl,
(2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl,
4-methoxyhydrocinnamoyl, and the like.
[0086] The term "aroyl" refers to an acyl group derived from an
arylcarboxylic acid, "aryl" having the meaning given above.
Examples of such aroyl groups include substituted and unsubstituted
benzoyl or naphthoyl such as benzoyl, 4-chlorobenzoyl,
4-carboxybenzoyl, 4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl,
2-naphthoyl, 6-carboxy-2 naphthoyl,
6-(benzyloxycarbonyl)-2-naphthoyl, 3-benzyloxy-2-naphthoyl,
3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the
like.
[0087] The term "haloalkyl" refers to an alkyl group having the
meaning as defined above wherein one or more hydrogens are replaced
with a halogen. Examples of such haloalkyl groups include
chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl,
trifluoromethyl, 1,1,1-trifluoroethyl, and the like.
[0088] The term "epoxide" refers to chemical compounds or reagents
comprising a bridging oxygen wherein the bridged atoms are also
bonded to one another either directly or indirectly. Examples of
epoxides include epoxyalkyl (e.g., ethylene oxide, and
1,2-epoxybutane), and epoxycycloalkyl (e.g., 1,2-epoxycyclohexane,
1,2-epoxy-1-methylcyclohexane), and the like.
[0089] The term "structural characteristics" refers to chemical
moieties, chemical motifs, and portions of chemical compounds.
These include R groups, such as but not limited to those defined
herein, ligands, appendages, and the like. For example, structural
characteristics may be defined by their properties, such as, but
not limited to, their ability to participate in intermolecular
interactions including Van der Waal's interactions (e.g.,
electrostatic interactions, dipole-dipole interactions, dispersion
forces, hydrogen bonding, and the like). Such characteristics may
impart desired pharmacokinetic properties and thus have an
increased ability to cause the desired effect and thus prevent or
treat the targeted diseases or conditions.
[0090] Compounds of formula (I) also comprise structural moieties
that may participate in inhibitory interactions with at least one
subsite of beta-secretase. For example, moieties of the compounds
of formula (I) may interact with at least one of the S1, S1' and
S2' subsites, wherein S1 comprises residues Leu30, Tyr71, Phe108,
Ile110, and Trp115, S1' comprises residues Tyr198, Ile226, Val227,
Ser 229, and Thr231, and S2' comprises residues Ser35, Asn37,
Pro70, Tyr71, Ile118, and Arg128. Such compounds and methods of
treatment may have an increased ability to cause the desired effect
and thus prevent or treat the targeted diseases or conditions.
[0091] The term "pharmaceutically acceptable" refers to those
properties and/or substances that are acceptable to the patient
from a pharmacological/toxicological point of view, and to the
manufacturing pharmaceutical chemist from a physical/chemical point
of view regarding composition, formulation, stability, patient
acceptance, and bioavailability.
[0092] The term "effective amount" as used herein refers to an
amount of a therapeutic agent administered to a host, as defined
herein, necessary to achieve a desired effect.
[0093] The term "therapeutically effective amount" as used herein
refers to an amount of a therapeutic agent administered to a host
to treat or prevent a condition treatable by administration of a
composition of the invention. That amount is the amount sufficient
to reduce or lessen at least one symptom of the disease being
treated or to reduce or delay onset of one or more clinical markers
or symptoms of the disease.
[0094] The term "therapeutically active agent" refers to a compound
or composition that is administered to a host, either alone or in
combination with another therapeutically active agent, to treat or
prevent a condition treatable by administration of a composition of
the invention.
[0095] The terms "pharmaceutically acceptable salt" and "salts
thereof" refer to acid addition salts or base addition salts of the
compounds in the present invention. A pharmaceutically acceptable
salt is any salt which retains the activity of the parent compound
and does not impart any deleterious or undesirable effect on the
subject to whom it is administered and in the context in which it
is administered. Pharmaceutically acceptable salts include salts of
both inorganic and organic acids. Pharmaceutically acceptable salts
include acid salts such as acetic, aspartic, benzenesulfonic,
benzoic, bicarbonic, bisulfuric, bitartaric, butyric, calcium
edetate, camsylic, carbonic, chlorobenzoic, citric, edetic,
edisylic, estolic, esyl, esylic, formic, fumaric, gluceptic,
gluconic, glutamic, glycolylarsanilic, hexamic, hexylresorcinoic,
hydrabamic, hydrobromic, hydrochloric, hydroiodic,
hydroxynaphthoic, isethionic, lactic, lactobionic, maleic, malic,
malonic, mandelic, methanesulfonic, methylnitric, methylsulfuric,
mucic, muconic, napsylic, nitric, oxalic, p-nitromethanesulfonic,
pamoic, pantothenic, phosphoric, monohydrogen phosphoric,
dihydrogen phosphoric, phthalic, polygalactouronic, propionic,
salicylic, stearic, succinic, sulfamic, sulfanilic, sulfonic,
sulfuric, tannic, tartaric, teoclic, toluenesulfonic, and the like.
Other acceptable salts may be found, for example, in Stahl et al.,
Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH;
1st edition (Jun. 15, 2002).
[0096] In an embodiment of the present invention, a
pharmaceutically acceptable salt is selected from hydrochloric,
hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, citric,
methanesulfonic, CH.sub.3--(CH.sub.2).sub.0-4--COOH,
HOOC--(CH.sub.2).sub.0-4--COOH, HOOC--CH.dbd.CH--COOH, phenyl-COOH,
and the like.
[0097] The term "unit dosage form" refers to physically discrete
units suitable as unitary dosages for human subjects or other
mammals, each unit containing a predetermined quantity of active
material calculated to produce the desired therapeutic effect, in
association with a suitable pharmaceutical vehicle. The
concentration of active compound in the drug composition will
depend on absorption, inactivation, and/or excretion rates of the
active compound, the dosage schedule, the amount administered and
medium and method of administration, as well as other factors known
to those of skill in the art.
[0098] The term "modulate" refers to a chemical compound's activity
of either enhancing or inhibiting a functional property of
biological activity or process.
[0099] The terms "interact" and "interactions" refer to a chemical
compound's association and/or reaction with another chemical
compound, such as an interaction between an inhibitor and
beta-secretase. Interactions include, but are not limited to,
hydrophobic, hydrophilic, lipophilic, lipophobic, electrostatic,
and van der Waal's interactions including hydrogen bonding.
[0100] An "article of manufacture" as used herein refers to
materials useful for the diagnosis, prevention or treatment of the
disorders described above, such as a container with a label. The
label can be associated with the article of manufacture in a
variety of ways including, for example, the label may be on the
container or the label may be in the container as a package insert.
Suitable containers include, for example, blister packs, bottles,
bags, vials, syringes, test tubes, and the like. The containers may
be formed from a variety of materials such as glass, metal,
plastic, rubber, paper, and the like. The container holds a
composition as described herein which is effective for diagnosing,
preventing, or treating a condition treatable by a compound or
composition of the present invention.
[0101] The article of manufacture may contain bulk quantities or
less of a composition as described herein. The label on, or
associated with, the container may provide instructions for the use
of the composition in diagnosing, preventing, or treating the
condition of choice, instructions for the dosage amount and for the
methods of administration. The label may further indicate that the
composition is to be used in combination with one or more
therapeutically active agents wherein the therapeutically active
agent is selected from an antioxidant, an anti-inflammatory, a
gamma-secretase inhibitor, a neurotrophic agent, an acetyl
cholinesterase inhibitor, a statin, an A-beta, an anti-A-beta
antibody, and/or a beta-secretase complex or fragment thereof. The
article of manufacture may further comprise multiple containers,
also referred to herein as a kit, comprising a therapeutically
active agent or a pharmaceutically-acceptable buffer, such as
phosphate-buffered saline, Ringer's solution and/or dextrose
solution. It may further include other materials desirable from a
commercial and user standpoint, including other buffers, diluents,
filters, needles, syringes, and/or package inserts with
instructions for use.
[0102] The compounds of formula (I), their compositions, and
methods of treatment employing them, can be enclosed in multiple or
single dose containers. The enclosed compounds and/or compositions
can be provided in kits, optionally including component parts that
can be assembled for use. For example, a compound inhibitor in
lyophilized form and a suitable diluent may be provided as
separated components for combination prior to use. A kit may
include a compound inhibitor and at least one additional
therapeutic agent for co-administration. The inhibitor and
additional therapeutic agents may be provided as separate component
parts.
[0103] A kit may include a plurality of containers, each container
holding at least one unit dose of the compound of the present
invention. The containers are preferably adapted for the desired
mode of administration, including, for example, pill, tablet,
capsule, powder, gel or gel capsule, sustained-release capsule, or
elixir form, and/or combinations thereof, and the like for oral
administration, depot products, pre-filled syringes, ampoules,
vials, and the like for parenteral administration, and patches,
medipads, creams, and the like for topical administration.
[0104] The term "C.sub.max" refers to the peak plasma concentration
of a compound in a host.
[0105] The term "T.sub.max" refers to the time at peak plasma
concentration of a compound in a host.
[0106] The term "half-life" refers to the period of time required
for the concentration or amount of a compound in a host to be
reduced to exactly one-half of a given concentration or amount.
DETAILED DESCRIPTION OF THE PRESENT INVENTION
[0107] The present invention is directed to novel compounds and
also to methods of treating at least one condition, disorder, or
disease associated with amyloidosis using such compounds.
Amyloidosis refers to a collection of diseases, disorders, or
conditions associated with abnormal deposition of amyloidal
protein.
[0108] An embodiment of the present invention is to provide methods
of preventing or treating at least one condition associated with
amyloidosis using compounds of formula (I) with a high degree of
efficacy. Compounds and methods of treatment that are efficacious
are those that have an increased ability to cause the desired
effect and thus prevent or treat the targeted diseases or
conditions.
[0109] Another embodiment of the present invention is to provide
compounds of formula (I), ##STR6##
[0110] or pharmaceutically acceptable salts thereof, for preventing
or treating at least one condition that benefits from inhibition of
at least one aspartyl-protease, and wherein R.sub.1, R.sub.2, and
R.sub.C are defined below.
[0111] Another embodiment of the present invention is to provide
methods for preventing or treating at least one condition that
benefits from inhibition of at least one aspartyl-protease,
comprising compounds of formula (I), or pharmaceutically acceptable
salts thereof, wherein the inhibition is at least 10% for a dose of
100 mg/kg or less, and wherein R.sub.1, R.sub.2, and R.sub.C are
defined below.
[0112] Another embodiment of the present invention is to provide a
method of preventing or treating at least one condition that
benefits from inhibition of at least one aspartyl-protease,
comprising administering to a host a composition comprising a
therapeutically effective amount of at least one compound of
formula (I), or pharmaceutically acceptable salts thereof, wherein
##STR7## [0113] wherein n is 0 or 1; q is 0 or 1; r is 0, 1, or 2;
[0114] K is selected from --(CR.sub.3aR.sub.3b)--, --O--,
--SO.sub.2--, --C(O)--, and --CH(NR.sub.55R.sub.60)--; [0115]
R.sub.55 and R.sub.60 are each independently selected from hydrogen
and alkyl; [0116] R.sub.3a and R.sub.3b are independently selected
from hydrogen, halogen, --O-alkyl, and alkyl optionally substituted
with at least one group independently selected from halogen, --CN,
--CF.sub.3, and --OH; [0117] W is selected from
--(CH.sub.2).sub.1-4--, --O--, --S(O).sub.0-2--, --N(R.sub.55)--,
and --C(O)--; [0118] E is a bond or alkyl; [0119] A is selected
from aryl optionally substituted with at least one group
independently selected from R.sub.50, cycloalkyl optionally
substituted with at least one group independently selected from
R.sub.50, heteroaryl optionally substituted with at least one group
independently selected from R.sub.50, and heterocycle optionally
substituted with at least one group independently selected from
R.sub.50, [0120] wherein at least one atom of the heterocycle is
optionally replaced with --C(O)-- and --S(O).sub.0-2--, [0121]
wherein at least one heteroatom of the heteroaryl or heterocycle is
optionally substituted with a group independently selected from
--(CO).sub.0-1R.sub.215, --(CO).sub.0-1R.sub.220,
--S(O).sub.0-2R.sub.200, and --N(R.sub.200)--S(O).sub.0-2R.sub.200;
[0122] R.sub.50 is independently selected from --OH, halogen,
--OCF.sub.3, --NO.sub.2, --CN, --N(R)C(O)R, --CO.sub.2--R,
--NH--CO.sub.2--R, --O-(alkyl)-CO.sub.2H, --NRR', --SR,
--CH.sub.2OH, --C(O)--R.sub.25, --C(O)NRR', --SO.sub.2NRR',
--S(O).sub.1-2R.sub.25, alkyl (optionally substituted with at least
one group independently selected from --CF.sub.3, halogen,
--O-alkyl, --OCF.sub.3, --NRR', --OH, and --CN), cycloalkyl
(optionally substituted with at least one group independently
selected from --CF.sub.3, halogen, --O-alkyl, --OCF.sub.3, --NRR',
--OH, and --CN), --O-alkyl (optionally substituted with at least
one group independently selected from --CF.sub.3, halogen,
--O-alkyl, --OCF.sub.3, --NRR', --OH, and --CN), --O-benzyl
(optionally substituted with at least one group independently
selected from --H, --OH, halogen, and alkyl),
--O--(CH.sub.2).sub.0-2--O--(CH.sub.2).sub.1-2--O-alkyl, and
--(CH.sub.2).sub.0-2--O--(CH.sub.2).sub.1-2--OH; [0123] R and R'
are each independently selected from hydrogen, alkyl,
--(CH.sub.2).sub.0-2-aryl and --(CH.sub.2).sub.0-2-cycloalkyl,
wherein each aryl or cycloalkyl is optionally substituted with at
least one group independently selected from halogen, hydroxy,
alkyl, --O-alkyl, amino, monoalkylamino, and dialkylamino; [0124]
R.sub.25 is selected from alkyl, --(CH.sub.2).sub.0-2-aryl and
--(CH.sub.2).sub.0-2-cycloalkyl, wherein each aryl or cycloalkyl is
optionally substituted with at least one group independently
selected from halogen, hydroxy, alkyl, --O-alkyl, amino,
monoalkylamino, and dialkylamino; [0125] L is selected from a bond,
--C(O)--, --S(O).sub.1-2--, --O--, --C(R.sub.110)(R.sub.112)O--,
--OC(R.sub.110)(R.sub.112)--, --N(R.sub.110)--,
--C(O)N(R.sub.110)--, --N(R.sub.110)C(O)--, --C(R.sub.110)(R')--,
--C(OH)R.sub.110--, --SO.sub.2NR.sub.110--,
--N(R.sub.110)SO.sub.2--, --N(R.sub.110)C(O)N(R.sub.112)--,
--N(R.sub.110)C(S)N(R.sub.112)--, --OCO.sub.2--, --NCO.sub.2--, and
--OC(O)N(R.sub.110)--; [0126] R.sub.110 and R.sub.112 are each
independently selected from hydrogen and alkyl optionally
substituted with at least one group independently selected from
--OH, --O-alkyl, and halogen; [0127] G is selected from [0128]
-alkyl optionally substituted with at least one group independently
selected from --CO.sub.2H, --CO.sub.2(alkyl), --O-alkyl, --OH,
--NRR', alkyl, haloalkyl, -alkyl-O-alkyl, aryl (optionally
substituted with at least one group independently selected from
R.sub.50), and heteroaryl (optionally substituted with at least one
group independently selected from R.sub.50); [0129]
--(CH.sub.2).sub.0-3-cycloalkyl wherein cycloalkyl is optionally
substituted with at least one group independently selected from
--CO.sub.2H, --CO.sub.2-- (alkyl), --O-alkyl, --OH, --NH.sub.2,
haloalkyl, alkyl, -alkyl-O-alkyl, mono(alkyl)amino, di(alkyl)amino,
aryl (optionally substituted with at least one group independently
selected from R.sub.50), and heteroaryl (optionally substituted
with at least one group independently selected from R.sub.50);
[0130] --(CRR).sub.0-4-aryl wherein the aryl is optionally
substituted with at least one group independently selected from
R.sub.50; [0131] --(CH.sub.2.sub.0-4-heteroaryl wherein the
heteroaryl is optionally substituted with at least one group
independently selected from R.sub.50; [0132]
--(CH.sub.2).sub.0-4-heterocycle, wherein the heterocycle is
optionally substituted with at least one group independently
selected from R.sub.50; and [0133]
--C(R.sub.10)(R.sub.12)--C(O)--NH--R.sub.14; [0134] R.sub.10 and
R.sub.12 are each independently selected from --H, alkyl,
-(alkyl).sub.0-1-aryl, -(alkyl).sub.0-1-heteroaryl,
-(alkyl).sub.0-1-heterocycle, aryl, heteroaryl, heterocycle,
--(CH.sub.2).sub.1-4--OH,
--(CH.sub.2).sub.1-4-Z-(CH.sub.2).sub.1-4-aryl, and
--(CH.sub.2).sub.1-4-Z-(CH.sub.2).sub.1-4-heteroaryl; wherein the
heterocycle, aryl, and heteroaryl groups included within R.sub.10
and R.sub.12 are optionally substituted with at least one group
independently selected from R.sub.50; [0135] Z is selected from
--O--, --S--, and --NR.sub.16--; [0136] R.sub.14 is selected from
--H, alkyl, aryl, heteroaryl, heterocycle, -(alkyl)-aryl,
-(alkyl)-heteroaryl, alkyl, and
--(CH.sub.2).sub.0-2--O--(CH.sub.2).sub.0-2--OH; wherein the
heterocycle, aryl, and heteroaryl groups included within R.sub.14
are optionally substituted with at least one group independently
selected from R.sub.50, [0137] R.sub.16 is selected from hydrogen
and alkyl; or [0138] R.sub.1 is selected from ##STR8## [0139]
alkyl; [0140] wherein [0141] X, Y, and Z are independently selected
from --C(H).sub.0-2--, --O--, --C(O)--, --NH--, and --N--; [0142]
wherein at least one bond of the (IIf) ring may optionally be a
double bond; [0143] R.sub.50, R.sub.50a, and R.sub.50b are
independently selected from --H, halogen, --OH, --SH, --CN,
--C(O)-alkyl, --NR.sub.7R.sub.8, --NO.sub.2, --S(O).sub.0-2-alkyl,
alkyl, alkoxy, --O-benzyl (optionally substituted with at least one
group independently selected from --H, --OH, and alkyl),
--C(O)--NR.sub.7R.sub.8, alkyloxy, alkoxyalkoxyalkoxy, and
cycloalkyl; [0144] wherein the alkyl, alkoxy, and cycloalkyl groups
within R.sub.50, R.sub.50a, and R.sub.50b are optionally
substituted with at least one group independently selected from
alkyl, halogen, OH, NR.sub.5R.sub.6, CN, haloalkoxy,
NR.sub.7R.sub.8, and alkoxy; [0145] R.sub.5 and R.sub.6 are
independently selected from --H and alkyl, or [0146] R.sub.5 and
R.sub.6, and the nitrogen to which they are attached, form a 5 or 6
membered heterocycloalkyl ring; and [0147] R.sub.7 and R.sub.8 are
independently selected from --H, alkyl optionally substituted with
at least one group independently selected from --OH, --NH.sub.2,
and halogen, -cycloalkyl, and -alkyl-O-alkyl; [0148] R.sub.2 is
selected from H, --OH, --O-alkyl (optionally substituted with at
least one group independently selected from R.sub.200), --O-aryl
(optionally substituted with at least one group independently
selected from R.sub.200), alkyl (optionally substituted with at
least one group independently selected from R.sub.200), --NH-alkyl
(optionally substituted with at least one group independently
selected from R.sub.200), heterocycloalkyl, (wherein at least one
carbon is optionally replaced with a group independently selected
from --(CR.sub.245R.sub.250)--, --O--, --C(O)--, --C(O)C(O)--,
--N(R.sub.200).sub.0-2--, and --S(O).sub.0-2--, and wherein the
heterocycloalkyl is optionally substituted with at least one group
independently selected from R.sub.200), --NH-heterocycloalkyl,
(wherein at least one carbon is optionally replaced with a group
independently selected from --(CR.sub.245R.sub.250)--, --O--,
--C(O)--, --C(O)C(O)--, --N(R.sub.200).sub.0-1--, and
--S(O).sub.0-2--, and wherein the heterocycloalkyl is optionally
substituted with at least one group independently selected from
R.sub.200), --C(O)--N(R.sub.315)(R.sub.320), (wherein R.sub.315 and
R.sub.320 are each independently selected from H, alkyl, and aryl),
--O--C(O)--N(R.sub.315)(R.sub.320), --NH--R.sub.400, R.sub.400,
--NH--R.sub.500, R.sub.500, --NH--R.sub.600, R.sub.600, and
--NH--R.sub.700; [0149] R.sub.400 is ##STR9## [0150] wherein
R.sub.405 is selected from H, --N(R.sub.515).sub.2 and O-alkyl;
[0151] R.sub.500 is a heteroaryl selected from III(a) and III(b)
##STR10## [0152] wherein [0153] M.sub.1 and M.sub.4 are
independently selected from --C(R.sub.505)--, --N--,
--N(R.sub.515)--, --S--, and --O--; [0154] M.sub.2 and M.sub.3 are
independently selected from --C(R.sub.510)--,
--N(R.sub.520).sub.0-1--, --S--, and --O--; [0155] M.sub.5 is
selected from --C-- and --N--; [0156] R.sub.505 is independently
selected from H, alkyl, halogen, --NO.sub.2, --CN, --R.sub.200, and
aryl; [0157] R.sub.510 is independently selected from H, alkyl,
halogen, amino, --CF.sub.3, --R.sub.200, and aryl; [0158] R.sub.515
is independently selected from H, alkyl, and aryl; [0159] R.sub.520
is independently selected from H, alkyl, --(CH.sub.2).sub.0-2-aryl,
and --C(Ph).sub.3; [0160] R.sub.600 is a monocyclic, bicyclic, or
tricyclic heteroaryl ring system of 6, 7, 8, 9, 10, 11, 12, 13, or
14 atoms, optionally substituted with at least one group
independently selected from R.sub.605; [0161] R.sub.605 is selected
from hydrogen, halogen, alkyl, aryl, --CO.sub.2-alkyl, nitro, --CN,
amino, --NR.sub.220R.sub.225, -thioalkyl, --CF.sub.3, --OH,
--O-alkyl, and heterocycloalkyl; [0162] R.sub.700 is aryl
optionally substituted with at least one R.sub.205; [0163] R.sub.C
is selected from formula (IIIa), (IIIb), (IIIc), (IIId), (IIIe),
and (IIIf) ##STR11## [0164] wherein, [0165] A.sub.1 and A.sub.2 are
independently selected from --(CH.sub.2).sub.1-2--,
--CH(R.sub.200)--, --C(R.sub.200).sub.2--, --NH--, --NR.sub.220--,
--C(.dbd.N--R.sub.230)--, --C(.dbd.CH--R.sub.230)--,
--C(.dbd.N--C(O)--R.sub.230)--, and
--C(.dbd.CH--C(O)--R.sub.230)--; [0166] A.sub.3, A.sub.4, A.sub.5,
and A.sub.6 are independently selected from --CH.sub.2--,
--CH(R.sub.200)--, --C(R.sub.200).sub.2--, --O--, --C(O)--,
--S(O).sub.0-2--, --NH--, --NR.sub.220--,
--N(CO).sub.0-1R.sub.200--, --N(S(O.sub.2)alkyl)-,
--C(.dbd.N--R.sub.230)--, --C(.dbd.N--NH(alkyl))-,
--C(.dbd.N--N(alkyl)(alkyl))-,
--C(.dbd.N--O--(CH.sub.2).sub.1-4--OH)--,
--C(.dbd.CH--R.sub.230)--, --C(.dbd.N--C(O)--R.sub.230)--, and
--C(.dbd.CH--C(O)--R.sub.230)--; [0167] R.sub.230 is independently
selected from --H, --OH, R.sub.215 (optionally substituted with
--OH, --NH.sub.2, --C(O)H, and --CN), alkyl, cycloalkyl, alkoxy,
-alkyl-OH, -alkyl-NH.sub.2, -alkyl-C(O)H, --O--R.sub.215
(optionally substituted with --OH, --NH.sub.2, --C(O)H, and --CN),
--O-alkyl, --O-alkyl-OH, --O-alkyl-NH.sub.2, --O-alkyl-C(O)H,
--NH.sub.2, --NHR.sub.215, --N(R.sub.215).sub.2,
--NR.sub.235R.sub.240, and --CN; [0168] wherein at least one carbon
of the alkyl or cycloalkyl within R.sub.230 is optionally
independently replaced with --C(O)-- or a heteroatom; [0169]
wherein the cycloalkyl and heterocylcoalkyl within formulae (IIIa),
(IIIb), (IIIc), (IIId), (IIIe), and (IIIf) may optionally contain
at least one double bond; [0170] wherein in formulae (IIIa),
(IIIb), (IIIc), and (IIId), at least one of A.sub.1, A.sub.2,
A.sub.3, A.sub.4, or A.sub.5 is selected from
--C(.dbd.N--R.sub.230)--, --C(.dbd.N--NH(alkyl))-,
--C(.dbd.N--N(alkyl)(alkyl))-,
C(.dbd.N--O--(CH.sub.2).sub.1-4--OH)--, --C(.dbd.CH--R.sub.230)--,
--C(.dbd.N--C(O)--R.sub.230)--, and
--C(.dbd.CH--C(O)--R.sub.230)--; [0171] wherein in formulae (IIIe)
and (IIIf), when A.sub.1, A.sub.2, and A.sub.6 are selected from
--(CH.sub.2).sub.0-2--, --CH(R.sub.200)--, --C(R.sub.200).sub.2--,
--O--, --C(O)--, --S(O).sub.0-2--, --NH--, --NR.sub.220--,
--N(CO).sub.0-1R.sub.200--, and --N(S(O.sub.2)alkyl)-, at least one
carbon of the aryl ring group within (IIIe) and (IIIf) is
optionally independently replaced with a group selected from --N--,
--NH--, --O--, --C(O)--, and --S(O).sub.0-2--; [0172] wherein each
aryl or heteroaryl group attached directly or indirectly to R.sub.C
is optionally substituted with at least one group independently
selected from R.sub.200; [0173] wherein each cycloalkyl or
heterocycloalkyl attached directly or indirectly to R.sub.C is
optionally substituted with at least one group independently
selected from R.sub.210; and [0174] R.sub.x is selected from [0175]
-aryl, heteroaryl, cycloalkyl, heterocycloalkyl, and
--R.sub.xa--R.sub.xb, [0176] wherein R.sub.xa and R.sub.xb are
independently selected from -aryl, -heteroaryl, -cycloalkyl, and
-heterocycloalkyl; [0177] wherein each aryl or heteroaryl group
within R.sub.X is optionally substituted with at least one group
independently selected from R.sub.200; [0178] wherein each
cycloalkyl or heterocycloalkyl within R.sub.X is optionally
substituted with at least one group independently selected from
R.sub.210; and [0179] wherein at least one carbon of the heteroaryl
or heterocycloalkyl group within R.sub.X is independently
optionally replaced with a group independently selected from
--NH--, --N--, --N(CO)O .sub.0-1R.sub.215--,
--N(CO).sub.0-1R.sub.220--, --O--, --C(O)--, --S(O).sub.0-2--, and
--NS(O).sub.0-2R.sub.200; [0180] R.sub.200 at each occurrence is
independently selected from [0181] -alkyl optionally substituted
with at least one group independently selected from R.sub.205,
--OH, --NO.sub.2, -halogen, --CN, --(CH.sub.2).sub.0-4--C(O)H,
--(CO).sub.0-1R.sub.215, --(CO).sub.0-1R.sub.220,
--(CH.sub.2).sub.0-4--(CO).sub.0-1--NR.sub.220R.sub.225,
--(CH.sub.2).sub.0-4--(CO).sub.0-1--NH(R.sub.215),
--(CH.sub.2).sub.0-4--C(O)-alkyl,
--(CH.sub.2).sub.0-4--(CO).sub.0-1-cycloalkyl,
--(CH.sub.2).sub.0-4--(CO).sub.0-1-heterocycloalkyl,
--(CH.sub.2).sub.0-4--(CO).sub.0-1-aryl,
--(CH.sub.2).sub.0-4--(CO).sub.0-1-heteroaryl,
--(CH.sub.2).sub.0-4--C(O)--O--R.sub.215,
--(CH.sub.2).sub.0-4--SO.sub.2--NR.sub.220R.sub.225,
--(CH.sub.2).sub.0-4--S(O).sub.0-2-alkyl,
--(CH.sub.2).sub.0-4--S(O).sub.0-2-cycloalkyl,
--(CH.sub.2).sub.0-4--N(H or R.sub.215)--C(O)--O--R.sub.215,
--(CH.sub.2).sub.0-4--N(H or R.sub.215
)--SO.sub.2--R.sub.220, --(CH.sub.2).sub.0-4--N(H or
R.sub.215)--C(O)--N(R.sub.215).sub.2, --(CH.sub.2).sub.0-4--N(H or
R.sub.215)--C(O)--R.sub.220, --(CH.sub.2).sub.0-4--O--C(O)-alkyl,
--(CH.sub.2).sub.0-4--O--(R.sub.215),
--(CH.sub.2).sub.0-4--S--(R.sub.215), --(CH.sub.2).sub.0-4--O-alkyl
optionally substituted with at least one halogen, and -adamantane;
[0182] wherein each aryl and heteroaryl group included within
R.sub.200 is optionally substituted with at least one group
independently selected from R.sub.205, R.sub.210, and alkyl
(optionally substituted with at least one group independently
selected from R.sub.205 and R.sub.210); [0183] wherein each
cycloalkyl or heterocycloalkyl group included within R.sub.200 is
optionally substituted with at least one group independently
selected from R.sub.210; [0184] R.sub.205 at each occurrence is
independently selected from -alkyl, -haloalkoxy,
--(CH.sub.2).sub.0-3-cycloalkyl, -halogen,
--(CH.sub.2).sub.0-6--OH, --O-aryl, --OH, --SH,
--(CH.sub.2).sub.0-4--C(O)H, --(CH.sub.2).sub.0-6--CN,
--(CH.sub.2).sub.0-6--C(O)--NR.sub.235R.sub.240,
--(CH.sub.2).sub.0-6--C(O)--R.sub.235, --(CH.sub.2).sub.0-4--N(H or
R.sub.215)--SO.sub.2--R.sub.235, --OCF.sub.3, --CF.sub.3, -alkoxy,
-alkoxycarbonyl, and --NR.sub.235R.sub.240;R.sub.210 at each
occurrence is independently selected from --(CH.sub.2).sub.0-4--OH,
--(CH.sub.2).sub.0-4--CN, --(CH.sub.2).sub.0-4--C(O)H, -alkyl
optionally substituted with at least one group independently
selected from R.sub.205, -alkanoyl, --S-alkyl; --S(O).sub.2-alkyl,
-halogen, -alkoxy, -haloalkoxy, --NR.sub.220R.sub.225, -cycloalkyl
optionally substituted with at least one group independently
selected from R.sub.205, -heterocycloalkyl, -heteroaryl,
--(CH.sub.2).sub.0-4--NR.sub.235R.sub.240,
--(CH.sub.2).sub.0-4--NR.sub.235(alkoxy), [0185]
--(CH.sub.2).sub.0-4--S--(R.sub.215),
--(CH.sub.2).sub.0-4--NR.sub.235--C(O)H,
--(CH.sub.2).sub.0-4--NR.sub.235--C(O)-(alkoxy),
--(CH.sub.2).sub.0-4--NR.sub.235--C(O)--R.sub.240,
--C(O)--NHR.sub.215, --C(O)-alkyl, --C(O)--NR.sub.235R.sub.240, and
--S(O).sub.2--NR.sub.235R.sub.240; [0186] R.sub.215 at each
occurrence is independently selected from -alkyl,
--(CH.sub.2).sub.0-2-aryl, --(CH.sub.2).sub.0-2-cycloalkyl,
--(CH.sub.2).sub.0-2-heteroaryl,
--(CH.sub.2).sub.0-2-heterocycloalkyl, and [0187]
--CO.sub.2--CH.sub.2-aryl; wherein the aryl group included within
R.sub.215 is optionally substituted with at least one group
independently selected from R.sub.205 and R.sub.210, and wherein
the heterocycloalkyl and heteroaryl groups included within
R.sub.215 are optionally substituted with at least one group
independently selected from R.sub.210; [0188] R.sub.220 and
R.sub.225 at each occurrence are independently selected from --H,
alkyl, --(CH.sub.2).sub.0-4--C(O)H, alkylhydroxyl, alkoxycarbonyl,
alkylamino, --S(O).sub.2-alkyl, alkanoyl (optionally substituted
with at least one halogen), --C(O)--NH.sub.2, --C(O)--NH(alkyl),
--C(O)--N(alkyl)(alkyl), haloalkyl,
--(CH.sub.2).sub.0-2-cycloalkyl, -(alkyl)-O-(alkyl), aryl,
heteroaryl, and heterocycloalkyl; [0189] wherein the aryl,
heteroaryl, cycloalkyl and heterocycloalkyl groups included within
R.sub.220 and R.sub.225 are each optionally substituted with at
least one group independently selected from R.sub.270; [0190]
R.sub.270 at each occurrence is independently selected from
--R.sub.205, alkyl (optionally substituted with at least one group
independently selected from R.sub.205), aryl, halogen, alkoxy,
haloalkoxy, --NR.sub.235R.sub.240, --OH, --CN, cycloalkyl
(optionally substituted with at least one group independently
selected from R.sub.205), --C(O)-alkyl,
--S(O).sub.2--NR.sub.235R.sub.240, --C(O)--NR.sub.235R.sub.240,
--S(O).sub.2-alkyl, and --(CH.sub.2).sub.0-4--C(O)H; [0191]
R.sub.235 and R.sub.240 at each occurrence are independently
selected from --H, --OH, --CF.sub.3, --OCF.sub.3, --OCH.sub.3,
--NHCH.sub.3, --N(CH.sub.3).sub.2, --(CH.sub.2).sub.0-4--C(O)(H or
alkyl), alkyl, alkanoyl, --SO.sub.2-alkyl, and aryl.
[0192] Exemplary R.sub.600 substituents of monocyclic, bicyclic, or
tricyclic heteroaryls include
Benzo[4,5]thieno[3,2-d]pyrimidin-4-yl,
4,6-Diamino-[1,3,5]triazin-2-yl, 3-nitro-pyridin-2-yl,
5-trifluoromethyl-pyridin-2-yl, 8-trifluoromethyl-quinolin-4-yl,
4-trifluoromethyl-pyrimidin-2-yl, 2-phenyl-quinazolin-4-yl,
6-Chloro-pyrazin-2-yl, pyrimidin-2-yl, quinolin-2-yl,
3-Chloro-pyrazin-2-yl, 6-Chloro-2,5-diphenyl-pyrimidin-4-yl,
3-Chloro-quinoxalin-2-yl, 5-ethyl-pyrimidin-2-yl,
6-Chloro-2-methylsulfanyl-5-phenyl-pyrimidin-4-yl, quinolin-4-yl,
3-ethoxycarbonyl-pyridin-2yl, 5-Cyano-pyridin-2-yl,
2-phenyl-quinolin-4-yl, 7H-purin-6-yl, 3-Cyano-pyridin-2-yl,
4,6-dimethoxy-[1,3,5]triazin-2-yl, 3-Cyano-pyrazin-2-yl,
9-(tetrahydro-pyran-2-yl)-9H-purin-6-yl, 2-Chloro-7H-purin-6-yl,
2-Amino-6-chloro-pyrimidin-4-yl, 2-Chloro-6-methyl-pyrimidin-4-yl,
2-Amino-6-methyl-pyrimidin-4-yl, 4-Chloro-pyrimidin-2-yl,
2-Amino-7H-purin-6-yl, 4-trifluoromethyl-pyrimidin-2-yl, and the
like.
[0193] Exemplary R.sub.2 substituents include
3-Allyl-5-benzyl-2-oxo-imidazolidin-1-yl,
6-Benzyl-3,3-dimethyl-2-oxo-piperazin-1-yl,
3-Allyl-5-benzyl-2-oxo-pyrrolidin-1-yl,
5-Benzyl-3-isobutyl-2-oxo-imidazolidin-1-yl,
3-Benzyl-5-methyl-1,1-dioxo-1.lamda..sup.6-[1,2,5]thiadiazolidin-2-yl,
3-Benzyl-1,1-dioxo-1.lamda..sup.6-isothiazolidin-2-yl,
2-Benzyl-5-oxo-pyrrolidin-1-yl,
5-Benzyl-3-ethyl-2-oxo-pyrrolidin-1-yl,
3-Amino-5-benzyl-2-oxo-pyrrolidin-1-yl,
3-Acetylamino-5-benzyl-2-oxo-pyrrolidin-1-yl,
5-Benzyl-3-[1,3]dioxolan-4-ylmethyl-2-oxo-pyrrolidin-1-yl,
3-Benzyl-5-oxo-morpholin-4-yl, 2-Benzyl-6-oxo-piperazin-1-yl,
8-Benzyl-6-methyl-10-oxo-6,9-diaza-spiro[4.5]dec-9-yl,
5-Benzyl-3-furan-2-ylmethylene-2-oxo-pyrrolidin-1-yl,
3-acetylamino-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-acetylamino-3-(cyclopropylmethyl)-2-oxo-pyrrolidin-1-yl,
3-(2-amino-5-carboxypentanoylamino)-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-(2-methoxy-acetylamino)-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-ethoxycarbonylamino-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-ethylureido-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl, and
3-hydroxypropionylamino-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl.
[0194] In an embodiment, R.sub.1 is selected from
3-allyloxy-5-fluoro-benzyl, 3-benzyloxy-5-fluoro-benzyl,
3-propyl-thiophen-2-yl-methyl, 3,5-difluoro-2-propylamino-benzyl,
2-ethylamino-3,5-difluoro-benzyl, 2-hydroxy-5-methyl-benzamide,
3-fluoro-5-[2-(2-methoxy-ethoxy)-ethoxy]-benzyl,
3-fluoro-5-heptyloxy-benzyl, and 3-fluoro-5-hexyloxy-benzyl.
[0195] In another embodiment, R.sub.1 is selected from a
--CH.sub.2-aryl, wherein the aryl ring is optionally substituted
with at least one group independently selected from halogen,
--C.sub.1-C.sub.2 alkyl, --C1-C.sub.2 alkoxy, and --OH.
[0196] In another embodiment, R.sub.1 is selected from
3-Allyloxy-5-fluoro-benzyl, 3-Benzyloxy-5-fluoro-benzyl,
4-hydroxy-benzyl, 3-hydroxy-benzyl, 3-propyl-thiophen-2-yl-methyl,
3,5-difluoro-2-propylamino-benzyl, 5-chloro-thiophen-2-yl-methyl,
5-chloro-3-ethyl-thiophen-2-yl-methyl,
3,5-difluoro-2-hydroxy-benzyl, 2-ethylamino-3,5-difluoro-benzyl,
piperidin-4-yl-methyl, 2-oxo-piperidin-4-yl-methyl,
2-oxo-1,2-dihydro-pyridin-4-yl-methyl,
5-hydroxy-6-oxo-6H-pyran-2-yl-methyl, 2-Hydroxy-5-methyl-benzamide,
3,5-Difluoro-4-hydroxy-benzyl, 3,5-Difluoro-benzyl,
3-Fluoro-4-hydroxy-benzyl,
3-Fluoro-5-[2-(2-methoxy-ethoxy)-ethoxy]-benzyl,
3-Fluoro-5-heptyloxy-benzyl, 3-Fluoro-5-hexyloxy-benzyl,
3-Fluoro-5-hydroxy-benzyl, 3-Fluoro-benzyl, and the like.
[0197] Exemplary R.sub.2 substituents include
3-Allyl-5-benzyl-2-oxo-imidazolidin-1-yl,
6-Benzyl-3,3-dimethyl-2-oxo-piperazin-1-yl,
3-Allyl-5-benzyl-2-oxo-pyrrolidin-1-yl,
5-Benzyl-3-isobutyl-2-oxo-imidazolidin-1-yl,
3-Benzyl-5-methyl-1,1-dioxo-1.lamda..sup.6-[1,2,5]thiadiazolidin-2-yl,
3-Benzyl-1,1-dioxo-1.lamda..sup.6-isothiazolidin-2-yl,
2-Benzyl-5-oxo-pyrrolidin-1-yl,
5-Benzyl-3-ethyl-2-oxo-pyrrolidin-1-yl,
3-Amino-5-benzyl-2-oxo-pyrrolidin-1-yl,
3-Acetylamino-5-benzyl-2-oxo-pyrrolidin-1-yl,
5-Benzyl-3-[1,3]dioxolan-4-ylmethyl-2-oxo-pyrrolidin-1-yl,
3-Benzyl-5-oxo-morpholin-4-yl, 2-Benzyl-6-oxo-piperazin-1-yl,
8-Benzyl-6-methyl-10-oxo-6,9-diaza-spiro[4.5]dec-9-yl,
5-Benzyl-3-furan-2-ylmethylene-2-oxo-pyrrolidin-1-yl,
3-acetylamino-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-acetylamino-3-(cyclopropylmethyl)-2-oxo-pyrrolidin-1-yl,
3-(2-amino-5-carboxypentanoylamino)-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-(2-methoxy-acetylamino)-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-ethoxycarbonylamino-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-ethylureido-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl,
3-hydroxypropionylamino-3-(sec-butyl)-2-oxo-pyrrolidin-1-yl, and
the like.
[0198] In another embodiment, R.sub.2 is selected from hydrogen,
3-Bromo-[1,2,4]thiadiazol-5-ylamino, [1,2,4]thiadiazol-5-ylamino,
4-Chloro-[1,2,5]thiadiazol-3-ylamino, [1,2,5]thiadiazol-3-ylamino,
thiazol-2-ylamino, 5-Bromo-[1,3,4]thiadiazol-2-ylamino,
[1,3,4]thiadiazol-2-ylamino, 5-Amino-[1,3,4]thiadiazol-2-ylamino,
2-Bromo-thiazol-5-ylamino, thiazol-5-ylamino,
5-trifluoromethyl-[1,3,4]thiadiazol-2-ylamino,
5-trifluoromethyl-[1,3,4]oxadiazol-2-ylamino,
5-Amino-[1,3,4]oxadiazol-2-ylamino,
1-trityl-1H-[1,2,4]triazol-3-ylamino, 1H-[1,2,4]triazol-3-ylamino,
oxazol-2-ylamino, 5-Bromo-2-trityl-2H-[1,2,3]triazol-4-ylamino,
2-trityl-2H-[1,2,3]triazol-4-ylamino,
5-Bromo-2H-[1,2,3]triazol-4-ylamino, 2H-[1,2,3]triazol-4-ylamino,
thiophen-2-ylamino, 3-methyl-5-nitro-3H-imidazol-4-ylamino,
4-Cyano-5-phenyl-isothiazol-3-ylamino,
4-phenyl-[1,2,5]thiadiazol-3-ylamino,
3,4-dioxo-cyclobut-1-enylamino,
2-methoxy-3,4-dioxo-cyclobut-1-enylamino, and
2-methylamino-3,4-dioxo-cyclobut-1-enylamino, and the like.
[0199] In another embodiment, R.sub.C is selected from ##STR12##
wherein A.sub.5 is --C(.dbd.N--R.sub.230) and A.sub.1, A.sub.2,
A.sub.3, A.sub.4, R.sub.X and R.sub.230 are defined above.
[0200] In another embodiment, A.sub.5 is selected from
--C(.dbd.N--OH)--, --C(.dbd.N--O--CH.sub.3)--,
--C(.dbd.N--O--CH.sub.2CH.sub.3)--,
--C(.dbd.N--O--CH.sub.2CH.sub.2OH)--,
--C(.dbd.N--O--CH.sub.2CH.sub.2NH.sub.2)--,
--C(.dbd.N--NHCH.sub.3)--, and --C(.dbd.N--CN)--, and A.sub.1,
A.sub.2, A.sub.3, and A.sub.4 are --CH.sub.2--.
[0201] In another embodiment, A.sub.5 is selected from
--C(.dbd.N--OH)--, --C(.dbd.N--O--CH.sub.3)--,
--C(.dbd.N--O--CH.sub.2CH.sub.3)--,
--C(.dbd.N--O--CH.sub.2CH.sub.2OH)--,
--C(.dbd.N--O--CH.sub.2CH.sub.2NH.sub.2)--,
--C(.dbd.N--NHCH.sub.3)--, and --C(.dbd.N--CN)--.
[0202] In another embodiment, R.sub.C is selected from
1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexyl,
1-(3-tert-Butyl-phenyl)-4-methoxyimino-cyclohexyl,
1-(3-tert-Butyl-phenyl)-4-ethoxyimino-cyclohexyl,
1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethoxyimino)-cyclohexyl,
1-(3-tert-Butyl-phenyl)-4-(2-amino-ethoxyimino)-cyclohexyl,
5-(3-tert-Butyl-phenyl)-2-hydroxyimino-hexahydro-pyrimidin-5-yl,
1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-cyclohexyl,
1-(3-tert-Butyl-phenyl)-4-cyanoimino-cyclohexyl,
5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-yl,
5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-benzo[c]isoxazol-5-yl,
1-(Acrylic acid methyl
ester)-4-(tert-Butyl-phenyl)-cyclohexane-4-yl,
1-(Acrylamide)-4-(tert-Butyl-phenyl)-cyclohexane-4-yl,
1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethylidene)-cyclohex-1-yl,
1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-cyclohex-1-yl,
1-(3-tert-Butyl-phenyl)-4-(dimethyl-hydrazono)-cyclohex-1-yl,
4-methoxyimino-1-(3-thiophen-3-yl-phenyl)-cyclohexyl,
1-(3-furan-3-yl-phenyl)-4-methoxyimino-cyclohexyl,
4-methoxyimino-1-[3-(1H-pyrrol-2-yl)-phenyl]-cyclohexyl,
4-methoxyimino-1-(3-pyridin-4-yl-phenyl)-cyclohexyl,
4-methoxyimino-1-(3-pyrimidin-5-yl-phenyl)-cyclohexyl,
4-methoxyimino-1-(3-pyrazol-1-yl-phenyl)-cyclohexyl,
2-Acetyl-5-(3-tert-butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-yl,
1-(3-tert-Butyl-phenyl)-4methylene-cyclohexyl, ethyl
2-(4-(3-tert-butylphenyl)cyclohexylidene)acetate, and the like.
[0203] In another embodiment, R.sub.X is selected from
3-(1,1-dimethyl-propyl)-phenyl, 3-(1-ethyl-propyl)-phenyl,
3-(1H-pyrrol-2-yl)-phenyl, 3-(1-hydroxy-1-methyl-ethyl)-phenyl,
3-(1-methyl-1H-imidazol-2-yl)-phenyl,
3-(1-methyl-cyclopropyl)-phenyl, 3-(2,2-dimethyl-propyl)-phenyl,
3-(2,5-dihydro-1H-pyrrol-2-yl)-phenyl,
3-(2-Chloro-thiophen-3-yl)-phenyl,
3-(2-Cyano-thiophen-3-yl)-phenyl, 3-(2-fluoro-benzyl)-phenyl,
3-(3,5-dimethyl-3H-pyrazol-4-yl)-phenyl,
3-(3,6-dimethyl-pyrazin-2-yl)-phenyl,
3-(3-Cyano-pyrazin-2-yl)-phenyl, 3-(3-formyl-furan-2-yl)-phenyl,
3-(3H-[1,2,3]triazol-4-yl)-phenyl, 3-(3H-imidazol-4-yl)-phenyl,
3-(3-methyl-butyl)-phenyl, 3-(3-methyl-pyridin-2-yl)-phenyl,
3-(3-methyl-thiophen-2-yl)-phenyl, 3-(4-Cyano-pyridin-2-yl)-phenyl,
3-(4-fluoro-benzyl)-phenyl, 3-(4H-[1,2,4]triazol-3-yl)-phenyl,
3-(4-methyl-thiophen-2-yl)-phenyl,
3-(5-Acetyl-thiophen-2-yl)-phenyl,
3-(5-Acetyl-thiophen-3-yl)-phenyl,
3-(5-formyl-thiophen-2-yl)-phenyl,
3-(5-oxo-pyrrolidin-2-yl)-phenyl,
3-(6-methyl-pyridazin-3-yl)-phenyl,
3-(6-methyl-pyridin-2-yl)-phenyl, 3-(Cyano-dimethyl-methyl)-phenyl,
3-[1-(2-tert-Butyl-pyrimidin-4-yl)-cyclohexylamino,
3-[1,2,3]triazol-1-yl-phenyl, 3-[1,2,4]oxadiazol-3-yl-phenyl,
3-[1,2,4]oxadiazol-5-yl-phenyl, 3-[1,2,4]thiadiazol-3-yl-phenyl,
3-[1,2,4]thiadiazol-5-yl-phenyl, 3-[1,2,4]triazol-4-yl-phenyl,
3-Acetyl-5-tert-butyl-phenyl, 3'-Acetylamino-biphenyl-3-yl,
3-Adamantan-2-yl-phenyl, 3-Bromo-[1,2,4]thiadiazol-5-yl)-phenyl,
3-Bromo-5-tert-butyl-phenyl, 3-Cyano-phenyl, 3-Cyclobutyl-phenyl,
3-Cyclopentyl-phenyl, 3-Cyclopropyl-phenyl, 3-ethyl-phenyl,
3-ethynyl-phenyl, 3-fluoro-5-(2-hydroxy-1,1-dimethyl-ethyl)-phenyl,
3-furan-3-yl-phenyl, 3-imidazol-1-yl-phenyl, 3-isobutyl-phenyl,
3-isopropyl-phenyl, 3-isoxazol-3-yl-phenyl, 3-isoxazol-4-yl-phenyl,
3-isoxazol-5-yl-phenyl, 3-pent-4-enyl-phenyl, 3-pentyl-phenyl,
3-Phenyl-propionic acid ethyl ester, 3-pyrazin-2-yl-phenyl,
3-pyridin-2-yl-phenyl, 3-pyrrolidin-2-yl-phenyl,
3-sec-Butyl-phenyl, 3-tert-Butyl-4-chloro-phenyl,
3-tert-Butyl-4-cyano-phenyl, 3-tert-Butyl-4-ethyl-phenyl,
3-tert-Butyl-4-methyl-phenyl,
3-tert-Butyl-4-trifluoromethyl-phenyl,
3-tert-Butyl-5-chloro-phenyl, 3-tert-Butyl-5-cyano-phenyl,
3-tert-Butyl-5-ethyl-phenyl, 3-tert-Butyl-5-fluoro-phenyl,
3-tert-Butyl-5-methyl-phenyl,
3-tert-Butyl-5-trifluoromethyl-phenyl, 3-tert-Butyl-phenyl,
3-thiazol-2-yl-phenyl, 3-thiazol-4-yl-phenyl,
3-thiophen-3-yl-phenyl, 3-trifluoromethyl-phenyl,
4-Acetyl-3-tert-butyl-phenyl, 4-tert-Butyl-pyridin-2-yl,
4-tert-Butyl-pyrimidin-2-yl, 5-tert-Butyl-pyridazin-3-yl, and
6-tert-Butyl-pyridazin-4-yl, 6-tert-Butyl-pyrimidin-4-yl, and the
like.
[0204] In another embodiment, R.sub.X is 3-tert-Butyl-phenyl.
[0205] In another embodiment, the present invention provides a
method of preventing or treating at least one condition that
benefits from inhibition of at least one aspartyl-protease,
comprising administering to a host a composition comprising a
therapeutically effective amount of at least one compound of the
formula, ##STR13## or pharmaceutically acceptable salts thereof,
wherein R.sub.1, R.sub.2, and R.sub.C are as defined below and
R.sub.0 is selected from --CH(alkyl)-, --C(alkyl).sub.2--,
--CH(cycloalkyl)-, --C(alkyl)(cycloalkyl)-, and
--C(cycloalkyl).sub.2--.
[0206] In another embodiment, the present invention encompasses
compounds of formula (I) wherein the hydroxyl substituent alpha to
the --(CHR.sub.1)-- group, as shown in formula (I), may optionally
be replaced by --NH.sub.2, --NH(R.sub.700),
--N(R.sub.700)(R.sub.700), --SH, and --SR.sub.700, wherein
R.sub.700 is alkyl optionally substituted with at least one group
independently selected from R.sub.200, R.sub.205, R.sub.210,
R.sub.215, R.sub.220, and R.sub.225.
[0207] Among the compounds of formula (I), or pharmaceutically
acceptable salts thereof, examples include
4-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexylamino]-2-(3,5-difluor-
o-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-methoxyimino-cyclohexylamino]-2-(3,5-difluor-
o-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-ethoxyimino-cyclohexylamino]-2-(3,5-difluoro-
-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethoxyimino)-cyclohexylamino]-2-(-
3,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[4-(2-Amino-ethoxyimino)-1-(3-tert-butyl-phenyl)-cyclohexylamino]-2-(3,-
5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-2-hydroxyimino-hexahydro-pyrimidin-5-ylamino]--
2-(3,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-cyclohexylamino]-2-(3,5-d-
ifluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(dimethyl-hydrazono)-cyclohexylamino]-2-(3,5-
-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-cyanoimino-cyclohexylamino]-2-(3,5-difluoro--
benzyl)-3-hydroxy-N-methyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamino]-2-(3,-
5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-benzo[c]isoxazol-5-ylamino]-
-2-(3,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-methylcarbamoylmethylene-cyclohexylamino]-2--
(3,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
{4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-methylcar-
bamoyl-butylamino]-cyclohexylidene}-acetic acid methyl ester,
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethylidene)-cyclohexylamino]-2-(3-
,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexylamino]-2-(3,5-difluor-
o-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-methoxyimino-cyclohexylamino]-2-(3,5-difluor-
o-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-ethoxyimino-cyclohexylamino]-2-(3,5-difluoro-
-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethoxyimino)-cyclohexylamino]-2-(-
3,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[4-(2-Amino-ethoxyimino)-1-(3-tert-butyl-phenyl)-cyclohexylamino]-2-(3,-
5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-2-hydroxyimino-hexahydro-pyrimidin-5-ylamino]--
2-(3,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-cyclohexylamino]-2-(3,5-d-
ifluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-(dimethyl-hydrazono)-cyclohexylamino]-2-(3,5-
-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-cyanoimino-cyclohexylamino]-2-(3,5-difluoro--
benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamino]-2-(3,-
5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-benzo[c]isoxazol-5-ylamino]-
-2-(3,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-[1-(3-tert-Butyl-phenyl)-4-methylcarbamoylmethylene-cyclohexylamino]-2--
(3,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
{4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-phenylcar-
bamoyl-butylamino]-cyclohexylidene}-acetic acid methyl ester,
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethylidene)-cyclohexylamino]-2-(3-
,5-difluoro-benzyl)-3-hydroxy-N-phenyl-butyramide,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-(1H-imidaz-
ol-2-yl)-butylamino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-butylamino]--
cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[3-(3,5-difluoro-phenoxy)-2-hydroxy-propylamino-
]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[3-(3,5-difluoro-benzenesulfonyl)-2-hydroxy-pro-
pylamino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-4-oxo-butyla-
mino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-pentylamino]-
-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-pentylamino]-
-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-tetrazol-1-
-yl-butylamino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-(5-trifluo-
romethyl-[1,3,4]oxadiazol-2-yl)-butylamino]-cyclohexanone oxime,
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-hydroxy-3-([1,2,4]th-
iadiazol-5-ylamino)-butylamino]-cyclohexanone oxime,
3-[3-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexylamino]-1-(3,5-difl-
uoro-benzyl)-2-hydroxy-propylamino]-4-methylamino-cyclobut-3-ene-1,2-dione-
,
3-[3-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-cyclohexylamino]-1-(3,5-dif-
luoro-benzyl)-2-hydroxy-propylamino]-4-methoxy-cyclobut-3-ene-1,2-dione,
4-(3-tert-Butyl-phenyl)-4-[2-hydroxy-4-(3-propyl-thiophen-2-yl)-3-([1,2,4-
]thiadiazol-5-ylamino)-butylamino]-cyclohexanone oxime,
1-(5-(3-tert-butylphenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamino)-4-(3,5-
-difluorophenyl)butan-2-ol,
1-(5-(3-tert-butylphenyl)-2-methyl-4,5,6,7-tetrahydro-2H-indazol-5-ylamin-
o)-4-(3,5-difluorophenyl)butan-2-ol, and the like.
[0208] The present invention encompasses methods of treatment using
compounds with structural characteristics designed for interacting
with their target molecules. Such characteristics include at least
one moiety capable of interacting with at least one subsite of
beta-secretase. Such characteristics also include at least one
moiety capable of enhancing the interaction between the target and
at least one subsite of beta-secretase.
[0209] It is preferred that the compounds of formula (I) are
efficacious. For example, it is preferred that the compounds of
formula (I) decrease the level of beta-secretase using low dosages
of the compounds. Preferably, the compounds of formula (I) decrease
the level of A-beta by at least 10% using dosages of about 100
mg/kg. It is more preferred that the compounds of formula (I)
decrease the level of A-beta by at least 10% using dosages of less
than 100 mg/kg. It is also more preferred that the compounds of
formula (I) decrease the level of A-beta by greater than 10% using
dosages of about 100 mg/kg. It is most preferred that the compounds
of formula (I) decrease the level of A-beta by greater than 10%
using dosages of less than 100 mg/kg.
[0210] In an embodiment, the host is a cell.
[0211] In another embodiment, the host is an animal.
[0212] In another embodiment, the host is human.
[0213] In another embodiment, at least one compound of formula (I)
is administered in combination with a pharmaceutically acceptable
carrier or diluent.
[0214] In another embodiment, the pharmaceutical compositions
comprising compounds of formula (I) can be used to treat a wide
variety of disorders or conditions including Alzheimer's disease,
Down's syndrome or Trisomy 21 (including mild cognitive impairment
(MCI) Down's syndrome), hereditary cerebral hemorrhage with
amyloidosis of the Dutch type, chronic inflammation due to
amyloidosis, prion diseases (including. Creutzfeldt-Jakob disease,
Gerstmann-Straussler syndrome, kuru scrapie, and animal scrapie),
Familial Amyloidotic Polyneuropathy, cerebral amyloid angiopathy,
other degenerative dementias including dementias of mixed vascular
and degenerative origin, dementia associated with Parkinson's
disease, dementia associated with progressive supranuclear palsy
and dementia associated with cortical basal degeneration, diffuse
Lewy body type of Alzheimer's disease, and frontotemporal dementias
with parkinsonism (FTDP).
[0215] In another embodiment, the condition is Alzheimer's
disease.
[0216] In another embodiment, the condition is dementia.
[0217] When treating or preventing these diseases, the methods of
the present invention can either employ the compounds of formula
(I) individually or in combination, as is best for the patient.
[0218] In treating a patient displaying any of the conditions
discussed above, a physician may employ a compound of formula (I)
immediately and continue administration indefinitely, as needed. In
treating patients who are not diagnosed as having Alzheimer's
disease, but who are believed to be at substantial risk for it, the
physician may start treatment when the patient first experiences
early pre-Alzheimer's symptoms, such as memory or cognitive
problems associated with aging. In addition, there are some
patients who may be determined to be at risk for developing
Alzheimer's disease through the detection of a genetic marker such
as APOE4 or other biological indicators that are predictive for
Alzheimer's disease and related conditions. In these situations,
even though the patient does not have symptoms of the disease or
condition, administration of the compounds of formula (I) may be
started before symptoms appear, and treatment may be continued
indefinitely to prevent or delay the onset of the disease. Similar
protocols are provided for other diseases and conditions associated
with amyloidosis, such as those characterized by dementia.
[0219] In an embodiment, the methods of preventing or treating at
least one condition associated with amyloidosis, comprising
administering to a host a composition comprising a therapeutically
effective amount of at least one compound of formula (I), which may
include beta-secretase complexed with at least one compound of
formula (I), or at least one pharmaceutically acceptable salt
thereof, wherein R.sub.1, R.sub.2, and R.sub.C are as previously
defined.
[0220] One embodiment of the present invention provides a method of
preventing or treating the onset of Alzheimer's disease comprising
administering to a patient a therapeutically effective amount of at
least one compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined.
[0221] Another embodiment of the present invention provides a
method of preventing or treating the onset of dementia comprising
administering to a patient a therapeutically effective amount of at
least one compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined.
[0222] Another embodiment of the present invention provides a
method of preventing or treating at least one condition associated
with amyloidosis by administering to a host an effective amount of
at least one compound of formula (I), or at least one
pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2,
and R.sub.C are as previously defined.
[0223] Another embodiment of the present invention provides a
method of preventing or treating Alzheimer's disease by
administering to a host an effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined.
[0224] Another embodiment of the present invention provides a
method of preventing or treating dementia by administering to a
host an effective amount of at least one compound of formula (I),
or at least one pharmaceutically acceptable salt thereof, wherein
R.sub.1, R.sub.2, and R.sub.C are as previously defined.
[0225] Another embodiment of the present invention provides a
method of inhibiting beta-secretase activity in a cell. This method
comprises administering to the cell an effective amount of at least
one compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined.
[0226] Another embodiment of the present invention provides a
method of inhibiting beta-secretase activity in a host. This method
comprises administering to the host an effective amount of at least
one compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined.
[0227] Another embodiment of the present invention provides a
method of inhibiting beta-secretase activity in a host. This method
comprises administering to the host an effective amount of at least
one compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined, and wherein the host is a human.
[0228] Another embodiment of the present invention provides methods
of affecting beta-secretase-mediated cleavage of amyloid precursor
protein in a patient, comprising administering a therapeutically
effective amount of at least one compound of formula (I), or at
least one pharmaceutically acceptable salt thereof, wherein
R.sub.1, R.sub.2, and R.sub.C are as previously defined.
[0229] Another embodiment of the present invention provides a
method of inhibiting cleavage of amyloid precursor protein at a
site between Met596 and Asp597 (numbered for the APP-695 amino acid
isotype), or at a corresponding site of an isotype or mutant
thereof, comprising administering a therapeutically effective
amount of at least one compound of formula (I), or at least one
pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2,
and R.sub.C are as previously defined.
[0230] Another embodiment of the present invention provides a
method of inhibiting cleavage of amyloid precursor protein or
mutant thereof at a site between amino acids, comprising
administering a therapeutically effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined, and wherein the site between amino acids
corresponds to between Met652 and Asp653 (numbered for the APP-751
isotype), between Met671 and Asp672 (numbered for the APP-770
isotype), between Leu596 and Asp597 of the APP-695 Swedish
Mutation, between Leu652 and Asp653 of the APP-751 Swedish
Mutation, or between Leu671 and Asp672 of the APP-770 Swedish
Mutation.
[0231] Another embodiment of the present invention provides a
method of inhibiting production of A-beta, comprising administering
to a patient a therapeutically effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined.
[0232] Another embodiment of the present invention provides a
method of preventing or treating deposition of A-beta, comprising
administering a therapeutically effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined.
[0233] Another embodiment of the present invention provides a
method of preventing, delaying, halting, or reversing a disease
characterized by A-beta deposits or plaques, comprising
administering a therapeutically effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined.
[0234] In one embodiment the A-beta deposits or plaques are in a
human brain.
[0235] Another embodiment of the present invention provides a
method of preventing, delaying, halting, or reversing a condition
associated with a pathological form of A-beta in a host comprising
administering to a patient in need thereof an effective amount of
at least one compound of formula (I), or at least one
pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2,
and R.sub.C are as previously defined.
[0236] Another embodiment of the present invention provides a
method of inhibiting the activity of at least one aspartyl protease
in a patient in need thereof, comprising administering a
therapeutically effective amount of at least one compound of
formula (I), or at least one pharmaceutically acceptable salt
thereof to the patient, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined.
[0237] In one embodiment, the at least one aspartyl protease is
beta-secretase.
[0238] Another embodiment of the present invention provides a
method of interacting an inhibitor with beta-secretase, comprising
administering to a patient in need thereof a therapeutically
effective amount of at least one compound of formula (I), or at
least one pharmaceutically acceptable salt thereof, wherein
R.sub.1, R.sub.2, and R.sub.C are as previously defined, and
wherein the at least one compound interacts with at least one
beta-secretase subsite such as S1, S1', or S2'.
[0239] Another embodiment provides a method of selecting compounds
of formula (I) wherein the pharmacokinetic parameters are adjusted
for a an increase in desired effect (e.g., increased brain
uptake).
[0240] Another embodiment provides a method of selecting at least
one compound of formula (I) wherein C.sub.max, T.sub.max, and/or
half-life are adjusted to provide for maximum efficacy.
[0241] Another embodiment of the present invention provides a
method of treating a condition in a patient, comprising
administering a therapeutically effective amount of at least one
compound of formula (I), or at least one pharmaceutically
acceptable salt, derivative or biologically active metabolite
thereof, to the patient, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined.
[0242] In an embodiment, the condition is Alzheimer's disease.
[0243] In another embodiment, the condition is dementia.
[0244] In another embodiment, the compounds of formula (I) are
administered in oral dosage form. The oral dosage forms are
generally administered to the patient 1, 2, 3, or 4 times daily. It
is preferred that the compounds be administered either three or
fewer times daily, more preferably once or twice daily. It is
preferred that, whatever oral dosage form is used, it be designed
so as to protect the compounds from the acidic environment of the
stomach. Enteric coated tablets are well known to those skilled in
the art. In addition, capsules filled with small spheres, each
coated to be protected from the acidic stomach, are also well known
to those skilled in the art.
[0245] Therapeutically effective amounts include, for example, oral
administration from about 0.1 mg/day to about 1,000 mg/day,
parenteral, sublingual, intranasal, intrathecal administration from
about 0.2 mg/day to about 100 mg/day, depot administration and
implants from about 0.5 mg/day to about 50 mg/day, topical
administration from about 0.5 mg/day to about 200 mg/day, and
rectal administration from about 0.5 mg/day to about 500
mg/day.
[0246] When administered orally, an administered amount
therapeutically effective to inhibit beta-secretase activity, to
inhibit A-beta production, to inhibit A-beta deposition, or to
treat or prevent Alzheimer's disease is from about 0.1 mg/day to
about 1,000 mg/day.
[0247] In various embodiments, the therapeutically effective amount
may be administered in, for example, pill, tablet, capsule, powder,
gel, or elixir form, and/or combinations thereof. It is understood
that, while a patient may be started at one dose or method of
administration, that dose or method of administration may vary over
time as the patient's condition changes.
[0248] Another embodiment of the present invention provides a
method of prescribing a medication for preventing, delaying,
halting, or reversing at least one disorder, condition or disease
associated with amyloidosis. The method includes identifying in a
patient symptoms associated with at least one disorder, condition
or disease associated with amyloidosis, and prescribing at least
one dosage form of at least one compound of formula (I), or at
least one pharmaceutically acceptable salt, to the patient, wherein
R.sub.1, R.sub.2, and R.sub.C are as previously defined.
[0249] Another embodiment of the present invention provides an
article of manufacture, comprising (a) at least one dosage form of
at least one compound of formula (I), or at least one
pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2,
and R.sub.C are as previously defined, (b) a package insert
providing that a dosage form comprising a compound of formula (I)
should be administered to a patient in need of therapy for at least
one disorder, condition or disease associated with amyloidosis, and
(c) at least one container in which at least one dosage form of at
least one compound of formula (I) is stored.
[0250] Another embodiment provides a packaged pharmaceutical
composition for treating at least one condition related to
amyloidosis, comprising (a) a container which holds an effective
amount of at least one compound of formula (I), or at least one
pharmaceutically acceptable salt thereof, and (b) instructions for
using the pharmaceutical composition.
[0251] Another embodiment of the present invention provides an
article of manufacture, comprising (a) a therapeutically effective
amount of at least one compound of formula (I), or pharmaceutically
acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.C are
as previously defined, (b) a package insert providing an oral
dosage form should be administered to a patient in need of therapy
for at least one disorder, condition or disease associated with
amyloidosis, and (c) at least one container comprising at least one
oral dosage form of at least one compound of formula (I).
[0252] Another embodiment of the present invention provides an
article of manufacture, comprising (a) at least one oral dosage
form of at least one compound of formula (I), or at least one
pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2,
and R.sub.C are as previously defined, in a dosage amount ranging
from about 2 mg to about 1000 mg, associated with (b) a package
insert providing that an oral dosage form comprising a compound of
formula (I) in a dosage amount ranging from about 2 mg to about
1000 mg should be administered to a patient in need of therapy for
at least one disorder, condition or disease associated with
amyloidosis, and (c) at least one container in which at least one
oral dosage form of at least one compound of formula (I) in a
dosage amount ranging from about 2 mg to about 1000 mg is
stored.
[0253] Another embodiment of the present invention provides an
article of manufacture, comprising (a) at least one oral dosage
form of at least one compound of formula (I) in a dosage amount
ranging from about 2 mg to about 1000 mg in combination with (b) at
least one therapeutically active agent, associated with (c) a
package insert providing that an oral dosage form comprising a
compound of formula (I) in a dosage amount ranging from about 2 mg
to about 1000 mg in combination with at least one therapeutically
active agent should be administered to a patient in need of therapy
for at least one disorder, condition or disease associated with
amyloidosis, and (d) at least one container in which at least one
dosage form of at least one compound of formula (I) in a dosage
amount ranging from about 2 mg to about 1000 mg in combination with
a therapeutically active agent is stored.
[0254] Another embodiment of the present invention provides an
article of manufacture, comprising (a) at least one parenteral
dosage form of at least one compound of formula (I) or at least one
pharmaceutically acceptable salt thereof, in a dosage amount
ranging from about 0.2 mg/mL to about 50 mg/mL, associated with (b)
a package insert providing that a parenteral dosage form comprising
a compound of formula (I) in a dosage amount ranging from about 0.2
mg/mL to about 50 mg/mL should be administered to a patient in need
of therapy for at least one disorder, condition or disease
associated with amyloidosis, and (c) at least one container in
which at least one parenteral dosage form of at least one compound
of formula (I), or at least one pharmaceutically acceptable salt
thereof, in a dosage amount ranging from about 0.2 mg/mL to about
50 mg/mL is stored.
[0255] A further embodiment of the present invention provides an
article of manufacture comprising (a) a medicament comprising an
effective amount of at least one compound of formula (I) or at
least one pharmaceutically acceptable salt thereof, in combination
with active and/or inactive pharmaceutical agents, (b) a package
insert providing that an effective amount of at least one compound
of formula (I) should be administered to a patient in need of
therapy for at least one disorder, condition or disease associated
with amyloidosis, and (c) a container in which a medicament
comprising an effective amount of at least one compound of formula
(I) in combination with a therapeutically active and/or inactive
agent is stored.
[0256] In an embodiment, the therapeutically active agent is
selected from an antioxidant, an anti-inflammatory, a
gamma-secretase inhibitor, a neurotrophic agent, an acetyl
cholinesterase inhibitor, a statin, an A-beta, and/or an
anti-A-beta antibody.
[0257] Another embodiment of the present invention provides an
article of manufacture comprising: (a) a medicament comprising: an
effective amount of at least one compound of formula (I), ##STR14##
or at least one pharmaceutically acceptable salt thereof, wherein
R.sub.1, R.sub.2, and R.sub.C are defined bellow, in combination
with active and/or inactive pharmaceutical agents; (b) a package
insert providing that an effective amount of at least one compound
of formula (I) should be administered to a patient in need of
therapy for at least one disorder, condition or disease associated
with amyloidosis; and (c) a container in which a medicament
comprising: an effective amount of at least one compound of formula
(I) in combination with active and/or inactive pharmaceutical
agents is stored.
[0258] Another embodiment of the present invention provides a kit
comprising: (a) at least one dosage form of at least one compound
of formula (I); and (b) at least one container in which at least
one dosage form of at least one compound of formula (I) is
stored.
[0259] In an embodiment, the kit further comprises a package
insert: a) containing information of the dosage amount and duration
of exposure of a dosage form containing at least one compound of
formula (I), or at least one pharmaceutically acceptable salt
thereof, and b) providing that the dosage form should be
administered to a patient in need of therapy for at least one
disorder, condition or disease associated with amyloidosis.
[0260] In another embodiment, the kit further comprises at least
one therapeutically active agent.
[0261] In another embodiment of a kit, the therapeutically active
agent is selected from an antioxidant, an anti-inflammatory, a
gamma-secretase inhibitor, a neurotrophic agent, an acetyl
cholinesterase inhibitor, a statin, an A-beta, and an anti-A-beta
antibody.
[0262] A further embodiment of the present invention provides
method of preventing or treating at least one condition associated
with amyloidosis, comprising: administering to a host a composition
comprising a therapeutically effective amount of at least one
selective beta-secretase inhibitor of formula (I), or at least one
pharmaceutically acceptable salt thereof, further comprising a
composition including beta-secretase complexed with at least one
compound of formula (I), wherein R.sub.1, R.sub.2, and R.sub.C are
defined bellow, or pharmaceutically acceptable salt thereof.
[0263] Another embodiment of the present invention provides a
method of producing a beta-secretase complex comprising exposing
beta-secretase to a compound of formula (I), or at least one
pharmaceutically acceptable salt thereof, in a reaction mixture
under conditions suitable for the production of the complex.
[0264] Another embodiment of the present invention provides a
manufacture of a medicament for preventing, delaying, halting, or
reversing Alzheimer's disease, comprising adding an effective
amount of at least one compound of formula (I), or at least one
pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2,
and R.sub.C are defined bellow, to a pharmaceutically acceptable
carrier.
[0265] Another embodiment of the present invention provides a
method of selecting a beta-secretase inhibitor comprising targeting
at least one moiety of at least one formula (I) compound, or at
least one pharmaceutically acceptable salt thereof, to interact
with at least one beta-secretase subsite such as but not limited to
S1, S1', or S2'.
[0266] The methods of treatment described herein include
administering the compounds of formula (I) orally, parenterally
(via intravenous injection (IV), intramuscular injection (IM),
depo-IM, subcutaneous injection (SC or SQ), or depo-SQ),
sublingually, intranasally (inhalation), intrathecally, topically,
or rectally. Dosage forms known to those skilled in the art are
suitable for delivery of the compounds of formula (I).
[0267] In treating or preventing the above diseases, the compounds
of formula (I) are administered using a therapeutically effective
amount. The therapeutically effective amount will vary depending on
the particular compound used and the route of administration, as is
known to those skilled in the art.
[0268] The compositions are preferably formulated as suitable
pharmaceutical preparations, such as for example, pill, tablet,
capsule, powder, gel, or elixir form, and/or combinations thereof,
for oral administration or in sterile solutions or suspensions for
parenteral administration. Typically the compounds described above
are formulated into pharmaceutical compositions using techniques
and/or procedures well known in the art.
[0269] For example, a therapeutically effective amount of a
compound or mixture of compounds of formula (I), or a
physiologically acceptable salt is combined with a physiologically
acceptable vehicle, carrier, binder, preservative, stabilizer,
flavor, and the like, in a unit dosage form as called for by
accepted pharmaceutical practice and is defined herein. The amount
of active substance in those compositions or preparations is such
that a suitable dosage in the range indicated is obtained. The
compound concentration is effective for delivery of an amount upon
administration that lessens or ameliorates at least one symptom of
the disorder for which the compound is administered. For example,
the compositions can be formulated in a unit dosage form, each
dosage containing from about 2 mg to about 1000 mg.
[0270] The active ingredient may be administered in a single dose,
or may be divided into a number of smaller doses to be administered
at intervals of time. It is understood that the precise dosage and
duration of treatment is a function of the disease or condition
being treated and may be determined empirically using known testing
protocols or by extrapolation from in vivo or in vitro test data.
It is to be noted that concentrations and dosage values may vary
with the severity of the condition to be alleviated. It is also to
be understood that the precise dosage and treatment regimens may be
adjusted over time according to the individual need and the
professional judgment of the person administering or supervising
the administration of the compositions, and that the concentration
ranges set forth-herein are exemplary only and are not intended to
limit the scope or practice of the claimed compositions. A dosage
and/or treatment method for any particular patient also may depend
on, for example, the age, weight, sex, diet, and/or health of the
patient, the time of administration, and/or any relevant drug
combinations or interactions.
[0271] To prepare compositions to be employed in the methods of
treatment, at least one compound of formula (I) or at least one
pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2,
and R.sub.C are defined below, is mixed with a suitable
pharmaceutically acceptable carrier. Upon mixing or addition of the
compound(s), the resulting mixture may be a solution, suspension,
emulsion, or the like. Liposomal suspensions may also be suitable
as pharmaceutically acceptable carriers. These may be prepared
according to methods known to those skilled in the art. The form of
the resulting mixture depends upon a number of factors, including
the intended mode of administration and the solubility of the
compound in the selected carrier or vehicle. An effective
concentration is sufficient for lessening or ameliorating at least
one symptom of the disease, disorder, or condition treated and may
be empirically determined.
[0272] Pharmaceutical carriers or vehicles suitable for
administration of the compounds provided herein include any such
carriers known to those skilled in the art to be suitable for the
particular mode of administration. Additionally, the active
materials can also be mixed with other active materials that do not
impair the desired action, or with materials that supplement the
desired action, or have another action. For example, the compounds
of formula (I) may be formulated as the sole pharmaceutically
active ingredient in the composition or may be combined with other
active ingredients.
[0273] Where the compounds exhibit insufficient solubility, methods
for solubilizing may be used. Such methods are known and include,
for example, using co-solvents (such as dimethylsulfoxide (DMSO)),
using surfactants (such as Tween.RTM.), and/or dissolution in
aqueous sodium bicarbonate. Derivatives of the compounds, such as
salts, metabolites, and/or pro-drugs, may also be used in
formulating effective pharmaceutical compositions. Such derivatives
may improve the pharmacokinetic properties of treatment
administered.
[0274] A kit may include a plurality of containers, each container
holding at least one unit dose of the compound of the present
invention. The containers are preferably adapted for the desired
mode of administration, including, for example, pill, tablet,
capsule, powder, gel or gel capsule, sustained-release capsule, or
elixir form, and/or combinations thereof and the like for oral
administration, depot products, pre-filled syringes, ampoules,
vials, and the like for parenteral administration, and patches,
medipads, creams, and the like for topical administration.
[0275] The tablets, pills, capsules, troches, and the like may
contain a binder (e.g., gum tragacanth, acacia, corn starch,
gelatin, and the like); a vehicle (e.g., microcrystalline
cellulose, starch, lactose, and the like); a disintegrating agent
(e.g., alginic acid, corn starch, and the like); a lubricant (e.g.,
magnesium stearate, and the like); a gildant (e.g., colloidal
silicon dioxide, and the like); a sweetening agent (e.g., sucrose,
saccharin, and the like); a flavoring agent (e.g., peppermint,
methyl salicylate, and the like); or fruit flavoring; compounds of
a similar nature, and/or mixtures thereof.
[0276] When the dosage unit form is a capsule, it can contain, in
addition to material described above, a liquid carrier such as a
fatty oil. Additionally, dosage unit forms can contain various
other materials, which modify the physical form of the dosage unit,
for example, coatings of sugar or other enteric agents. A method of
treatment can also administer the compound as a component of an
elixir, suspension, syrup, wafer, chewing gum, or the like. A syrup
may contain, in addition to the active compounds, sucrose as a
sweetening agent, flavors, preservatives, dyes and/or
colorings.
[0277] The methods of treatment may employ at least one carrier
that protects the compound against rapid elimination from the body,
such as time-release formulations or coatings. Such carriers
include controlled release formulations, such as, for example,
implants or microencapsulated delivery systems, and the like or
biodegradable, biocompatible polymers such as collagen, ethylene
vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters,
polylactic acid, and the like. Methods for preparation of such
formulations are known to those in the art.
[0278] When orally administered, the compounds of the present
invention can be administered in usual dosage forms for oral
administration as is well known to those skilled in the art. These
dosage forms include the usual solid unit dosage forms of tablets
and capsules as well as liquid dosage forms such as solutions,
suspensions, and elixirs. When solid dosage forms are used, it is
preferred that they be of the sustained release type so that the
compounds of the present invention need to be administered only
once or twice daily. When liquid oral dosage forms are used, it is
preferred that they be of about 10 mL to about 30 mL each. Multiple
doses may be administered daily.
[0279] The methods of treatment may also employ a mixture of the
active materials and other active or inactive materials that do not
impair the desired action, or with materials that supplement the
desired action.
[0280] Solutions or suspensions used for parenteral, intradermal,
subcutaneous, or topical application can include a sterile diluent
(e.g., water for injection, saline solution, fixed oil, and the
like); a naturally occurring vegetable oil (e.g., sesame oil,
coconut oil, peanut oil, cottonseed oil, and the like); a synthetic
fatty vehicle (e.g., ethyl oleate, polyethylene glycol, glycerine,
propylene glycol, and the like, including other synthetic
solvents); antimicrobial agents (e.g., benzyl alcohol, methyl
parabens, and the like); antioxidants (e.g., ascorbic acid, sodium
bisulfite, and the like); chelating agents (e.g.,
ethylenediaminetetraacetic acid (EDTA) and the like); buffers
(e.g., acetates, citrates, phosphates, and the like); and/or agents
for the adjustment of tonicity (e.g., sodium chloride, dextrose,
and the like); or mixtures thereof.
[0281] Parenteral preparations can be enclosed in ampoules,
disposable syringes, or multiple dose vials made of glass, plastic,
or other suitable material. Buffers, preservatives, antioxidants,
and the like can be incorporated as required.
[0282] Where administered intravenously, suitable carriers include
physiological saline, phosphate buffered saline (PBS), and
solutions containing thickening and solubilizing agents such as
glucose, polyethylene glycol, polypropyleneglycol, and the like,
and mixtures thereof. Liposomal suspensions including
tissue-targeted liposomes may also be suitable as pharmaceutically
acceptable carriers. These may be prepared according to methods
known, for example, as described in U.S. Pat. No. 4,522,811.
[0283] The methods of treatment include delivery of the compounds
of the present invention in a nano crystal dispersion formulation.
Preparation of such formulations is described, for example, in U.S.
Pat. No. 5,145,684. Nano crystalline dispersions of HIV protease
inhibitors and their method of use are described in U.S. Pat. No.
6,045,829. The nano crystalline formulations typically afford
greater bioavailability of drug compounds.
[0284] The methods of treatment include administration of the
compounds parenterally, for example, by IV, IM, SC, or depo-SC.
When administered parenterally, a therapeutically effective amount
of about 0.2 mg/mL to about 50 mg/mL is preferred. When a depot or
IM formulation is used for injection once a month or once every two
weeks, the preferred dose should be about 0.2 mg/mL to about 50
mg/mL.
[0285] The methods of treatment include administration of the
compounds sublingually. When given sublingually, the compounds of
the present invention should be given one to four times daily in
the amounts described above for IM administration.
[0286] The methods of treatment include administration of the
compounds intranasally. When given by this route, the appropriate
dosage forms are a nasal spray or dry powder, as is known to those
skilled in the art. The dosage of the compounds of the present
invention for intranasal administration is the amount described
above for IM administration.
[0287] The methods of treatment include administration of the
compounds intrathecally. When given by this route the appropriate
dosage form can be a parenteral dosage form as is known to those
skilled in the art. The dosage of the compounds of the present
invention for intrathecal administration is the amount described
above for IM administration.
[0288] The methods of treatment include administration of the
compounds topically. When given by this route, the appropriate
dosage form is a cream, ointment, or patch. When topically
administered, the dosage is from about 0.2 mg/day to about 200
mg/day. Because the amount that can be delivered by a patch is
limited, two or more patches may be used. The number and size of
the patch is not important. What is important is that a
therapeutically effective amount of a compound of the present
invention be delivered as is known to those skilled in the art. The
compound can be administered rectally by suppository as is known to
those skilled in the art. When administered by suppository, the
therapeutically effective amount is from about 0.2 mg to about 500
mg.
[0289] The methods of treatment include administration of the
compounds by implants as is known to those skilled in the art. When
administering a compound of the present invention by implant, the
therapeutically effective amount is the amount described above for
depot administration.
[0290] Given a particular compound of the present invention and/or
a desired dosage form and medium, one skilled in the art would know
how to prepare and administer the appropriate dosage form and/or
amount.
[0291] The methods of treatment include use of the compounds of the
present invention, or acceptable pharmaceutical salts thereof, in
combination, with each other or with other therapeutic agents, to
treat or prevent the conditions listed above. Such agents or
approaches include acetylcholine esterase inhibitors such as
tacrine (tetrahydroaminoacridine, marketed as COGNEX.RTM.),
donepezil hydrochloride, (marketed as Aricept.RTM.) and
rivastigmine (marketed as Exelon.RTM.), gamma-secretase inhibitors,
anti-inflammatory agents such as cyclooxygenase II inhibitors,
anti-oxidants such as Vitamin E or ginkolides, immunological
approaches, such as, for example, immunization with A-beta peptide
or administration of anti-A-beta peptide antibodies, statins, and
direct or indirect neurotropic agents such as Cerebrolysin.RTM.,
AIT-082 (Emilien, 2000, Arch. Neurol. 57:454), and other
neurotropic agents, and complexes with beta-secretase or fragments
thereof.
[0292] Additionally, methods of treatment of the present invention
also employ the compounds of the present invention with inhibitors
of P-glycoprotein (P-gp). P-gp inhibitors and the use of such
compounds are known to those skilled in the art. See, for example,
Cancer Research, 53, 4595-4602 (1993), Clin. Cancer Res., 2, 7-12
(1996), Cancer Research, 56, 4171-4179 (1996), International
Publications WO 99/64001 and WO 01/10387. The blood level of the
P-gp inhibitor should be such that it exerts its effect in
inhibiting P-gp from decreasing brain blood levels of the compounds
of formula (I). To that end the P-gp inhibitor and the compounds of
formula (I) can be administered at the same time, by the same or
different route of administration, or at different times. Given a
particular compound of formula (I), one skilled in the art would
know whether a P-gp inhibitor is desirable for use in the method of
treatment, which P-gp inhibitor should be used, and how to prepare
and administer the appropriate dosage form and/or amount.
[0293] Suitable P-gp inhibitors include cyclosporin A, verapamil,
tamoxifen, quinidine, Vitamin E-TGPS, ritonavir, megestrol acetate,
progesterone, rapamycin, 10,11-methanodibenzosuberane,
phenothiazines, acridine derivatives such as GF120918, FK506,
VX-710, LY335979, PSC-833, GF-102,918, quinoline-3-carboxylic acid
(2-{4-[2-(6,7-dimethyl-3,4-dihydro-1H-isoquinoline-2-yl)-ethyl]phenylcarb-
amoyl}-4,5-dimethylphenyl)-amide (Xenova), or other compounds.
Compounds that have the same function and therefore achieve the
same outcome are also considered to be useful.
[0294] The P-gp inhibitors can be administered orally,
parenterally, (via IV, IM, depo-IM, SQ, depo-SQ), topically,
sublingually, rectally, intranasally, intrathecally, or by
implant.
[0295] The therapeutically effective amount of the P-gp inhibitors
is from about 0.1 mg/kg to about 300 mg/kg daily, preferably about
0.1 mg/kg to about 150 mg/kg daily. It is understood that while a
patient may be started on one dose, that dose may vary over time as
the patient's condition changes.
[0296] When administered orally, the P-gp inhibitors can be
administered in usual dosage forms for oral administration as is
known to those skilled in the art. These dosage forms include the
usual solid unit dosage forms of tablets or capsules as well as
liquid dosage forms such as solutions, suspensions or elixirs. When
the solid dosage forms are used, it is preferred that they be of
the sustained release type so that the P-gp inhibitors need to be
administered only once or twice daily. The oral dosage forms are
administered to the patient one through four times daily. It is
preferred that the P-gp inhibitors be administered either three or
fewer times a day, more preferably once or twice daily. Hence, it
is preferred that the P-gp inhibitors be administered in solid
dosage form and further it is preferred that the solid dosage form
be a sustained release form which permits once or twice daily
dosing. It is preferred that the dosage form used is designed to
protect the P-gp inhibitors from the acidic environment of the
stomach. Enteric coated tablets are well known to those skilled in
the art. In addition, capsules filled with small spheres each
coated to protect from the acidic stomach, are also well known to
those skilled in the art.
[0297] In addition, the P-gp inhibitors can be administered
parenterally. When administered parenterally they can be
administered via IV, IM, depo-IM, SQ or depo-SQ.
[0298] The P-gp inhibitors can be given sublingually. When given
sublingually, the P-gp inhibitors should be given one through four
times daily in the same amount as for IM administration.
[0299] The P-gp inhibitors can be given intranasally. When given by
this route of administration, the appropriate dosage forms are a
nasal spray or dry powder as is known to those skilled in the art.
The dosage of the P-gp inhibitors for intranasal administration is
the same as for IM administration.
[0300] The P-gp inhibitors can be given intrathecally. When given
by this route of administration the appropriate dosage form can be
a parenteral dosage form as is known to those skilled in the
art.
[0301] The P-gp inhibitors can be given topically. When given by
this route of administration, the appropriate dosage form is a
cream, ointment or patch. Because of the amount of the P-gp
inhibitors needed to be administered the patch is preferred.
However, the amount that can be delivered by a patch is limited.
Therefore, two or more patches may be required. The number and size
of the patch is not important, what is important is that a
therapeutically effective amount of the P-gp inhibitors be
delivered as is known to those skilled in the art.
[0302] The P-gp inhibitors can be administered rectally by
suppository or by implants, both of which are known to those
skilled in the art.
[0303] It should be apparent to one skilled in the art that the
exact dosage and frequency of administration will depend on the
particular compounds of the present invention administered, the
particular condition being treated, the severity of the condition
being treated, the age, weight, or general physical condition of
the particular patient, or any other medication the individual may
be taking as is well known to administering physicians who are
skilled in this art.
[0304] Another embodiment of the present invention provides a
method of preventing or treating at least one condition associated
with amyloidosis using compounds with increased oral
bioavailability (increased F values).
[0305] Another embodiment of the present invention provides methods
for preventing or treating at least one condition associated with
amyloidosis, comprising administering to a host, a therapeutically
effective amount of at least one compound of formula (I), or at
least one pharmaceutically acceptable salt thereof, wherein
R.sub.1, R.sub.2, and R.sub.C are as previously defined, and
wherein the compound has an F value of at least 10%.
[0306] In another embodiment, the host is an animal.
[0307] In another embodiment, the host is human.
[0308] In another embodiment, the F value is greater than about
20%. In yet a further embodiment, the F value is greater than about
30%.
[0309] Another embodiment of the present invention provides methods
of preventing or treating at least one condition associated with
amyloidosis using compounds with a high degree of selectivity.
[0310] Investigation of potential beta-secretase inhibitors
produced compounds with increased selectivity for beta-secretase
over other aspartyl proteases such as cathepsin D (catD), cathepsin
E (catE), Human Immunodeficiency Viral (HIV) protease, and renin.
Selectivity was calculated as a ratio of inhibition (IC.sub.50)
values in which the inhibition of beta-secretase was compared to
the inhibition of other aspartyl proteases. A compound is selective
when the IC.sub.50 value (i.e., concentration required for 50%
inhibition) of a desired target (e.g., beta-secretase) is less than
the IC.sub.50 value of a secondary target (e.g., catD).
[0311] Alternatively, a compound is selective when its binding
affinity is greater for its desired target (e.g., beta-secretase)
versus a secondary target (e.g., catD).
[0312] Accordingly, methods of treatment include administering
selective compounds of formula (I) having a lower IC.sub.50 value
for inhibiting beta-secretase, or greater binding affinity for
beta-secretase, than for other aspartyl proteases such as catD,
catE, HIV protease, or renin. A selective compound is also capable
of producing a higher ratio of desired effects to adverse effects,
resulting in a safer method of treatment.
[0313] Exemplary compounds of formula (I) are provided in the
Examples below.
EXAMPLE 1
EXEMPLARY FORMULA (I) COMPOUNDS
[0314] TABLE-US-00001 EXAMPLE No. Compound 1-1. ##STR15##
4-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
methyl-butyramide 1-2. ##STR16##
4-[1-(3-tert-Butyl-phenyl)-4-methoxyimino-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
methyl-butyramide 1-3. ##STR17##
4-[1-(3-tert-Butyl-phenyl)-4-ethoxyimino-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
methyl-butyramide 1-4. ##STR18##
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethoxyimino)-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
methyl-butyramide 1-5. ##STR19##
4-[4-(2-Amino-ethoxyimino)-1-(3-tert-butyl-phenyl)-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-
N-methyl-butyramide 1-6. ##STR20##
4-[5-(3-tert-Butyl-phenyl)-2-hydroxyimino-hexahydro-
pyrimidin-5-ylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
methyl-butyramide 1-7. ##STR21##
4-[1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
methyl-butyramide 1-8. ##STR22##
4-[1-(3-tert-Butyl-phenyl)-4-(dimethyl-hydrazono)-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
methyl-butyramide 1-9. ##STR23##
4-[1-(3-tert-Butyl-phenyl)-4-cyanoimino-cyclohexylamino]-
2-(3,5-difluoro-benzyl)-3-hydroxy-N-methyl-butyramide 1-10.
##STR24##
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-
ylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N- methyl-butyramide
1-11. ##STR25## 4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-
benzo[c]isoxazol-5-ylamino]-2-(3,5-difluoro-benzyl)-
3-hydroxy-N-methyl-butyramide 1-12. ##STR26##
4-[1-(3-tert-Butyl-phenyl)-4-methylcarbamoylmethylene-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
methyl-butyramide 1-13. ##STR27##
{4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-
hydroxy-3-methylcarbamoyl-butylamino]- cyclohexylidene}-acetic acid
methyl ester 1-14. ##STR28##
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethylidene)-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
methyl-butyramide 1-15. ##STR29##
4-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
phenyl-butyramide 1-16. ##STR30##
4-[1-(3-tert-Butyl-phenyl)-4-methoxyimino-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
phenyl-butyramide 1-17. ##STR31##
4-[1-(3-tert-Butyl-phenyl)-4-ethoxyimino-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
phenyl-butyramide 1-18. ##STR32##
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethoxyimino)-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
phenyl-butyramide 1-19. ##STR33##
4-[4-(2-Amino-ethoxyimino)-1-(3-tert-butyl-phenyl)-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
phenyl-butyramide 1-20. ##STR34##
4-[5-(3-tert-Butyl-phenyl)-2-hydroxyimino-hexahydro-
pyrimidin-5-ylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
phenyl-butyramide 1-21. ##STR35##
4-[1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
phenyl-butyramide 1-22. ##STR36##
4-[1-(3-tert-Butyl-phenyl)-4-(dimethyl-hydrazono)-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
phenyl-butyramide 1-23. ##STR37##
4-[1-(3-tert-Butyl-phenyl)-4-cyanoimino-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
phenyl-butyramide 1-24. ##STR38##
4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-
ylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-phenyl- butyramide
1-25. ##STR39## 4-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-
benzo[c]isoxazol-5-ylamino]-2-(3,5-difluoro-benzyl)-
3-hydroxy-N-phenyl-butyramide 1-26. ##STR40##
4-[1-(3-tert-Butyl-phenyl)-4-methylcarbamoylmethylene-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
phenyl-butyramide 1-27. ##STR41##
{4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-
hydroxy-3-phenylcarbamoyl-butylamino]-cyclohexylidene}- acetic acid
methyl ester 1-28. ##STR42##
4-[1-(3-tert-Butyl-phenyl)-4-(2-hydroxy-ethylidene)-
cyclohexylamino]-2-(3,5-difluoro-benzyl)-3-hydroxy-N-
phenyl-butyramide 1-29. ##STR43##
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-
hydroxy-3-(1H-imidazol-2-yl)-butylamino]-cyclohexanone oxime 1-30.
##STR44## 4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-
hydroxy-butylamino]-cyclohexanone oxime 1-31. ##STR45##
4-(3-tert-Butyl-phenyl)-4-[3-(3,5-difluoro-phenoxy)-2-
hydroxy-propylamino]-cyclohexanone oxime 1-32. ##STR46##
4-(3-tert-Butyl-phenyl)-4-[3-(3,5-difluoro-benzenesulfonyl)-
2-hydroxy-propylamino]-cyclohexanone oxime 1-33. ##STR47##
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-
hydroxy-4-oxo-butylamino]-cyclohexanone oxime 1-34. ##STR48##
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-
hydroxy-pentylamino]-cyclohexanone oxime 1-35. ##STR49##
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-
hydroxy-pentylamino]-cyclohexanone oxime 1-36. ##STR50##
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-
hydroxy-3-tetrazol-1-yl-butylamino]-cyclohexanone oxime 1-37.
##STR51## 4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-
hydroxy-3-(5-trifluoromethyl-[1,3,4]oxadiazol-2-yl)-
butylamino]-cyclohexanone oxime 1-38. ##STR52##
4-(3-tert-Butyl-phenyl)-4-[4-(3,5-difluoro-phenyl)-2-
hydroxy-3-([1,2,4]thiadiazol-5-ylamino)-butylamino]- cyclohexanone
oxime 1-39. ##STR53## 3-[3-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-
cyolohexylamino]-1-(3,5-difluoro-benzyl)-2-hydroxy-
propylamino]-4-methylamino-cyclobut-3-ene-1,2-dione 1-40. ##STR54##
3-[3-[1-(3-tert-Butyl-phenyl)-4-hydroxyimino-
cyclohexylamino]-1-(3,5-difluoro-benzyl)-2-hydroxy-
propylamino]-4-methoxy-cyclobut-3-ene-1,2-dione 1-41. ##STR55##
4-(3-tert-Butyl-phenyl)-4-[2-hydroxy-4-(3-propyl-thiophen-
2-yl)-3-([1,2,4]thiadiazol-5-ylamino)-butylamino]- cyclohexanone
oxime 1-42 ##STR56##
1-(5-(3-tert-butylphenyl)-4,5,6,7-tetrahydro-2H-indazol-5-
ylamino)-4-(3,5-difluorophenyl)butan-2-ol 1-43 ##STR57##
1-(5-(3-tert-butylphenyl)-2-methyl-4,5,6,7-tetrahydro-2H-
indazol-5-ylamino)-4-(3,5-difluorophenyl)butan-2-ol
Experimental Procedures
[0315] The compounds and the methods of treatment of the present
invention can be prepared by one skilled in the art based on
knowledge of the compound's chemical structure. The chemistry for
the preparation of the compounds employed in the methods of
treatment of this invention is known to those skilled in the art.
In fact, there is more than one process to prepare the compounds
employed in the methods of treatment of the present invention.
Specific examples of methods of preparation can be found in the
art. For examples, see Zuccarello et al., J. Org. Chem. 1998, 63,
4898-4906; Benedetti et al., J. Org. Chem. 1997, 62, 9348-9353;
Kang et al., J. Org. Chem. 1996, 61, 5528-5531; Kempf et al., J.
Med. Chem. 1993, 36, 320-330; Lee et al., J. Am. Chem. Soc. 1999,
121, 1145-1155; and references cited therein; Chem. Pharm. Bull.
(2000), 48(11), 1702-1710; J. Am. Chem. Soc. (1974), 96(8),
2463-72; Ind. J. Chem., .sctn.B: Organic Chemistry Including
Medicinal Chemistry (2003), 42B(4), 910-915; and J. Chem. Soc.
.sctn.C: Organic (1971), (9), 1658-10. See also U.S. Pat. Nos.
6,150,530, 5,892,052, 5,696,270, and 5,362,912, and references
cited therein, which are incorporated herein by reference.
[0316] .sup.1H and .sup.13C NMR spectra were obtained on a Varian
400 MHz, Varian 300 MHz, or Bruker 300 MHz instrument and as
described in the above examples. Unless otherwise stated, HPLC
samples were analyzed using a YMC ODS-AQ S-3 120 A 3.0.times.50 mm
cartridge, with a standard gradient from 5% acetonitrile containing
0.01% heptafluorobutyric acid (HFBA) and 1% isopropanol in water
containing 0.01% HFBA to 95% acetonitrile containing 0.01% HFBA and
1% isopropanol in water containing 0.01% HFBA over 5 minutes. Mass
spec samples were performed with electron spray ionization
(ESI).
Exemplary HPLC Procedures
[0317] Various High Pressure Liquid Chromatography (HPLC)
procedures employed the following methods:
[0318] Method [1] utilizes a 20% [B]: 80% [A] to 70% [B]: 30% [A]
gradient in 1.75 min, then hold, at 2 mL/min, where [A]=0.1%
trifluoroacetic acid in water; [B]=0.1% trifluoroacetic acid in
acetonitrile on a Phenomenex Luna C18 (2) 4.6 mm.times.30 cm
column, 3 micron packing, 210 nm detection, at 35.degree. C.
[0319] Method [2] utilizes a 50% [B]: 50% [A] to 95% [B]: 5% [A]
gradient in 2.5 min, then hold, at 2 mL/min, where [A]=0.1%
trifluoroacetic acid in water; [B]=0.1% trifluoroacetic acid in
acetonitrile on a Phenomenex Luna C18 (2) 4.6 mm.times.30 cm
column, 3 micron packing, 210 nm detection, at 35.degree. C.
[0320] Method [3] utilizes a 5% [B]: 95% [A] to 20% [B]: 80% [A]
gradient in 2.5 min, then hold, at 2 mL/min, where [A]=0.1%
trifluoroacetic acid in water; [B]=0.1% trifluoroacetic acid in
acetonitrile on a Phenomenex Luna C18 (2) 4.6 mm.times.30 cm
column, 3 micron packing, 210 nm detection, at 35.degree. C.
[0321] Method [4] utilizes a 20% [B]: 80% [A] to 70% [B]: 30% [A]
gradient in 2.33 min, then hold, at 1.5 mL/min, where [A]=0.1%
trifluoroacetic acid in water; [B]=0.1% trifluoroacetic acid in
acetonitrile on a Phenomenex Luna C18 (2) 4.6 mm.times.30 cm
column, 3 micron packing, 210 nm detection, at 35.degree. C.
[0322] Method [5] utilizes a 50% [B]: 50% [A] to 95% [B]: 5% [A]
gradient in 3.33 min, then hold, at 1.5 mL/min, where [A]=0.1%
trifluoroacetic acid in water; [B]=0.1% trifluoroacetic acid in
acetonitrile on a Phenomenex Luna C18 (2) 4.6 mm.times.30 cm
column, 3 micron packing, 210 nm detection, at 35.degree. C.
[0323] Method [6] utilizes a 5% [B]: 95% [A] to 20% [B]: 80% [A]
gradient in 3.33 min, then hold, at 1.5 mL/min, where [A]=0.1%
trifluoroacetic acid in water; [B]=0.1% trifluoroacetic acid in
acetonitrile on a Phenomenex Luna C18 (2) 4.6 mm.times.30 cm
column, 3 micron packing, 210 nm detection, at 35.degree. C.
[0324] Method [7] utilizes a 20% [B]: 80% [A] to 70% [B]: 30% [A]
gradient in 1.75 min, then hold, at 2 mL/min, where [A]=0.1%
trifluoroacetic acid in water; [B]=0.1% trifluoroacetic acid in
acetonitrile on a Phenomenex Luna C18 (2) 4.6 mm.times.30 cm
column, 3 micron packing, 210 nm detection, at 35.degree. C.
[0325] Method [8] utilizes a YMC ODS-AQ S-3 120 A 3.0.times.50 mm
cartridge, with a standard gradient from 5% acetonitrile containing
0.01% heptafluorobutyric acid (HFBA) and 1% isopropanol in water
containing 0.01% HFBA to 95% acetonitrile containing 0.01% HFBA and
1% isopropanol in water containing 0.01% HFBA over 5 min.
[0326] Method [9] utilizes a 20% [B]: 80% [A] to 70% [B]: 30% [A]
gradient in 10.0 min, then hold, at 1.5 mL/min, where [A]=0.1%
trifluoroacetic acid in water; [B]=0.1% trifluoroacetic acid in
acetonitrile on a Phenomenex Luna C18 (2) 4.6 mm.times.3 cm column,
3 micron packing, 210 nm detection, at 35.degree. C.
EXAMPLE 2
GENERAL PREPARATION OF FORMULA (I) COMPOUNDS
[0327] ##STR58##
[0328] The general synthesis of compounds of formula (I) are shown
in the above Scheme 1, and Schemes 2 and 3 below. In Scheme 1,
chiral epoxides (1), which were derived from amino acids and are
known in the art (see Luly, J. R. et al. J. Org. Chem. 1987, 52,
1487; Tucker, T. J. et al. J. Med. Chem. 1992, 35, 2525), were
treated with 1.5-5 equivalents of primary amine H.sub.2N--R.sub.C
in a C.sub.1-C.sub.6 alcoholic solvent, such as ethanol,
isopropanol, or sec-butanol to effect ring opening of the epoxide.
The reactions can be run at temperatures ranging from about
20-25.degree. C. up to about the reflux temperature of the alcohol
employed. The preferred temperature range for conducting the
reaction is between 40.degree. C. and the refluxing temperature of
the alcohol employed. A more preferred embodiment is to perform
this reaction at reflux in isopropanol.
[0329] The resulting amino alcohol is protected with capping group
P.sub.2. Appropriate protecting groups such as tert-butoxycarbonyl
(Boc) or benzyloxycarbonyl (Cbz) may be introduced via treatment
with the appropriate anhydride or carbamoyl chloride as known in
the art in order to provide compounds of type 2. It is preferred to
select protecting groups P.sub.2 which may be orthogonally removed
independently from P.sub.1.
[0330] The protecting group P.sub.1 is removed affording the
corresponding amine by means known to those skilled in the art for
removal of amine protecting groups. For example, it is preferred to
remove the preferred protecting group, Boc, by dissolving 2 in a
trifluoroacetic acid/dichloromethane (1/1) mixture. When complete,
the solvents are removed under reduced pressure yielding the
corresponding amine (3) (as the corresponding salt, i.e.
trifluoroacetic acid salt) which is used without further
purification. If desired, the amine can be purified further by
means well known to those skilled in the art, such as, for example,
recrystallization. Further, if the non-salt form is desired, it
also can be obtained by means known to those skilled in the art,
such as, for example, preparing the free base amine via treatment
of the salt with mild basic conditions. Additional Boc deprotection
conditions and deprotection conditions for other protecting groups
can be found in T. W. Green and P. G. M. Wuts in Protecting Groups
in Organic Chemistry, 3.sup.rd edition, John Wiley and Sons,
1999.
[0331] The addition of the group R may be achieved by a variety of
methods known in the art, depending on the nature of R, and can be
found in R. C. Larock's Comprehensive Organic Transformations, VCH
Publishers, 1989, e.g., pp. 972, 979, and 981. Removal of the
protecting group P.sub.2 by methods known in the art would then
afford 4.
EXAMPLE 3
ALTERNATIVE PREPARATION OF FORMULA (I) COMPOUNDS
[0332] ##STR59##
[0333] An alternative approach was to use a common advanced
intermediate 7 by which a reactive group could be converted to
yield compounds 4. Epoxides 1 were treated with 1.5-5 equivalents
of primary amine H.sub.2N--R.sub.c1 in an alcoholic solvent, such
as ethanol, isopropanol, or sec-butanol to effect ring opening of
the epoxide. In an embodiment, this reaction is prepared at
elevated temperatures from 40.degree. C. to reflux. In another
embodiment, this reaction is performed at reflux in isopropanol.
The resulting amino alcohol 5 was then deprotected.
[0334] When R.sub.c1 contains a labile functional group, such as an
aryl iodide, aryl bromide, aryl trifluoromethanesulfonate, or aryl
boronic ester, which may be converted into R.sub.C via transition
metal-mediated coupling, this allows for the rapid synthesis of a
variety of analogs 4. Such conversions may include Suzuki (aryl
boronic acid or boronic ester and aryl halide), Negishi (arylzinc
and aryl or vinyl halide), and Sonogashira (arylzinc and alkynyl
halide) couplings. Subsequent to the coupling reaction, the
protecting group P.sub.2 is removed in methods known in the art to
yield compounds 4.
EXAMPLE 4
ALTERNATIVE PREPARATION OF FORMULA (I) COMPOUNDS
[0335] ##STR60##
[0336] As described herein, one embodiment of the present invention
provides for compounds of formula 8 as shown above in Scheme 3.
These compounds may be made by methods known to those skilled in
the art from starting compounds that are also known to those
skilled in the art. The process chemistry is further well known to
those skilled in the art. A suitable process for the preparation of
compounds of formula 8 is set forth in Scheme 3 above.
EXAMPLE 5
PREPARATION OF
8-(3-ISOPROPYLPHENYL)-1,4-DIOXA-SPIRO[4.5]DECANE-8-AMINE ACETATE
(11)
[0337] ##STR61##
Step 1. Preparation of
8-(3-isopropylphenyl)-1,4-dioxa-spiro[4.5]decane-8-alcohol (9)
[0338] A solution of 3-bromoisopropylbenzene (25 mmol) in 20 mL of
dry THF was added dropwise over 20 min to 1.22 g (50 mmol) of
magnesium turnings in 10 mL of refluxing THF under nitrogen and the
mixture was refluxed for an additional 25 min to form the Grignard
reagent. The Grignard solution was cooled and added by cannula to a
suspension of CuBr-dimethylsulfide complex (0.52 g, 2.5 mmol) in
dry THF at -25.degree. C. The suspension was stirred at -25.degree.
C. for 20 min, and then a solution of 1,4 cyclohexanedione,
monoethylene ketal (3.9 g, 25 mmol) in 15 mL of THF was added
dropwise over 5 min. The mixture was allowed to gradually warm to
ambient temperature. After chromatography over silica gel, eluting
with 20% to 30% ethyl acetate in heptane, alcohol 9 (5.6 g, 20
mmol, 80%) was isolated as a colorless oil which crystallized to a
white solid on cooling: .sup.1H NMR (CDCl.sub.3) .delta. 7.39 (s,
1H), 7.33 (m, 1H), 7.28 (t, J=7.5 Hz, 1H), 7.13 (d, J=7.5 Hz, 1H),
4.0 (m, 4H), 2.91 (hept, J=7 Hz, 1H), 2.15 (m, 4H), 1.82 (brd,
J=11.5 Hz, 2H), 1.70 (brd, J=11.5 Hz, 2H), 1.25 (d, J=7 Hz, 6H); MS
(CI) m/z 259.2 (M-OH).
Step 2. Preparation of
8-(3-isopropylphenyl)-1,4-dioxa-spiro[4.5]decane-8-azide (10)
[0339] 8-(3-isopropylphenyl)-1,4-dioxa-spiro[4.5]decane-8-alcohol 9
(5.5 g, 20 mmol) was reacted with sodium azide (2.9 g, 45 mmol) and
trifluoroacetic acid (TFA, 13 mL, 170 mmol) in 120 mL of
CH.sub.2Cl.sub.2 at 0.degree. C., allowing the reaction to stir 2 h
after dropwise addition of the TFA. The reaction was quenched by
dropwise addition of 18 mL of concentrated NH.sub.4OH.
[0340] The mixture was taken up in water, ethyl acetate, and
heptane, and the organic phase was washed three more times with
water and once with brine. The solution was dried
(Na.sub.2SO.sub.4), filtered, concentrated, and chromatographed
over silica gel, eluting with 3% acetone in heptane. Concentration
of the product-containing fractions afforded 2.2 g (7.3 mmol, 36%)
of 10 as a colorless oil: .sup.1H NMR (CDCl.sub.3) .delta.
7.33-7.26 (m, 3H), 7.17 (m, 1H), 3.98 (m, 4H), 2.92 (hept, J=7 Hz,
1H), 2.2-2.12 (m, 2H), 2.07-1.95 (m, 4H), 1.72 (m, 2H), 1.26 (d,
J=7 Hz, 6H).
Step 3. Preparation of
8-(3-isopropylphenyl)-1,4-dioxa-spiro[4.5]decane-8-amine acetate
(11)
[0341] 2.2 g (7.3 mmol) of
8-(3-isopropylphenyl)-1,4-dioxa-spiro[4.5]decane-8-azide (10) in
200 mL of ethanol was reduced under 16 psi of hydrogen in the
presence of 0.7 g of 10% palladium on carbon for 4.5 h. Filtration
and removal of solvents with a toluene azeotrope affords a white
solid which was triturated with pentane to yield 2.14 g (6.4 mmol,
87%) of 11 as a white solid: .sup.1H NMR (CDCl.sub.3) .delta.
7.37-7.33 (m, 2H), 7.30-7.26 (m, 1H), 7.13 (d, J=7.5 Hz, 1H), 5.91
(br, 3H), 3.96 (m, 4H), 2.90 (hept., J=7 Hz, 1H), 2.32 (m, 2H),
2.03 (s, 3H), 2.0-1.85 (m, 4H), 1.63 (m, 2H), 1.25 (d, J=7 Hz, 6H);
MS (CI) m/z 259.2 (M-NH.sub.2).
EXAMPLE 6
EXEMPLARY PREPARATION OF OXIME PRECURSOR
[0342] ##STR62##
EXAMPLE 7
EXEMPLARY PREPARATION OF AN OXIME
[0343] ##STR63##
EXAMPLE 8
EXEMPLARY PREPARATION OF A HYDRAZONE
[0344] ##STR64##
EXAMPLE 9
PREPARATION OF
N-((1S,2R)-1-(3,5-DIFLUOROBENZYL)-2-HYDROXY-3-{[1-(3-ISOPROPYLPHENYL)CYCL-
OHEXAN-4-ONE]AMINO}PROPYL) ACETAMIDE (15)
[0345] ##STR65##
Step 1. Preparation of tert-butyl
(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{8-(3-isopropylphenyl)-1,4-dio-
xa-spiro[4.5]decane-8-amino}propylcarbamate (13)
[0346] 8-(3-isopropylphenyl)-1,4-dioxa-spiro[4.5]decane-8-amine
acetate 11 (3.2 mmol) was neutralized and reacted with
[2-(3,5-Difluoro-phenyl)-1-oxiranyl-ethyl]-carbamic acid tert-butyl
ester 12 (0.6 g, 2.0 mmol) in refluxing isopropanol (15 mL) for
15.5 h. The reaction mixture was concentrated and chromatographed
over silica gel, eluting with 4% methanol (containing 2% of
NH.sub.4OH) in CH.sub.2Cl.sub.2 to separate the crude product from
excess 8-(3-isopropylphenyl)-1,4-dioxa-spiro[4.5]decane-8-amine.
The crude product was then re-chromatographed over silica gel,
eluting with 10% to 20% acetone in CH.sub.2Cl.sub.2 yielding 0.600
g (1.04 mmol, 52%) of 13 as a colorless oil: .sup.1H NMR
(CDCl.sub.3) .delta. 7.27-7.20 (m, 3H), 7.09 (d, J=7 Hz, 1H), 6.69
(m, 2H), 6.63 (m, 1H), 4.64 (d, J=9 Hz, 1H), 3.95 (m, 4H), 3.72 (m,
1H), 3.28 (m, 1H), 2.88 (m, 2H), 2.69 (dd, J=8.5, 14 Hz, 1H), 2.32
(m, 2H), 2.15 (m, 2H), 1.99-1.86 (m, 4H), 1.63 (m, 2H), 1.35 (s,
9H), 1.24 (d, J=7 Hz, 6H); MS (CI) m/z 575.4 (MH+)
Step 2. Preparation of
N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{8-(3-isopropylphenyl)-1,4--
dioxa-spiro[4.5]decane-8-amino}propyl)acetamide (14)
[0347] Tert-butyl
(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{8-(3-isopropylphenyl)-1,4-dio-
xa-spiro[4.5]decane-8-amino}propylcarbamate 13 (0.600 g, 1.04 mmol)
was deprotected, acetylated, and saponified yielding, after
chromatography on silica gel, eluting with 32.5% acetone and 2.5%
methanol in CH.sub.2Cl.sub.2, acetamide 14 (335 mg, 0.65 mmol, 62%)
as a white solid by concentration from ethyl ether: .sup.1H NMR
(CDCl.sub.3) .delta. 7.31-7.26 (m, 3H), 7.15 (m, 1H), 6.69-6.61 (m,
3H), 5.9 (br, 1H), 4.13 (m, 1H), 3.95 (m, 4H), 3.48 (m, 1H),
2.92-2.83 (m, 2H), 2.73 (dd, J=8.5, 14 Hz, 1H), 2.45-2.25 (m, 4H),
2.10 (m, 2H), 1.88 (s+m, 5H), 1.62 (m, 2H), 1.25 (d, J=7 Hz, 6H);
MS (CI) m/z 517.4 (MH+).
Step 3. Preparation of
N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-([1-(3-isopropylphenyl)cycl-
ohexan-4-one]amino)propyl)acetamide (15)
[0348] To
N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{8-(3-isopropylph-
enyl)-1,4-dioxa-spiro[4.5]decane-8-amino}propyl) acetamide 14 (255
mg, 0.49 mmol) in 5 mL of ethanol and 5 mL of water was added 6 mL
of trifluoroacetic acid, and the mixture was refluxed for 2 h under
nitrogen. It was concentrated and taken up in aqueous 10%
Na.sub.2CO.sub.3 and ethyl acetate. The organic phase was washed
twice more with 10% Na.sub.2CO.sub.3 and then with brine. It was
dried over Na.sub.2SO.sub.4, and concentrated to a colorless oil.
Evaporation in vacuo from ethyl ether affords 15 (140 mg, 0.30
mmol, 60%) as a white solid: .sup.1H NMR (CDCl.sub.3) .delta.
7.35-7.18 (m, 4H), 6.71-6.64 (m, 3H), 5.65 (br, 1H), 4.12 (m, 1H),
3.43 (m, 1H), 2.95-2.90 (m, 2H), 2.75 (dd, J=8.5, 14 Hz, 1H), 2.64
(m, 2H), 2.4-2.25 (m, 8H), 1.87 (s, 3H), 1.25 (d, J=7 Hz, 6H); MS
(CI) m/z 473.4 (MH+). The LC-MS spectrum in methanol solvent showed
a small signal at 505.4 (MH+CH.sub.3OH) due to hemiketal formation.
IR (diffuse reflectance) 3311, 2958, 1710, 1646, 1628, 1595, 1550,
1544, 1460, 1372, 1315, 1116, 983, 846, 707 cm.sup.-1.
[0349] MS (EI) m/z (relative intensity) 472 (M+, 6), 472 (6), 417
(5), 416 (33), 415 (99), 398 (8), 397 (30), 327 (11), 244 (9), 215
(13), 214 (6). HRMS (ESI) calculated for
C.sub.27H.sub.34N.sub.2O.sub.3F.sub.2+H.sub.1 473.2615, found
473.2627. Anal. Calc'd for
C.sub.27H.sub.34F.sub.2N.sub.2O.sub.3+0.5H.sub.2O: C, 67.34; H,
7.33; N, 5.82; Found (av): C, 67.89; H, 7.32; N, 5.86.
EXAMPLE 10
PREPARATION OF
N-[3-[1-(3-TERT)-BUTYL-PHENYL)-4-HYDROXYIMINO-CYCLOHEXYLAMINO]-1-(3,5-DIF-
LUORO-BENZYL)-2-HYDROXY-PROPYL]-ACETAMIDE
[0350] ##STR66##
[0351] To a solution of
N-[3-[1-(3-tert)-Butyl-phenyl)-4-oxo-cyclohexylamino]-1-(3,5-difluoro-ben-
zyl)-2-hydroxy-propyl]-acetamide (0.208 g, 0.43 mmol) in ethanol (4
mL) was added hydroxylamine hydrochloride (0.074 g, 1.07 mmol) and
sodium acetate (0.17 g, 2.05 mmol). The reaction mixture was
stirred at room temperature for 2.5 h prior to partitioning between
H.sub.2O and CH.sub.2Cl.sub.2. The organic layer was separated,
dried (Na.sub.2SO.sub.4) and concentrated under reduced pressure.
The residue was purified by flash chromatography (5%
MeOH/CH.sub.2Cl.sub.2) to yield the desired product (0.11 g, 53%).
MS (ESI): 502.2 (M+H). See Bravo, P., et al., J. Fluorine Chem., 59
(1992), 153-56.
EXAMPLE 11
PREPARATION OF
N-[3-[1-(3-TERT)-BUTYL-PHENYL)-4-METHOXYIMINO-CYCLOHEXYLAMINO]-1-(3,5-DIF-
LUORO-BENZYL)-2-HYDROXY-PROPYL]-ACETAMIDE
[0352] ##STR67##
[0353]
N-[3-[1-(3-tert)-Butyl-phenyl)-4-methoxyimino-cyclohexylamino]-1-(-
3,5-difluoro-benzyl)-2-hydroxy-propyl]-acetamide was prepared
according to essentially the same procedure as described in EXAMPLE
10. MS (ESI): 516.3 (M+H).
EXAMPLE 12
N-[3-[1-(3-TERT)-BUTYL-PHENYL)-4-ETHOXYIMINO-CYCLOHEXYLAMINO]-1-(3,5-DIFLU-
ORO-BENZYL)-2-HYDROXY-PROPYL]-ACETAMIDE
[0354] ##STR68##
[0355]
N-[3-[1-(3-tert)-Butyl-phenyl)-4-methoxyimino-cyclohexylamino]-1-(-
3,5-difluoro-benzyl)-2-hydroxy-propyl]-acetamide was prepared
according to essentially the same procedure as described in EXAMPLE
10. MS (ESI): 530.2 (M+H).
EXAMPLE 13
2-AMINOETHANOL HYDROCHLORIDE
[0356] ##STR69##
[0357] Tert-Butyl N-hydroxycarbamate (Aldrich, 2.64 g, 19.8 mmol)
was dissolved in 1,8-diazabicyclo[5.4.0]undec-7-ene (3.0 mL, 20
mmol) and 2-bromoethanol (1.7 mL, 24 mmol). The reaction mixture
was allowed to stir at room temperature overnight and quenched with
1N HCl. The product was extracted with CH.sub.2Cl.sub.2, dried
(Na.sub.2SO.sub.4), and concentrated under reduced pressure. The
residue was purified by flash chromatography (Hexane:EtOAc, 1:1)
yielding the desired product (2.48 g, 71%). MS (ESI): 200.1
(M+Na).
[0358] The N-Boc intermediate was deprotected by treatment with 4 N
HCl in dioxane. The reaction mixture was allowed to stir at room
temperature for 2 h prior to concentration under reduced pressure.
See Jones, D. S., et al., Tet. Lett., 41, (2000) 1531-33.
EXAMPLE 14
N-[3-[1-(3-TERT)-BUTYL-PHENYL)-4-(2-HYDROXY-ETHOXYIMINO-CYCLOHEXYLAMINO]-1-
-(3,5-DIFLUORO-BENZYL)-2-HYDROXY-PROPYL]-ACETAMIDE
[0359] ##STR70##
[0360]
N-[3-[1-(3-tert)-Butyl-phenyl)-4-methoxyimino-cyclohexylamino]-1-(-
3,5-difluoro-benzyl)-2-hydroxy-propyl]-acetamide was prepared
according to essentially the same procedure as described in EXAMPLE
10. MS (ESI): 546.3 (M+H). See Jones, D. S., et al., Tet. Lett.,
41, (2000) 1531-33.
EXAMPLE 15
PREPARATION OF
N-{1-(3,5-DIFLUORO-BENZYL)-2-HYDROXY-3-[4-METHOXYIMINO-1-(3-R--PHENYL)-CY-
CLOHEXYLAMINO]-PROPYL}-ACETAMIDE
[0361] ##STR71##
[0362] 25 mg (0.04 mmol) of the
N-[3-[1-(3-Bromo-phenyl)-4-oxo-cyclohexylamino]-1-(3,5-difluoro-benzyl)-2-
-hydroxy-propyl]-acetamide 15 was dissolved in 1 mL DME and placed
in a 4 mL reaction vial. Under N.sub.2(g), a solution of the
boronic acid (0.06 mmol), tetrakis(triphenylphosphine) palladium(0)
(0.006 mmol), and 0.125 mL of aqueous 2M Na.sub.2CO.sub.3 dissolved
in 1 mL DME was added to the reaction mixture. The reaction was
then stirred at 95.degree. C. for 15 h. The reaction mixture was
then concentrated yielding product 16.
[0363] The product 16 (0.048 mmol) was then dissolved in 1 mL
ethanol and placed in a 4 mL reaction vial. Methoxylamine
hydrochloride (0.23 mmol) and sodium acetate (0.13 mmol) are added
in the vial. The reaction was then stirred for 2.5 h at room
temperature. The reaction mixture was then concentrated and the
product 17 was isolated via preparative HPLC: Method [1].
EXAMPLE 16
PROCEDURE OF
N-[3-[1-(3-BROMO-PHENYL)-4-OXO-CYCLOHEXYLAMINO]-1-(3,5-DIFLUORO-BENZYL)-2-
-HYDROXY-PROPYL]-ACETAMIDE (19)
[0364] ##STR72##
Step 1: Procedure of 2-Methyl-propane-2-sulfinic acid
(1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide (15)
[0365] An oven dried round-bottom flask was cooled to room
temperature by flushing with N.sub.2(g) for 30 min.
1,4-Dioxa-spiro[4.5]decan-8-one (1.35 g, 8.66 mmol) (dissolved in
12 mL THF), 2-Methyl-propane-2-sulfinic acid amide (1.0 g, 8.25
mmol) (dissolved in THF), and titanium(IV) ethoxide (3.77 g, 16.50
mmol) were added. The reaction was stirred for 4 h at room
temperature. To the mixture was added 15 mL saturated NaHCO.sub.3
followed by filtration and an EtOAc rinse. The organic layer was
dried with MgSO.sub.4, filtered and concentrated under reduced
pressure yielding 0.98 g of Compound 15.
[0366] MS m/z 260.1; retention time: 0.754, method [8].
Step 2: Procedure for
8-(3-Bromo-phenyl)-1,4-dioxa-spiro[4.5]dec-8-ylamine Hydrochloride
(16)
[0367] Two oven dried round-bottom flask were cooled to room
temperature by flushing with N.sub.2(g). n-Butyl Lithium (2.5 M in
hexanes) (0.46 g, 7.14 mmol) was added dropwise to a stirring
solution of 1-Bromo-3-iodo-benzene (2.02 g, 7.14 mmol) in 3.2 mL
toluene at 0.degree. C. The reaction stirred from 0.degree. C. to
room temperature over 2 h. A separate solution of compound 15 (0.98
g, 3.4 mmol) and AlMe.sub.3 (0.269 g, 3.74 mmol) were added to a
second flask cooled to -78.degree. C. and stirred for 10 min. This
second mixture was added by cannula to the first. The combined
material was at 0.degree. C. and allowed to reach room temperature
over 3 h. The reaction was then quenched with
Na.sub.2SO.sub.4.6H.sub.2O. MgSO.sub.4 was added to the reaction
mixture, which was then filtered and concentrated under reduced
pressure. The reaction provided 1.6 g of crude material. A column
on silica gel (50% EtOAc:hexanes) provided 0.29 g of pure material.
The pure material was treated with 0.69 mL 4M HCl in dioxanes and
stirred for 1 h at room temperature. The reaction mixture was then
placed under reduced pressure. 0.23 g of Compound 16 were
recovered.
[0368] MS m/z 295.0 (M-NH.sub.2); retention time: 0.979, method
[8].
Step 3: Procedure for
[3-[8-(3-Bromo-phenyl)-1,4-dioxa-spiro[4.5]dec-8-ylamino]-1-(3,5-difluoro-
-benzyl)-2-hydroxy-propyl]-carbamic acid tert-butyl ester (17)
[0369] Compound 16 was dissolved in 1 mL MeOH and added to a round
bottom flask. 2M NaOH was added until the pH was approximately 10.
The reaction mixture was rinsed six times with CH.sub.2Cl.sub.2.
The organic layer was dried with MgSO.sub.4, filtered and
concentrated under reduced pressure to get 0.16 grams of product.
The product was then dissolved in 1.0 mL isopropyl alcohol and
added to a sealed tube containing
[2-(3,5-Difluoro-phenyl)-1-oxiranyl-ethyl]-carbamic acid tert-butyl
ester (0.72 mmol). The reaction was heated to 80.degree. C. over
night. The reaction was concentrated by reduced pressure yielding
Compound 17.
[0370] MS m/z 611.1; retention time: 1.919, method [7].
Step 4: Procedure for
N-[3-[8-(3-Bromo-phenyl)-1,4-dioxa-spiro[4.5]dec-8-ylamino]-1-(3,5-difluo-
ro-benzyl)-2-hydroxy-propyl]-acetamide (18)
[0371] Compound 17 was dissolved in 1 mL (1:1) trifluoroacetic acid
(TFA) and CH.sub.2Cl.sub.2. The reaction stirred at room
temperature for 2 h and concentrated under reduced pressure. The
residue was dissolved in 4 mL CH.sub.2Cl.sub.2 and
N-Methylmorpholine (NMM) (3.12 mmol). The reaction was stirred at
0.degree. C. Acetic Acid (0.76 mmol) was added slowly to the
reaction mixture and the mixture stirred at 0.degree. C. for five
min. Then 1-Hydroxylbenzotriazole hydrate (HOBt) (0.76 mmol) and
1-Ethyl-3-(3'-Dimethylaminopropyl)carbodiimide Hydrochloride
(EDC.HCl) (0.76 mmol) were added sequentially. The reaction was
stirred at room temperature for two h. CH.sub.2Cl.sub.2 was removed
by reduced pressure and the residue dissolved in EtOAc. The organic
layer was rinsed with a saturated NaHCO.sub.3 solution three times
and once with Brine. The organic layer was dried with MgSO.sub.4,
filtered and concentrated under reduced pressure. Compound 22 was
purified by preparative HPLC.
[0372] MS m/z 509.0; retention time: 1.335, method [7].
Step 5: Procedure for
N-[3-[1-(3-Bromo-phenyl)-4-oxo-cyclohexylamino]-1-(3,5-difluoro-benzyl)-2-
-hydroxy-propyl]-acetamide (19)
[0373] Compound 18 (0.4 g, 0.78 mmol), p-Toluenesulfonic acid
monohydrate (TsOH) (0.16 g, 0.84 mmol), and poly(Ethylene glycol)
(8.9 g, 143.4 mmol) were added to 25 mL benzene. The reaction was
heated to 100.degree. C. for 30 min. The benzene was removed under
reduced pressure and fresh benzene was added. The resulting mixture
was treated with saturated NaHCO.sub.3 and extracted
CH.sub.2Cl.sub.2. The organic layer was washed with brine and dried
with MgSO.sub.4, filtered and concentrated under reduced pressure
providing 0.4 g of Compound 19.
[0374] MS m/z 553.1; retention time: 1.523, method [7].
EXAMPLE 17
N-{1-(3,5-DIFLUORO-BENZYL)-2-HYDROXY-3-[8-(3-PYRAZOL-1-YL-PHENYL)-1,4-DIOX-
A-SPIRO[4.5]DEC-8-YLAMINO]-PROPYL}-ACETAMIDE (21)
[0375] ##STR73##
[0376] Compound 18 (0.4 g, 0.72 mmol), pyrazole (0.059 g, 0.87
mmol), and cesium carbonate (0.47 g, 1.45 mmol) were added to a
round-bottom flask. Diglyme was added to
trans-1,2-diaminocyclohexane (0.0082 g, 0.072 mmol). This mixture
was added to Copper(I) Iodide (0.014 g, 0.072 mmol). The mixture
was then added to the round-bottom flask. The reaction mixture was
then heated to 130.degree. C. for 4 days. The crude material was
purified by preparative HPLC (13.0 mg) yielding Compound 20.
[0377] .sup.1H NMR (CD.sub.3OD) .delta. 7.87 (s, 1H), 7.72-7.65 (m,
2H), 7.52-7.46 (m, 1H), 6.82-6.79 (m, 3H), 4.00-3.87 (m, 4H),
3.57-3.54 (m, 1H), 3.23-3.17 (m, 1H), 2.83-2.65 (m, 3H), 2.58-2.53
(m, 1H), 2.27-2.19 (m, 2H), 1.87 (s, 2H), 1.80 (s, 2H), 1.80 (s,
3H), 1.51-1.29 (m, 4H).
[0378] MS m/z 541.2; retention time: 1.412, method [7].
EXAMPLE 18
N-{1-(3,5-DIFLUORO-BENZYL)-2-HYDROXY-3-[4-METHOXYIMINO-1-(3-PYRAZOL-1-YL-P-
HENYL)-CYCLOHEXYLAMINO]-PROPYL}-ACETAMIDE (21)
[0379] ##STR74##
[0380] Compound 20 was treated with a (1:1) 2M HCl and THF solution
(10 mL) and refluxed overnight. Almost all the THF was removed
under reduced pressure and 10% NaOH was added until the pH was
approximately 10. The reaction mixture was then rinsed six times
with CH.sub.2Cl.sub.2. The organic layer was rinsed with
MgSO.sub.4, filtered and concentrated under reduced pressure to
provide 0.044 g of about 85% pure product. The ketone was then
transferred to a round-bottom flask containing
CH.sub.3ONH.sub.2.HCl (0.013 g, 0.20 mmol), NaOAc (0.032 g, 0.39
mmol), and 5 mL EtOH. The reaction stirred at room temperature for
2.5 h. The reaction was quenched with H.sub.2O and extracted with
CH.sub.2Cl.sub.2. The CH.sub.2Cl.sub.2 was removed under reduced
pressure and the crude material was purified by preparative HPLC
(9.0 mg) yielding Compound 21.
[0381] .sup.1H NMR (CD.sub.3OD) .delta. 8.35-8.34 (bs, 1H), 8.12
(s, 1H), 7.91-7.88 (d, J=9 Hz, 1H), 7.77 (s, 1H), 7.72-7.63 (m,
2H), 6.79-6.73 (m, 3H), 6.58-6.57 (m, 1H), 3.86-3.83 (m, 1H), 3.77
(s, 3H), 3.58-3.54 (m, 1H), 3.23-3.15 (m, 2H), 2.93-2.89 (m, 2H),
2.76-2.73 (bs, 2H), 2.57-2.48 (m, 2H), 2.21-2.17 (m, 2H), 2.13-2.03
(m, 2H), 1.71 (s, 3H).
[0382] MS m/z 526.2; retention time: 1.464, method [7].
EXAMPLE 19
N-[3-[1-(3-TERT-BUTYL-PHENYL)-3-METHYLENE-CYCLOHEXYLAMINO]-1-(3,5-DIFLUORO-
-BENZYL)-2-HYDROXY-PROPYL]-ACETAMIDE
Step 1
[0383] ##STR75##
[0384] 3-oxo-cyclohexanecarboxylic acid (2.00 g, 14.1 mmol),
2-trimethylsilylethanol (2.5 mL, 17.4 mmol),
4-dimethylaminopyridine (148 mg, 1.21 mmol), and
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (3.44
g, 17.9 mmol) in methylene chloride (14 mL) was stirred for 18 h.
The solution was diluted with 10% aqueous hydrochloric acid and
extracted with methylene chloride. The combined organic extracts
were dried over magnesium sulfate, filtered, and concentrated to
yield 3.41 g (100% yield) of 3-oxo-cyclohexanecarboxylic acid
2-trimethylsilanyl-ethyl ester as a clear oil.
[0385] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 4.16 (m, 2H), 2.75
(m, 1H), 2.55 (d, J=7.9 Hz, 2H), 2.36 (m, 2H), 2.08 (m, 2H), 1.82
(m, 2H), 0.98 (m, 2H), 0.04 (s, 9H).
Step 2
[0386] ##STR76##
[0387] A solution of 1.6 M n-butyllithium in hexanes (14.0 mL, 22.4
mmol) was added to a heterogeneous mixture of
methyltriphenylphosphonium bromide (8.02 g, 22.4 mmol) in
tetrahydrofuran (50 mL) at -10.degree. C. After stirring for 30 min
at -10.degree. C., the yellow slurry was cooled to -78.degree. C.
and 3-oxo-cyclohexanecarboxylic acid 2-trimethylsilanyl-ethyl ester
(3.41 mg, 14.1 mmol) in tetrahydrofuran (20 mL) was added. After
stirring for 10 min at -78.degree. C., the dry ice/acetone bath was
removed and the heterogeneous mixture was stirred for 3 h, during
which time the solution warmed to ambient temperature. The
heterogeneous mixture was concentrated and the residue was flash
chromatographed with 99:1, 49:1, 24:1, and 23:2 hexanes:etheyl
acetate as the eluant to yield 3.38 g (100% yield) of
3-methylene-cyclohexanecarboxylic acid 2-trimethylsilanyl-ethyl
ester as a clear oil.
[0388] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 4.68 (s, 2H), 4.16
(m, 2H), 2.51 (m, 1H), 2.24 (broad m, 3H), 1.98 (m, 2H), 1.86 (m,
1H), 1.55 (m, 1H), 1.38 (m, 1H), 0.98 (m, 2H), 0.05 (s, 9H).
Step 3
[0389] ##STR77##
[0390] A 1.6 M solution of n-butyllithium (12.0 mL, 19.2 mmol) was
added to a solution of dicyclohexylamine (3.7 mL, 18.6 mmol) in
toluene (40 mL). After stirring for 5 min,
3-methylene-cyclohexanecarboxylic acid 2-trimethylsilanyl-ethyl
ester (3.45 g, 14.4 mmol) was added. After stirring for 30 min,
1-bromo-3-tert-butyl-benzene (3.16 g, 14.8 mmol) was added followed
by the simultaneous addition of tri-tert-butylphosphonium
tetrafluoroborate (220 mg, 758 mmol) and
tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct (380 mg,
367 mmol). The solution was placed into a preheated oil bath at
60.degree. C. After stirring for 16 h, the solution was directly
flash chromatographed with 99:1, 49:1, 24:1, and 23:2 hexanes:ethyl
acetate as the eluant to yield 4.31 g (81% yield) of
1-(3-tert-butyl-phenyl)-3-methylene-cyclohexanecarboxylic acid
2-trimethylsilanyl-ethyl ester as a light yellow oil.
[0391] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 7.43 (d, J=1.0 Hz,
1H), 7.25 (m, 3H), 4.82 (s, 1H), 4.78 (s, 1H), 4.12 (m, 2H), 3.06
(d, J=13.3 Hz, 1H), 2.52 (d, J=13.3 Hz, 2H), 2.26 (dt, J=13.1 Hz
and 4.5 Hz, 1H), 2.05 (m, 1H), 1.88-1.59 (broad m, 3H), 1.31 (s,
9H), 0.89 (m, 2H), -0.04 (s, 9H).
Step 4
[0392] ##STR78##
[0393] A 1.0 M solution of tetrabutylammonium fluoride in
tetrahydrofuran (15.0 mL, 15.0 mmol) was added to
1-(3-tert-butyl-phenyl)-3-methylene-cyclohexanecarboxylic acid
2-trimethylsilanyl-ethyl ester (2.67 mg, 7.16 mmol). After stirring
for 16 h, the solution was concentrated, diluted with 10% aqueous
hydrochloric acid, and extracted with diethyl ether. The combined
organic extracts were dried over magnesium sulfate, filtered, and
concentrated to yield 2.09 g (100% yield) of
1-(3-tert-butyl-phenyl)-3-methylene-cyclohexanecarboxylic acid as a
yellow oil.
[0394] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 7.50 (m, 1H), 7.29
(m, 3H), 4.84 (s, 1H), 4.79 (s, 1H), 3.06 (d, J=13.3 Hz, 1H), 2.58
(d, J=13.3 Hz, 1H), 2.51-1.20 (broad m, 6H), 1.34 (s, 9H).
Step 5
[0395] ##STR79##
[0396] Diphenylphosphoryl azide (0.53 mL, 2.46 mmol) was added to a
solution of
1-(3-tert-butyl-phenyl)-3-methylene-cyclohexanecarboxylic acid (554
mg, 2.03 mmol) and triethylamine (0.43 mL, 3.08 mmol) in toluene (4
mL). After stirring at ambient temperature for 18 h, the solution
was placed into a preheated oil bath at 80.degree. C. Bubbling was
observed. After stirring for 1 h at 80.degree. C., the bubbling had
ceased and the solution was cooled to ambient temperature. 10%
aqueous hydrochloric acid was added and stirred vigorously for 3 h.
The aqueous layer was made alkaline with aqueous 3 N NaOH and
extracted with methylene chloride. The combined organic extracts
were dried over magnesium sulfate, filtered, and concentrated. The
residue was flash chromatographed with 99:1:0.1, 49:1:0.1,
24:1:0.1, and 23:2:0.2 methylene chloride:methanol:concentrated
ammonium hydroxide as the eluant to yield 12 mg (2% yield) of
1-(3-tert-butyl-phenyl)-3-methylene-cyclohexylamine.
[0397] Method [1] Retention time 1.94 min by HPLC and 2.00 min by
MS (M-NH.sub.2=227).
Step 6
[0398] Using 1-(3-tert-butyl-phenyl)-3-methylene-cyclohexylamine,
[3-[1-(3-tert-Butyl-phenyl)-3-methylene-cyclohexylamino]-1-(3,5-difluoro--
benzyl)-2-hydroxy-propyl]-carbamic acid tert-butyl ester,
3-Amino-1-[1-(3-tert-butyl-phenyl)-3-methylene-cyclohexylamino]-4-(3,5-di-
fluoro-phenyl)-butan-2-ol, and
N-[3-[1-(3-tert-Butyl-phenyl)-3-methylene-cyclohexylamino]-1-(3,5-difluor-
o-benzyl)-2-hydroxy-propyl]-acetamide are prepared according to
essentially the same procedure as described in Example 9, steps 1
and 2. ##STR80##
[0399] Method [1] Retention time 2.27 min by HPLC and 2.33 min by
MS (M+=543). ##STR81##
[0400] Method [1] Retention time 1.65 min by HPLC and 1.70 min by
MS (M+=443). ##STR82##
[0401] Method [1] Retention time 1.92 min by HPLC and 1.98 min by
MS (M+=485).
EXAMPLE 20
N-[3-[1-(3-TERT-BUTYL-PHENYL)-4-METHYLENE-CYCLOHEXYLAMINO]-1-(3,5-DIFLUORO-
-BENZYL)-2-HYDROXY-PROPYL]-ACETAMIDE
Step 1
[0402] ##STR83##
[0403] A solution of 1.6 M n-butyllithium in hexanes (46 mL, 73.6
mmol) was slowly added to a heterogeneous mixture of
methyltriphenylphosphonium bromide (28.07 g, 78.6 mmol) in
tetrahydrofuran (150 mL) at -10.degree. C. After stirring for 1 h,
1,4-dioxa-spiro[4.5]decan-8-one (8.01 g, 51.3 mmol) was added.
After stirring for 3 h, during which time the solution warmed to
ambient temperature, acetone was added and the heterogeneous
mixture was concentrated. The residue Was diluted with 1:1
methylene chloride:ethyl ether, filtered and concentrated. The
residue was flash chromatographed with 49:1, 24:1, and 23:2
hexanes:etheyl acetate as the eluant to yield 6.22 g (79% yield) of
8-methylene-1,4-dioxa-spiro[4.5]decane as a yellow oil.
[0404] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 4.67 (s, 2H), 3.96
(s, 4H), 2.29 (m, 4H), 1.70 (m, 4H).
Step 2
[0405] ##STR84##
[0406] A solution of 8-methylene-1,4-dioxa-spiro[4.5]decane (6.22
g, 40.3 mmol) was stirred in tetrahydrofuran (100 mL) and 10%
aqueous hydrochloric acid (100 mL) for 18 h. The solution was
extracted with ethyl ether and the combined organic extracts were
dried over magnesium sulfate. The combined organic extracts were
filtered and concentrated to yield 3.89 g (88% yield) of
4-methylene-cyclohexanone as a yellow oil.
[0407] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 4.89 (s, 2H), 2.47
(m, 8H).
Step 3
[0408] ##STR85##
[0409] A solution of 1.7 M tert-butyllithium in pentane (32.0 mL,
54.4 mmol) was added to a solution of 1-bromo-3-tert-butyl-benzene
(5.54 g, 26.0 mmol) in tetrahydrofuran (60 mL) at -78.degree. C.
After stirring for 1 h, cyclohexanone (2.00 g, 18.2 mmol) in
tetrahydrofuran (15 mL) was added. After stirring for 18 h, during
which time the solution warmed to ambient temperature, the solution
was diluted with saturated aqueous ammonium chloride and extracted
with methylene chloride. The combined organic extracts were dried
over magnesium sulfate, filtered, and concentrated. The residue was
flash chromatographed with 49:1, 24:1, 23:2 hexanes:ethyl acetate
as the eluant to yield 3.61 g (81% yield) of
1-(3-tert-butyl-phenyl)-4-methylene-cyclohexanol as a yellow
oil.
[0410] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 7.56 (s, 1H), 7.30
(m, 3H), 4.72 (s, 2H), 2.60 (m, 2H), 2.27 (m, 2H), 1.93 (m, 4H),
1.33 (s, 9H).
Step 4
[0411] ##STR86##
[0412] Borontrifluoride-etherate (2.0 mL, 15.7 mmol) was added to a
solution of 1-(3-tert-butyl-phenyl)-4-methylene-cyclohexanol (3.60
g, 14.7 mmol) and azidotrimethylsilane (4.0 mL, 30.1 mmol) in
diethyl ether (30 mL) and placed into a preheated oil bath at
45.degree. C. After heating at reflux for 4 h, the solution was
diluted with saturated aqueous ammonium chloride and extracted with
diethyl ether. The combined organic extracts were dried over
magnesium sulfate, filtered, and concentrated. The residue was
flash chromatographed with 99:1, 49:1, and 24:1 hexanes:ethyl
acetate as the eluant to yield 1.46 g (37% yield) of
1-(1-azido-4-methylene-cyclohexyl)-3-tert-butyl-benzene as a clear
oil.
[0413] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 7.47 (s, 1H),
7.36-7.23 (broad m, 3H), 4.72 (s, 2H), 2.48 (m, 2H), 2.28 (m, 2H),
2.13 (m, 2H), 1.96 (m, 2H), 1.34 (s, 9H).
Step 5
[0414] ##STR87##
[0415] A solution of
1-(1-azido-4-methylene-cyclohexyl)-3-tert-butyl-benzene (820 mg,
3.04 mmol) in diethyl ether (10 mL) was added to a heterogeneous
mixture of lithium aluminum hydride (510 mg, 13.4 mmol) in diethyl
ether (10 mL) and was placed into a preheated oil bath at
40.degree. C. After heating at reflux for 24 h, the solution was
cooled to ambient temperature, and celite and sodium sulfate
decahydrate was added. After stirring for 1 h, the heterogeneous
mixture was filtered through celite to yield
1-(3-tert-butyl-phenyl)-4-methylene-cyclohexylamine.
[0416] Method [1] Retention time 1.62 min by HPLC and 1.67 min by
MS (M+=244).
Step 6
[0417] Using 1-(3-tert-butyl-phenyl)-4-methylene-cyclohexylamine,
[3-[1-(3-tert-Butyl-phenyl)-4-methylene-cyclohexylamino]-1-(3,5-difluoro--
benzyl)-2-hydroxy-propyl]-carbamic acid tert-butyl ester 29,
3-Amino-1-[1-(3-tert-butyl-phenyl)-4-methylene-cyclohexylamino]-4-(3,5-di-
fluoro-phenyl)-butan-2-ol 30, and
N-[3-[1-(3-tert-Butyl-phenyl)-4-methylene-cyclohexylamino]-1-(3,5-difluor-
o-benzyl)-2-hydroxy-propyl]-acetamide 31 are prepared according to
essentially the same procedure as described in Example 9, steps 1
and 2. ##STR88##
[0418] Method [1] Retention time 2.40 min by HPLC and 2.47 min by
MS (M+=543). ##STR89##
[0419] Method [1] Retention time 1.36 min by HPLC and 1.42 min by
MS (M+=443). ##STR90##
[0420] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 9.10 (broad d,
1H), 8.10 (broad d, 1H), 7.61 (s, 1H), 7.40 (broad m, 3H), 6.64
(broad s, 3H), 6.50 (m, 1H), 6.00 (broad s, 3H), 4.72 (s, 1H), 3.98
(broad s, 1H), 3.77 (broad s, 1H), 2.93 (m, 1H), 2.68 (m, 4H), 2.37
(m, 3H), 2.09 (m, 3H), 1.83 (s, 3H), 1.32 (s, 9H).
[0421] Method [1] Retention time 2.04 min by HPLC and 2.11 min by
MS (M+=485).
EXAMPLE 21
PREPARATION OF
[4-[3-ACETYLAMINO-4-(3,5-DIFLUORO-PHENYL)-2-HYDROXY-BUTYLAMINO]-4-(3-TERT-
-BUTYL-PHENYL)-CYCLOHEXYLIDENE]-ACETIC ACID METHYL ESTER AND OF
[4-[3-ACETYLAMINO-4-(3,5-DIFLUORO-PHENYL)-2-HYDROXY-BUTYLAMINO]-4-(3-TERT-
-BUTYL-PHENYL)-CYCLOHEXYLIDENE]-ACETIC ACID ETHYL ESTER
[0422] ##STR91##
[0423] To a solution of methyl diethylphosphonoacetate (0.20 mL,
1.102 mmol) in anhydrous THF (1 mL) was added a 60% dispersion of
sodium hydride in mineral oil (0.80 g, 20.0 mmol). Vigourous gas
evolution was observed while stirring at RT under N.sub.2(g) inlet.
After 2 h a solution of
N-[3-[1-(3-tert-butyl-phenyl)-4-oxo-cyclohexylamino]-1-(3,5-difluoro-benz-
yl)-2-hydroxyl-propyl]-acetamide (0.291 g, 0.598 mmol) in anhydrous
THF (1 mL) was added to the reaction flask. The mixture was allowed
to stir for 2 days. The reaction was quenched with H.sub.2O and
extracted with CH.sub.2Cl.sub.2. The organic layer was collected,
dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated.
The crude product was purified by flash chromatography, eluting
with 5% CH.sub.3OH in CH.sub.2Cl.sub.2 yielding 0.085 g of the
conjugated products. HPLC purification afforded the methyl ester:
retention time (min)=1.87, method [1]; .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 7.56 (s, 1H), .delta. 7.31-7.26 (m, 1H),
.delta. 7.24-7.26 (m, 2H), .delta. 6.70 (d, J=7 Hz, 3H), .delta.
3.80-3.78 (m, 1H), .delta. 3.70 (s, 3H), .delta. 3.36-3.33 (m, 1H),
.delta. 2.83-2.77 (m, 3H), .delta.2.51 (t, 1H), .delta. 2.30 (d,
J=4 Hz, 1H), .delta. 2.24 (d, J=10 Hz, 1H), .delta. 2.16-2.07 (m,
1H), .delta. 1.95-1.86 (m, 7H), 61.71 (s, 3H), .delta. 1.33 (s,
9H); MS (ESI) 543.2 (M+H).
[0424] HPLC purification afforded the ethyl ester: retention time
(min)=1.98, method [1]; .sup.1H NMR (300 MHz, CD.sub.3OD): .delta.
7.55 (s, 1H), .delta. 7.31-7.27 (m, 1H), .delta. 7.23 (d, J=4 Hz,
2H), .delta. 6.70 (d, J=8 Hz, 3H), .delta. 4.20-4.13 (m, 2H),
.delta. 3.82-3.76 (m, 1H), .delta. 3.36-3.35 (m, 1H), .delta. 2.82
(d, J=4 Hz, 1H), .delta. 2.78 (s, 2H), .delta. 2.50 (t, 1H),
.delta. 2.33 (d, J=10 Hz, 1H), .delta. 2.23 (d, J=10 Hz, 1H),
.delta. 2.16-2.07 (m, 1H), .delta. 1.95-1.80 (m, 7H), .delta. 1.70
(s, 3H), .delta. 1.32 (s, 9H), .delta. 1.30 (t, 3H); MS (ESI) 557.3
(M+H).
EXAMPLE 22
PREPARATION OF
2-[4-[3-ACETYLAMINO-4-3,5-DIFLUORO-PHENYL)-2-HYDROXY-BUTYLAMINO]-4-(3-TER-
T-BUTYL-PHENYL)-CYCLOHEXYLIDENE]-N,N-DIMETHYL-ACETAMIDE
[0425] ##STR92##
[0426] To a solution of dioctyl
(N,N-dimethylcarbamoylmethyl)phosphonate (0.05 g, 0.128 mmol) in
anhydrous THF (1 mL) was added a 60% dispersion of sodium hydride
in mineral oil (0.026 g, 0.65 mmol). Vigorous gas evolution was
observed while stirring at room temperature under N.sub.2(g) inlet.
After 3.5 h a solution of
N-[3-[1-(3-tert-butyl-phenyl)-4-oxo-cyclohexylamino]-1-(3,5-difluoro-benz-
yl)-2-hydroxyl-propyl]-acetamide (0.041 g, 0.084 mmol) in anhydrous
THF (1 mL) was added to the reaction flask. The mixture was allowed
to stir overnight. The reaction was quenched with H.sub.2O and
extracted with CH.sub.2Cl.sub.2. The organic layer was collected,
dried over anhydrous sodium sulfate, filtered and concentrated.
HPLC purification afforded the parent compound: retention time
(min)=1.83, method [1]; .sup.1H NMR (300 MHz, CD.sub.3OD): .delta.
7.53 (s, 1H), .delta. 7.24 (m, 1H), 7.22 (d, J=4 Hz, 2H), 6.68 (d,
J=8 Hz, 3H), 3.78 (m, 1H), 3.41 (m, 1H), 3.12 (s, 3H), 2.94 (s,
3H), 2.84 (s, 2H), 2.79 (d, J=15 Hz, 1H), 2.49 (t, 1H), 2.32-2.22
(m, 2H), 2.06 (m, 2H), 1.85 (m, 6H), 1.64 (s, 3H), 1.29 (s, 9H); MS
(ESI) 556.3 (M+H).
EXAMPLE 23
PREPARATION OF
N-[3-[1-(3-TERT-BUTYL-PHENYL)-4-CYANOMETHYLENE-CYCLOHEXYLAMINO]-1-(3,5-DI-
FLUORO-BENZYL)-2-HYDROXY-PROPYL]-ACETAMIDE
[0427] ##STR93##
[0428] To a solution of diethyl(cyanomethyl)phosphonate (0.05 mL,
0.309 mmol) in anhydrous THF (0.7 mL) was added a 60% dispersion of
sodium hydride in mineral oil (0.008 g, 0.20 mmol). Vigourous gas
evolution was observed while stirring at RT under N.sub.2(g) inlet.
After 1.5 h a solution of
N-[3-[1-(3-tert-butyl-phenyl)-4-oxo-cyclohexylamino]-1-(3,5-difluoro-benz-
yl)-2-hydroxyl-propyl]-acetamide (0.119 g, 0.123 mmol) in anhydrous
THF (0.5 mL) was added to the reaction flask. The mixture was
allowed to stir overnight. The reaction was quenched with H.sub.2O
and extracted with CH.sub.2Cl.sub.2. The organic layer was
collected, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated. The crude product was purified by HPLC yielding the
trifluoroacetic acid salt: retention time (min)=1.81, method [1];
MS (ESI) 510.2 (M+H).
EXAMPLE 24
PREPARATION OF HYDRAZONES
[0429] ##STR94##
[0430]
N-[3-[1-(3-tert-Butyl-phenyl)-4-(methyl-hydrazono)-cyclohexylamino-
]-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-acetamide was prepared
according to essentially the same procedure as described in
El-Barbary, A. A., J. Heterolytic Chem., 38 (2001), 1711-16.
EXAMPLE 25
PREPARATION OF
(2R,3S)-N-[3-[5-(3-TERT-BUTYL-PHENYL)-4,5,6,7-TETRAHYDRO-2H--INDAZOL-5-YL-
AMINO]-1-(3,5-DIFLUORO-BENZYL)-2-HYDROXY-PROPYL]-ACETAMIDE AND
(2R,3S)-N-[3-[2-ACETYL-5-(3-TERT-BUTYL-PHENYL)-4,5,6,7-TETRAHYDRO-2H-INDA-
ZOL-5-YLAMINO]-1-(3,5-DIFLUORO-BENZYL)-2-HYDROXY-PROPYL]-ACETAMIDE
[0431] ##STR95## ##STR96##
Step 1. 4-Amino-4-(3-tert-butyl-phenyl)-cyclohexanone
[0432] A solution of
8-(3-tert-Butyl-phenyl)-1,4-dioxa-spiro[4.5]dec-8-ylamine
hydrochloride (337 mg, 1.03 mmol) in glacial acetic acid (9 mL) and
water (4 mL) was heated to 75.degree. C. for 21 h, whereupon the
reaction was deemed complete by HPLC analysis. The reaction mixture
was basified with 2.5 N NaOH solution, then extracted with ethyl
acetate (3.times.25 mL). The combined organic layers were washed
(brine), dried (Na.sub.2SO.sub.4), filtered and concentrated under
reduced pressure. Material was pure by HPLC/MS: retention time=1.18
min, method [7]; mass spec (ESI) 246 (MH.sup.+, 33), 229
(M-NH.sub.2.sup.+, 100), 228 (28), 173 (47).
Step 2. [1-(3-tert-Butyl-phenyl)-4-oxo-cyclohexyl]-carbamic acid
tert-butyl ester
[0433] 4-Amino-4-(3-tert-butyl-phenyl)-cyclohexanone (441 mg, 1.8
mmol) was dissolved in dry methylene chloride (10 mL),
diisopropylethylamine (0.31 mL, 1.8 mmol) and di-tert-butyl
carbonate (400 mg, 1.83 mmol) were added in succession at room
temperature. After 19 h, the reaction was concentrated under
reduced pressure, and the desired product isolated by
chromatography (R.sub.f=0.35 in 20% EtOAc/hexanes). The resulting
oil was taken to the next reaction: retention time=2.57 min, method
[7]; mass spec (ESI) 369 (24), 368 (100), 272 (42), 211 (24).
Step 3.
[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-yl]-carba-
mic acid tert-butyl ester
[0434] [1-(3-tert-Butyl-phenyl)-4-oxo-cyclohexyl]-carbamic acid
tert-butyl ester (155 mg, 0.45 mmol) was heated with triethylamine
(0.010 mL, 0.07 mmol) and dimethylformamide dimethyl acetal (0.38
mL, 2.9 mmol) in benzene (.about.20 mL) to reflux in a round-bottom
flask fitted with a Dean-Stark trap and a condenser. Benzene was
distilled to about one third the original volume, then fresh
benzene was added and the distillation continued. This process was
repeated until reaction showed absence of starting material by TLC
(.about.24 h). The solvent was evaporated. The crude
[1-(3-tert-Butyl-phenyl)-3-dimethylaminomethylene-4-oxo-cyclohexyl]-
-carbamic acid tert-butyl ester was used in the next reaction
without further purification.
[0435] To crude
[1-(3-tert-Butyl-phenyl)-3-dimethylaminomethylene-4-oxo-cyclohexyl]-carba-
mic acid tert-butyl ester (91 mg, 0.227 mmol) was added ethanol (6
mL) and hydrazine hydrate (0.010 mL, 0.32 mmol). The reaction
mixture was stirred at room temperature for 12 h then placed in a
freezer overnight. The reaction mixture was concentrated under
reduced pressure yielding the title compound: R.sub.f=0.35 in 5%
MeOH/CH.sub.2Cl.sub.2; retention time=1.92 min, method [7]; mass
spec (ESI) 392 (25), 370 (2), 315 (24), 314 (100).
Step 4.
5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamine
[0436]
[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-yl]-carba-
mic acid tert-butyl ester (84 mg, 0.23 mmol) was dissolved in 4 N
hydrogen chloride in dioxane (2 mL, 8 mmol) at room temperatrure
for 90 min, whereupon the reaction was deemed complete by TLC. The
reaction mixture was concentrated under reduced pressure and the
amine hydrochloride salt was basified by partitioning between 1 N
aqueous NaOH and 33% isopropanol in chloroform. The organic layer
was separated and the aqueous layer extracted twice with additional
33% IPA/CHCl.sub.3. The combined organic layers were dried
(Na.sub.2SO.sub.4), filtered and concentrated. LC/MS analysis
showed 90% pure material, which was taken to subsequent reactions:
R.sub.f=0.098 in 25% MeOH/CH.sub.2Cl.sub.2; retention time=0.98
min, method [7]; mass spec (ESI) 270 (6), 254 (23), 253 (100), 197
(12).
Step 5.
(2R,3S)-[3-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol--
5-ylamino]-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-carbamic acid
tert-butyl ester
[0437] [2-(3,5-Difluorophenyl)-1-oxiranyl-ethyl]-carbamic acid
tert-butyl ester (80.2 mg, 0.268 mmol) was combined with
5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamine (61
mg, 0.227 mmol) in isopropanol (1 mL). This mixture was heated to
80.degree. C. for 16 h, whereupon the reaction mixture was
concentrated under reduced pressure and the crude reaction mixture
purified by flash chromatography yielding 61 mg (47%) desired
product: R.sub.f=0.40 in 10% MeOH/CH.sub.2Cl.sub.2; retention
time=1.84 min, method [7]; mass spec (ESI) 591 (20), 570 (42), 569
(100).
Step 6.
(2R,3S)-N-[3-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazo-
l-5-ylamino]-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-acetamide
and
(2R,3S)-N-[3-[2-Acetyl-5-(3-tert-butyl-phenyl)-4,5,6,7-tetrahydro-2H-inda-
zol-5-ylamino]-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-acetamide
[0438]
(2R,3S)-[3-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol--
5-ylamino]-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-carbamic acid
tert-butyl ester (61 mg, 0.11 mmol) was dissolved in 4 N hydrogen
chloride in dioxane (2 mL) at room temperature. After 90 min, the
reaction mixture was concentrated under reduced pressure. The crude
residue was partitioned between 1 N aqueous NaOH and
dichloromethane. The layers were separated and the aqueous layer
further extracted with dichloromethane twice. The combined organic
washes were dried (Na.sub.2SO.sub.4), filtered and concentrated
yielding a foam (50 mg), which was used in the subsequent reaction
without further purification.
[0439] The crude amine (50 mg, 0.11 mmol) was dissolved in dry
dichloromethane (1 mL), and N,N-diacetylhydroxylamine (0.025 mL,
0.21 mmol) was added dropwise by syringe. After 20 h at room
temperature, the reaction was concentrated under reduced pressure.
The crude residue was purified by HPLC.
[0440]
(2R,3S)-N-[3-[5-(3-tert-Butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazo-
l-5-ylamino]-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-acetamide
(1:1 mixture of two regioisomers): retention time=1.48 min, method
[7]; mass spec (ESI) 533 (18), 512 (39), 511 (100), 259 (18), 253
(16).
EXAMPLE 26
NH.sub.2 REPLACEMENT OF HYDROXYL ALPHA TO THE --(CHR.sub.1)-- GROUP
OF COMPOUNDS OF FORMULA (I)
[0441] ##STR97##
EXAMPLE 27
SH REPLACEMENT OF HYDROXYL ALPHA TO THE --(CHR.sub.1)-- GROUP OF
COMPOUNDS OF FORMULA (I)
[0442] ##STR98##
EXAMPLE 28
PREPARATION OF
1-[5-(3-TERT-BUTYL-PHENYL)-4,5,6,7-TETRAHYDRO-2H-INDAZOL-5-YLAMINO]-4-(3,-
5-DIFLUORO-PHENYL)-BUTAN-2-OL
[0443] ##STR99##
Step 1. Preparation of
[5-(3-tert-butyl-phenyl-2-(toluene-4-sulfonyl)-4,5,6,7-tetrahydro-2H-inda-
zol-5-yl]-carbamic acid tert-butyl ester
[0444] To
[5-(3-tert-butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-yl]-ca-
rbamic acid tert-butyl ester (0.58 g, 1.58 mmol) in THF (6 mL)
cooled to 0.degree. C. was added a 1.0 M solution of potassium
tert-butoxide (3.5 mL). After 1.5 h a solution of p-toluenesulfonyl
chloride (0.54 g, 2.81 mmol) was added and the mixture was stirred
overnight while warming to ambient temperature. The reaction
mixture was concentrated under reduced pressure, dissolved in
CH.sub.2Cl.sub.2 and washed with H.sub.2O followed by sat. NaCl
(aq). The organic layer was collected, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated. The crude product was
purified by flash chromatography, eluting with 30% ethyl acetate in
hexane to afford 0.63 g (1.20 mmol, 76%) of
[5-(3-tert-butyl-phenyl-2-(toluene-4-sulfonyl)-4,5,6,7-tetrahydro-2H-inda-
zol-5-yl]-carbamic acid tert-butyl ester: retention time
(min)=3.18, method [1]. MS (ESI) 524.2 (M+H).
Step 2. Preparation of
5-(3-tert-butyl-phenyl)-2-(toluene-4-sulfonyl)-4,5,6,7-tetrahydro-2H-inda-
zol-5-ylamine
[0445] To a solution of
[5-(3-tert-butyl-phenyl-2-(toluene-4-sulfonyl)-4,5,6,7-tetrahydro-2H-inda-
zol-5-yl]-carbamic acid tert-butyl ester (0.61 g, 1.17 mmol)
dissolved in CH.sub.2Cl.sub.2 (1 mL) was added trifluoacetic acid
(1 mL). The reaction mixture was allowed to stir for 1 h prior to
quenching with sat. NaHCO.sub.3 (aq) and conc. NH.sub.4OH. The
product was extracted with CH.sub.2Cl.sub.2 and the organic layer
was collected, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to afford 0.41 g of crude
5-(3-tert-butyl-phenyl)-2-(toluene-4-sulfonyl)-4,5,6,7-tetrahydro-2-
H-indazol-5-ylamine: retention time of diastereomers (min)=1.62 and
1.71, method [1]. MS (ESI) 407.4 (M+H).
Step 3. Preparation of
1-[5-(3-tert-butyl-phenyl)-2-(toluene-4-sulfonyl)-4,5,6,7-tetrahydro-2H-i-
ndazol-5-ylamino]-4-(3,5-difluoro-phenyl)-butan-2-ol
[0446] To a sealed tube was added a solution of
5-(3-tert-butyl-phenyl)-2-(toluene-4-sulfonyl)-4,5,6,7-tetrahydro-2H-inda-
zol-5-ylamine (0.41 g, 1.0 mmol) in isopropyl alcohol followed by
2-[2-(3,5-difluoro-phenyl)-ethyl]-oxirane (0.18 g, 1.0 mmol). The
reaction was heated at 50.degree. C. overnight and no product was
formed. After heating at 100.degree. C. for an additional 3.5 h the
reaction was complete. The reaction mixture was concentrated and
the crude product was purified by flash chromatography, eluting
with 3% methanol in CHCl.sub.3 to afford 0.25 g (0.41 mmol, 42%) of
1-[5-(3-tert-butyl-phenyl)-2-(toluene-4-sulfonyl)-4,5,6,7-tetrahydro-2H-i-
ndazol-5-ylamino]-4-(3,5-difluoro-phenyl)-butan-2-ol: retention
time (min)=2.15, method [1]. MS (ESI) 608.4 (M+H).
Step 4. Preparation of
1-[5-(3-tert-butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamino]-4-(3,-
5-difluoro-phenyl)-butan-2-ol
[0447] To a solution of
5-(3-tert-butyl-phenyl)-2-(toluene-4-sulfonyl)-4,5,6,7-tetrahydro-2H-inda-
zol-5-ylamine in methanol (4 mL) was added 1 N NaOH (1 mL). The
reaction mixture was stirred at ambient temperature 5.5 h prior to
quenching with H.sub.2O. The product was extracted with EtOAc and
the organic layer was collected, dried over anhydrous NaSO.sub.4,
filtered and concentrated. The crude product was purified by flash
chromatography, eluting solvent with 5% methanol in
CH.sub.2Cl.sub.2 and NH.sub.4OH to afford
1-[5-(3-tert-butyl-phenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylamino]-4-(3,-
5-difluoro-phenyl)-butan-2-ol. HPLC purification afforded the
parent compound: retention time (min)=4.77, method [1]; MS (ESI)
454.2 (M+H).
EXAMPLE 29
PREPARATION OF
1-[5-(3-TERT-BUTYL-PHENYL)-2-METHYL-4,5,6,7-TETRAHYDRO-2H-INDAZOL-5-YLAMI-
NO]-4-(3,5-DIFLUORO-PHENYL)-BUTAN-2-OL
[0448] ##STR100##
Step 1. Preparation of
5-(3-tert-butyl-phenyl)-2-methyl-4,5,6,7-tetrahydro-2H-indazol-5-yl
amine.
[0449] To a solution of
[5-(3-tert-butyl-phenyl-2-methyl-4,5,6,7-tetrahydro-2H-indazol-5-yl]-carb-
amic acid tert-butyl ester (0.33 g, 0.86 mmol) dissolved in
CH.sub.2Cl.sub.2 (1 mL) was added trifluoacetic acid (1 mL). The
reaction mixture was allowed to stir for 1.5 h prior to quenching
with sat. NaHCO.sub.3 (aq) and conc. NH.sub.4OH. The product was
extracted with CH.sub.2Cl.sub.2 and the organic layer was
collected, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to afford 0.17 g of crude
5-(3-tert-butyl-phenyl)-2-methyl-4,5,6,7-tetrahydro-2H-indazol-5-yl-
amine: retention time (min)=1.04, method [1]. MS (ESI) 267.2
(M+H).
Step 2. Preparation of
1-[5-(3-tert-butyl-phenyl)-2-methyl-4,5,6,7-tetrahydro-2H-indazol-5-ylami-
no]-4-(3,5-difluoro-phenyl)-butan-2-ol
[0450] To a sealed tube was added
2-[2-(3,5-difluoro-phenyl)-ethyl]-oxirane (0.124 g, 0.673 mmol) and
5-(3-tert-butyl-phenyl)-2-methyl-4,5,6,7-tetrahydro-2H-indazol-5-ylamine
(0.174 g, 0.614 mmol) in a solution of isopropyl alcohol (2.5 mL).
The reaction mixture was heated at 120.degree. C. for 4 h and
concentrated to yield crude product. The crude product was purified
by flash chromatography, eluting with 50% hexane in ethyl acetate,
5% CH.sub.3OH in CH.sub.2Cl.sub.2 and conc. NH.sub.4OH to afford
0.089 g (0.19 mmol, 31%) of the
1-[5-(3-tert-butyl-phenyl)-2-methyl-4,5,6,7-tetrahydro-2H-indazol-5-ylami-
no]-4-(3,5-difluoro-phenyl)-butan-2-ol 2. HPLC purification
afforded the trifluoroacetic acid salt: retention time (min)=1.80,
method [1]; .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 7.60 (d, J=2
Hz, 1H), .delta. 7.59-7.27 (m, 4H), .delta. 6.81-6.75 (m, 3H),
.delta. 3.81 (s, 3H), .delta. 3.75 (m, 1H), .delta. 3.70 (s, 2H),
.delta. 3.09-3.02 (m, 2H), .delta. 2.88-2.04 (m, 6H), .delta.
1.71-1.61 (m, 1H), .delta. 1.37 (m, 2H), .delta. 1.28 (s, 9H); MS
(ESI) 468.3 (M+H).
EXAMPLE 30
PREPARATION OF
5-(4-BROMOTHIOPHEN-2-YL)-4,5,6,7-TETRAHYDRO-2H-INDAZOL-5-AMINE
[0451] ##STR101## ##STR102##
Step 1: Preparation of tert-butyl
1-(4-bromothiophen-2-yl)-4-(1,3-dioxol-2-yl)cyclohexylcarbamate
[0452] To a stirred solution under nitrogen of 2,4-dibromothiophene
(2.24 g, 9.25 mmol) in Et.sub.2O (4 mL) at 0.degree. C. was added
isopropylmagnesium chloride (2.0 M, 4.78 mL, 9.56 mmol). The
reaction was stirred for 30 min to form the grignard reagent. After
this time the reaction was cooled to -78.degree. C. and a solution
of 2-Methylpropane-2-sulfinic acid
(1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide in Et.sub.2O (and minimal
toluene for solubility) was added to the reaction. Upon addition of
the 2-Methylpropane-2-sulfinic acid
(1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide the reaction was allowed
to warm to room temperature and stirred for 3 h. The reaction was
then cooled to 0.degree. C. and quenched with water. This mixture
was extracted with EtOAc (2.times.) and the organic phase washed
with brine and dried over MgSO.sub.4. The crude product was
analyzed by TLC (100% EtOAc), LC and LC/MS. The solution was then
concentrated and purified on the Biotage Horizon (65+M silica gel,
10% to 100% EtOAC/Hex51 mL-1836 mL, 100% EtOAc 51 mL-612 mL, 100%
EtOAc 51 mL-1224 mL). The appropriate fractions were combined (last
eluting) and concentrated to give the thiophene product as a
colorless foam in 72% yield: .sup.1H NMR (CDCl.sub.3) .delta.7.18
(s, 1H), 7.03 (s, 1H), 4.00-3.90 (m, 4H), 3.43 (s, 1H), 2.43-2.20
(m, 4H), 1.95-1.65 (m, 4H), 1.17 (s, 9H); retention time (min)=3.66
(method [8]); MS (ESI) 122.0.
Step 2:
4-amino-4-(4-bromothiophen-2-yl)-1(1,3-dioxol-2-yl)cyclohexane
[0453] To the sulfonylated amine (983 mg, 2.22 mmol) was added HCl
(4.0 M in p-dioxane, 5.56 mL, 22.2 mmol) and p-dioxane (4 mL). The
reaction was stirred for 2 h at room temperature and monitored by
LC/MS. Following addition of the acid a white precipitate formed
and persisted for the remainder of the reaction. After this time
the reaction was concentrated to a pale yellow oil to afford the
deprotected product as the HCl salt. The product was used crude in
step 3: retention time (min)=2.47 (method [8]); MS (ESI) 300.9.
Step 3: 4-amino-4-(4-bromothiophen-2-yl)cyclohexanone:
[0454] To the amine (837 mg, 2.63 mmol) was added an 80:20 solution
of AcOH:H.sub.2O (1.1.5 mL). The reaction was heated to 75.degree.
C. and allowed to stir at this temperature for 2 h. After LC/MS
analysis the reaction was allowed to cool to room temperature and
then concentrated. The resulting pale orange solid was then
re-dissolved in EtOAc and brought to a basic pH (10) with 2M NaOH.
The aqueous phase was then extracted with an additional amount of
EtOAc, and all organics combined, dried over MgSO.sub.4, and
concentrated to afford the crude product in 81% yield: retention
time (min)=1.47 (method [8]); MS (ESI) 273.9 (.sup.79Br
isotope).
Step 4: tert-butyl
1-(4-bromothiophen-2-yl)-4-oxocyclohexylcarbamate
[0455] To a stirred solution of the ketone (584 mg, 2.13 mmol) in
DCM (8 mL) was added Boc anhydride (697 mg, 3.20 mmol). The
reaction was allowed to stir at room temperature overnight. The
following morning the reaction was analyzed by TLC (4:1 Hex/EtOAc,
MeOH/DCM) and LC/MS. Based on these results more Boc anhydride was
added (1 eq) and the reaction allowed to continue stirring
overnight. After this time the reaction was concentrated and
purified on the Biotage Horizon (40+M silica gel). The appropriate
fractions were combined (TLC 4:1 Hex/EtOAc), concentrated to give
the desired product in 82% yield: .sup.1H NMR (CDCl.sub.3)
.delta.7.07 (s, 1H), 6.90 (s, 1H), 4.98 (s, 1H), 2.82-2.65 (m, 2H),
2.65-2.50 (m, 2H), 2.45-2.35 (m, 2H), 2.30-2.20 (m, 2H), 1.41 (s,
9H).
Step 5: (E)-tert-butyl
1-(4-bromothiophen-2-yl)-3-((dimethylamino)methylene)-4-oxocyclohexylcarb-
amate
[0456] To the ketone (657 mg, 1.76 mmol) in toluene (20 mL), at
room temperature under nitrogen, was added
tert-butoxybis(dimethylamino)methane (0.4 mL, 1.93 mmol). The
reaction was then heated to 80.degree. C. and left to stir
overnight. The following morning the reaction was analyzed by TLC
and determined to have gone to completion. The reaction was allowed
to cool, then concentrated and used directly in Step 6: retention
time (min)=2.08 (method [8]); MS (ESI) 430.9.
Step 6: tert-butyl
5-(4-bromothiophen-2-yl)-4,5,6,7-tetrahydro-2H-indazol-5-ylcarbamate
[0457] To a stirred solution of the enamine (557 mg, 1.91 mmol) in
EtOH (20 mL) at room temperature was added hydrazine (119 .mu.l,
3.81 mmol). The reaction was allowed to stir overnight and
monitored by LC/MS and TLC (10% MeOH in DCM). The following morning
the reaction was concentrated and then purified on the Biotage
Horizon (40+M silica gel, 5% to 75% B:20% MeOH/DCM, 21 mL-1512 mL).
The appropriate fractions were combined and concentrated to give a
yellow foam in 73% yield: retention time (min)=2.17 (method [8]);
MS (ESI) 399.8.
Step 7:
5-(4-bromothiophen-2-yl)-4,5,6,7-tetrahydro-2H-indazol-5-amine:
[0458] To a stirred solution of the indazole (557 mg, 1.40 mmol) in
p-dioxane (2 mL) was added HCl (4.0M in p-dioxane, 1.75 mL, 6.99
mmol). The reaction was allowed to stir for 2 h and monitored by
TLC (20% MeOH/DCM), LC and LC/MS. After this time the reaction was
concentrated and placed on the high vacuum for 48 h. After this
time the reaction was analyzed by LC and LC/MS and determined not
to have gone to completion. Therefore, p-dioxane (2 mL) and HCl
(4.0M in p-dioxane, 1.75 mL, 6.99 mmol) were added to the dried
reaction and allowed to stir for an additional two h. The reaction
was then concentrated, triturated with ether/DCM, and the desired
product collected as a light orangish yellow solid in 93% yield:
.sup.1H NMR (DMSO-d.sub.6) .delta.8.88 (s, 1H), 7.65 (s, 1H), 7.52
(s, 1H), 7.38 (s, 1H), 4.80 (br s, 2H), 3.33 (d, J=14 Hz, 1H), 3.14
(d, J=14 Hz, 1H), 2.85-2.72 (m, 1H), 2.50-2.30 (m, 3H); retention
time (min)=2.20 (method [8]); MS (ESI) 300.1 (60), 283.1
(.sup.81Br, 100).
EXAMPLE 31
PREPARATION OF
5-(3-TERT-BUTYLPHENYL)-4,5,6,7-TETRAHYDRO-2H-INDAZOL-5-AMINE
[0459] ##STR103##
Step 1: (E)-tert-butyl
1-(3-tert-butylphenyl)-3-((dimethylamino)methylene)-4-oxocyclohexylcarbam-
ate
[0460] To a stirred solution of tert-butyl
1-(3-tert-butylphenyl)-4-oxocyclohexylcarbamate (691 mg, 2.0 mmol)
in Toluene (5 mL) was added tert-butoxybis(dimethylamino)methane
(454 .mu.L, 2.2 mmol). The reaction was stirred at 85.degree. C.
overnight. The reaction was concentrated and used crude in the next
step.
Step 2: Tert-butyl
5-(3-tert-butylphenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylcarbamate
[0461] To a stirred solution of (E)-tert-butyl
1-(3-tert-butylphenyl)-3-((dimethylamino)
methylene)-4-oxocyclohexylcarbamate (801 mg, 2.0 mmol) in 6 mL of
ethanol was added hydrazine monohydrate (150 .mu.L, 3.0 mmol). The
reaction was allowed to stir for 3 h. The reaction was concentrated
and purified using a biotage 40S column eluting with DCM/MeOH
(95:5) to afford 500 mg (67% yield) of an off white foam. LCMS
corresponded to the desired material: retention time (min)=2.45
(method [8]); MS (ESI) 370.0.
Step 3:
5-(3-tert-butylphenyl)-4,5,6,7-tetrahydro-2H-indazol-5-amine
[0462] Tert-butyl
5-(3-tert-butylphenyl)-4,5,6,7-tetrahydro-2H-indazol-5-ylcarbamate
(499 mg, 1.35 mmol) was taken up in 2 mL of dioxane followed by the
addition of HCl (3.38 mL of a 4N solution in dioxane). The reaction
was stirred for 4 h and then concentrated to yield 350 mg (96%
yield) of a white solid. .sup.1H-NMR (CD.sub.3OD) .delta.8.17 (d,
J=2.7 Hz, 1H), 7.60 (s, 1H), 7.52-7.45 (m, 1H), 7.44-7.32 (m, 2H),
3.77 (d, J=14.8 Hz, 1H), 3.21 (d, J=14.8 Hz, 1H), 3.10-2.94 (m,
1H), 2.82-2.66 (m, 1H), 2.59-2.42 (m, 2H), 1.30 (s, 9H); retention
time (min)=1.70 (method [8]); MS (ESI) 253.3.
[0463] Generally, the protection of amines is conducted, where
appropriate, by methods known to those skilled in the art. See, for
example, Protecting Groups in Organic Synthesis, John Wiley and
Sons, New York, N.Y., 1981, Chapter 7; Protecting Groups in Organic
Chemistry, Plenum Press, New York, N.Y., 1973, Chapter 2. When the
amino protecting group is no longer needed, it is removed by
methods known to those skilled in the art. By definition the amino
protecting group must be readily removable. A variety of suitable
methodologies are known to those skilled in the art; see also T. W.
Green and P. G. M. Wuts in Protective Groups in Organic Chemistry,
John Wiley and Sons, 3.sup.rd edition, 1999. Suitable amino
protecting groups include t-butoxycarbonyl, benzyl-oxycarbonyl,
formyl, trityl, phthalimido, trichloro-acetyl, chloroacetyl,
bromoacetyl, iodoacetyl, 4-phenylbenzyloxycarbonyl,
2-methylbenzyloxycarbonyl, 4-ethoxybenzyloxycarbonyl,
4-fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl,
3-chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl,
2,4-dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl,
3-bromobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl,
4-cyanobenzyloxycarbonyl, 2-(4-xenyl)isopropoxycarbonyl,
1,1-diphenyleth-1-yloxycarbonyl, 1,1-diphenylprop-1-yloxycarbonyl,
2-phenylprop-2-yloxycarbonyl, 2-(p-toluyl)prop-2-yloxy-carbonyl,
cyclopentanyloxycarbonyl, 1-methylcyclo-pentanyloxycarbonyl,
cyclohexanyloxycarbonyl, 1-methyl-cyclohexanyloxycabonyl,
2-methylcyclohexanyloxycarbonyl,
2-(4-toluylsulfonyl)ethoxycarbonyl,
2-(methylsulfonyl)-ethoxycarbonyl,
2-(triphenylphosphino)ethoxycarbonyl, fluorenylmethoxycarbonyl,
2-(trimethylsilyl)ethoxy-carbonyl, allyloxycarbonyl,
1-(trimethylsilylmethyl)prop-1-enyloxycarbonyl,
5-benzisoxalylmethoxycarbonyl, 4-acetoxybenzyloxycarbonyl,
2,2,2-trichloroethoxycarbonyl, 2-ethynyl-2-propoxycarbonyl,
cyclopropylmethoxycarbonyl, 4-(decyloxyl)benzyloxycarbonyl,
isobornyloxycarbonyl, 1-piperidyloxycarbonyl, 9-fluoroenylmethyl
carbonate, --CH--CH.dbd.CH.sub.2, and the like.
[0464] In an embodiment, the protecting group is t-butoxycarbonyl
(Boc) and/or benzyloxycarbonyl (CBZ). In another embodiment, the
protecting group is Boc. One skilled in the art will recognize
suitable methods of introducing a Boc or CBZ protecting group and
may additionally consult Protective Groups in Organic Chemistry,
for guidance.
[0465] The compounds of the present invention may contain geometric
or optical isomers as tautomers. Thus, the present invention
includes all tautomers and pure geometric isomers, such as the E
and Z geometric isomers, as mixtures thereof. Further, the present
invention includes pure enantiomers, diastereomers and/or mixtures
thereof, including racemic mixtures. The individual geometric
isomers, enantiomers or diastereomers may be prepared or isolated
by methods known to those in the art, including, for example chiral
chromatography, preparing diastereomers, separating the
diastereomers and then converting the diastereomers into
enantiomers.
[0466] Compounds of the present invention with designated
stereochemistry can be included in mixtures, including racemic
mixtures, with other enantiomers, diastereomers, geometric isomers
or tautomers. In another embodiment, compounds of the present
invention are typically present in these mixtures in diastereomeric
and/or enantiomeric excess of at least 50%. Compounds of the
present invention may be present in these mixtures in
diastereomeric and/or enantiomeric excess of at least 80%.
Compounds of the present invention with the desired stereochemistry
may also be present in diastereomeric and/or enantiomeric excess of
at least 90%. Compounds of the present invention with the desired
stereochemistry may be present in diastereomeric and/or
enantiomeric excess of at least 99%. The compounds of the present
invention may have the "S" configuration at position 1. Compounds
may also have the "R" configuration at position 2. Compounds may,
for example, have the "1S,2R" configuration. ##STR104##
[0467] All compound names were generated using AutoNom (AUTOmatic
NOMenclature) version 2.1, ACD Namepro version 5.09, Chemdraw Ultra
(versions 6.0, 8.0, 8.03, and 9.0), or were derived therefrom.
[0468] Several of the compounds of formula (I) are amines, and as
such form salts when reacted with acids. Pharmaceutically
acceptable salts are preferred over the corresponding amines since
they produce compounds which are more water soluble, stable and/or
more crystalline.
EXAMPLE 32
BIOLOGICAL EXAMPLES
[0469] Properties such as efficacy, oral bioavailability,
selectivity, or blood-brain penetration can be assessed by
techniques and assays known to one skilled in the art. Exemplary
assays for determining such properties are found below.
Inhibition of APP Cleavage
[0470] The methods of treatment and compounds of the present
invention inhibit cleavage of APP between Met595 and Asp596
numbered for the APP695 isoform, or a mutant thereof, or at a
corresponding site of a different isoform, such as APP751 or
APP770, or a mutant thereof (sometimes referred to as the "beta
secretase site"). While many theories exist, inhibition of
beta-secretase activity is thought to inhibit production of
A-beta.
[0471] Inhibitory activity is demonstrated in one of a variety of
inhibition assays, whereby cleavage of an APP substrate in the
presence of beta-secretase enzyme is analyzed in the presence of
the inhibitory compound, under conditions normally sufficient to
result in cleavage at the beta-secretase cleavage site. Reduction
of APP cleavage at the beta-secretase cleavage site compared with
an untreated or inactive control is correlated with inhibitory
activity. Assay systems that can be used to demonstrate efficacy of
the compounds of formula (I) are known. Representative assay
systems are described, for example, in U.S. Pat. Nos. 5,942,400 and
5,744,346, as well as in the Examples below.
[0472] The enzymatic activity of beta-secretase and the production
of A-beta can be analyzed in vitro or in vivo, using natural,
mutated, and/or synthetic APP substrates, natural, mutated, and/or
synthetic enzyme, and the compound employed in the particular
method of treatment. The analysis can involve primary or secondary
cells expressing native, mutant, and/or synthetic APP and enzyme,
animal models expressing native APP and enzyme, or can utilize
transgenic animal models expressing the substrate and enzyme.
Detection of enzymatic activity can be by analysis of at least one
of the cleavage products, for example, by immunoassay, fluorometric
or chromogenic assay, HPLC, or other means of detection. Inhibitory
compounds are determined as those able to decrease the amount of
beta-secretase cleavage product produced in comparison to a
control, where beta-secretase mediated cleavage in the reaction
system is observed and measured in the absence of inhibitory
compounds.
[0473] Efficacy reflects a preference for a target tissue. For
example, efficacy values yield information regarding a compound's
preference for a target tissue by comparing the compound's effect
on multiple (e.g., two) tissues. See, for example, Dovey et al., J.
Neurochemistry, 2001, 76:173-181. Efficacy reflects the ability of
compounds to target a specific tissue and create the desired result
(e.g., clinically). Efficacious compositions and corresponding
methods of treatment are needed to prevent or treat conditions and
diseases associated with amyloidosis.
[0474] Efficacious compounds of the present invention are those
able to decrease the amount of A-beta produced compared to a
control, where beta-secretase mediated cleavage is observed and
measured in the absence of the compounds. Detection of efficacy can
be by analysis of A-beta levels, for example, by immunoassay,
fluorometric or chromogenic assay, HPLC, or other means of
detection. The efficacy of the compounds of formula (I) was
determined as a percentage inhibition corresponding to A-beta
concentrations for tissue treated and untreated with a compound of
formula (I).
Beta-Secretase
[0475] Various forms of beta-secretase enzyme are known, are
available, and useful for assaying of enzymatic activity and
inhibition of enzyme activity. These include native, recombinant,
and synthetic forms of the enzyme. Human beta-secretase is known as
Beta Site APP Cleaving Enzyme (BACE), BACE1, Asp2, and memapsin 2,
and has been characterized, for example, in U.S. Pat. No. 5,744,346
and published PCT patent applications WO 98/22597, WO 00/03819, WO
01/23533, and WO 00/17369, as well as in literature publications
(Hussain et al., 1999, Mol. Cell. Neurosci., 14:419-427; Vassar et
al., 1999, Science, 286:735-741; Yan et al., 1999, Nature,
402:533-537; Sinha et al., 1999, Nature, 40:537-540; and Lin et
al., 2000, Proceedings Natl. Acad. Sciences USA, 97:1456-1460).
Synthetic forms of the enzyme have also been described in, for
example (WO 98/22597 and WO 00/17369). Beta-secretase can be
extracted and purified from human brain tissue and can be produced
in cells, for example mammalian cells expressing recombinant
enzyme.
APP Substrate
[0476] Assays that demonstrate inhibition of
beta-secretase-mediated cleavage of APP can utilize any of the
known forms of APP, including the 695 amino acid "normal" isotype
described by Kang et al., 1987, Nature, 325:733-6, the 770 amino
acid isotype described by Kitaguchi et. al., 1981, Nature,
331:530-532, and variants such as the Swedish Mutation (KM670-1NL)
(APP-SW), the London Mutation (V7176F), and others. See, for
example, U.S. Pat. No. 5,766,846 and also Hardy, 1992, Nature Genet
1:233-234, for a review of known variant mutations. Additional
useful substrates include the dibasic amino acid modification,
APP-KK, disclosed, for example, in WO 00/17369, fragments of APP,
and synthetic peptides containing the beta-secretase cleavage site,
wild type (WT) or mutated form, (e.g., SW), as described, for
example, in U.S. Pat. No. 5,942,400 and WO 00/03819.
[0477] The APP substrate contains the beta-secretase cleavage site
of APP (KM-DA or NL-DA) for example, a complete APP peptide or
variant, an APP fragment, a recombinant or synthetic APP, or a
fusion peptide. Preferably, the fusion peptide includes the
beta-secretase cleavage site fused to a peptide having a moiety
useful for enzymatic assay, for example, having isolation and/or
detection properties. A useful moiety can be an antigenic epitope
for antibody binding, a label or other detection moiety, a binding
substrate, and the like.
Antibodies
[0478] Products characteristic of APP cleavage can be measured by
immunoassay using various antibodies, as described, for example, in
Pirttila et al., 1999, Neuro. Lett., 249:21-4, and in U.S. Pat. No.
5,612,486. Useful antibodies to detect A-beta include, for example,
the monoclonal antibody 6E10 (Senetek, St. Louis, Mo.) that
specifically recognizes an epitope on amino acids 1-16 of the
A-beta peptide, antibodies 162 and 164 (New York State Institute
for Basic Research, Staten Island N.Y.) that are specific for human
A-beta 1-40 and 1-42, respectively, and antibodies that recognize
the junction region of A-beta, the site between residues 16 and 17,
as described in U.S. Pat. No. 5,593,846. Antibodies raised against
a synthetic peptide of residues 591 to 596 of APP and SW192
antibody raised against 590-596 of the Swedish mutation are also
useful in immunoassay of APP and its cleavage products, as
described in U.S. Pat. Nos. 5,604,102 and 5,721,130.
Assay Systems
[0479] Assays for determining APP cleavage at the beta-secretase
cleavage site are well known in the art. Exemplary assays, are
described, for example, in U.S. Pat. Nos. 5,744,346 and 5,942,400,
and described in the Examples below.
Cell Free Assays
[0480] Exemplary assays that can be used to demonstrate the
inhibitory activity of the compounds of the present invention are
described, for example, in WO 00/17369, WO 00/03819, and U.S. Pat.
Nos. 5,942,400 and 5,744,346. Such assays can be performed in
cell-free incubations or in cellular incubations using cells
expressing a beta-secretase and an APP substrate having a
beta-secretase cleavage site.
[0481] An APP substrate containing the beta-secretase cleavage site
of APP, for example, a complete APP or variant, an APP fragment, or
a recombinant or synthetic APP substrate containing the amino acid
sequence KM-DA or NL-DA is incubated in the presence of
beta-secretase enzyme, a fragment thereof, or a synthetic or
recombinant polypeptide variant having beta-secretase activity and
effective to cleave the beta-secretase cleavage site of APP, under
incubation conditions suitable for the cleavage activity of the
enzyme. Suitable substrates optionally include derivatives that can
be fusion proteins or peptides that contain the substrate peptide
and a modification useful to facilitate the purification or
detection of the peptide or its beta-secretase cleavage products.
Useful modifications include the insertion of a known antigenic
epitope for antibody binding, the linking of a label or detectable
moiety, the linking of a binding substrate, and the like.
[0482] Suitable incubation conditions for a cell-free in vitro
assay include, for example, approximately 200 nM to 10 .mu.M
substrate, approximately 10 pM to 200 pM enzyme, and approximately
0.1 nM to 10 .mu.M inhibitor compound, in aqueous solution, at an
approximate pH of 4-7, at approximately 37.degree. C., for a time
period of approximately 10 min to 3 h. These incubation conditions
are exemplary only, and can vary as required for the particular
assay components and/or desired measurement system. Optimization of
the incubation conditions for the particular assay components
should account for the specific beta-secretase enzyme used and its
pH optimum, any additional enzymes and/or markers that might be
used in the assay, and the like. Such optimization is routine and
will not require undue experimentation.
[0483] One useful assay utilizes a fusion peptide having maltose
binding protein (MBP) fused to the C-terminal 125 amino acids of
APP-SW. The MBP portion is captured on an assay substrate by an
anti-MBP capture antibody. Incubation of the captured fusion
protein in the presence of beta-secretase results in cleavage of
the substrate at the beta-secretase cleavage site. Analysis of the
cleavage activity can be, for example, by immunoassay of cleavage
products. One such immunoassay detects a unique epitope exposed at
the carboxy terminus of the cleaved fusion protein, for example,
using the antibody SW192. This assay is described, for example, in
U.S. Pat. No. 5,942,400.
Cellular Assay
[0484] Numerous cell-based assays can be used to analyze
beta-secretase activity and/or processing of APP to release A-beta.
Contact of an APP substrate with a beta-secretase enzyme within the
cell and in the presence or absence of a compound inhibitor of the
present invention can be used to demonstrate beta-secretase
inhibitory activity of the compound. It is preferred that the assay
in the presence of a useful inhibitory compound provides at least
about 10% inhibition of the enzymatic activity, as compared with a
non-inhibited control.
[0485] In an embodiment, cells that naturally express
beta-secretase are used. Alternatively, cells are modified to
express a recombinant beta-secretase or synthetic variant enzyme as
discussed above. The APP substrate can be added to the culture
medium and is preferably expressed in the cells. Cells that
naturally express APP, variant or mutant forms of APP, or cells
transformed to express an isoform of APP, mutant or variant APP,
recombinant or synthetic APP, APP fragment, or synthetic APP
peptide or fusion protein containing the beta-secretase APP
cleavage site can be used, provided that the expressed APP is
permitted to contact the enzyme and enzymatic cleavage activity can
be analyzed.
[0486] Human cell lines that normally process A-beta from APP
provide useful means to assay inhibitory activities of the
compounds employed in the methods of treatment of the present
invention. Production and release of A-beta and/or other cleavage
products into the culture medium can be measured, for example by
immunoassay, such as Western blot or enzyme-linked immunoassay
(EIA) such as by ELISA.
[0487] Cells expressing an APP substrate and an active
beta-secretase can be incubated in the presence of a compound
inhibitor to demonstrate inhibition of enzymatic activity as
compared with a control. Activity of beta-secretase can be measured
by analysis of at least one cleavage product of the APP substrate.
For example, inhibition of beta-secretase activity against the
substrate APP would be expected to decrease the release of specific
beta-secretase induced APP cleavage products such as A-beta.
[0488] Although both neural and non-neural cells process and
release A-beta, levels of endogenous beta-secretase activity are
low and often difficult to detect by EIA. The use of cell types
known to have enhanced beta-secretase activity, enhanced processing
of APP to A-beta, and/or enhanced production of A-beta are
therefore preferred. For example, transfection of cells with the
Swedish Mutant form of APP (APP-SW), with APP-KK, or with APP-SW-KK
provides cells having enhanced beta-secretase activity and
producing amounts of A-beta that can be readily measured.
[0489] In such assays, for example, the cells expressing APP and
beta-secretase are incubated in a culture medium under conditions
suitable for beta-secretase enzymatic activity at its cleavage site
on the APP substrate. On exposure of the cells to the compound
inhibitor employed in the methods of treatment, the amount of
A-beta released into the medium and/or the amount of CTF99
fragments of APP in the cell lysates is reduced as compared with
the control. The cleavage products of APP can be analyzed, for
example, by immune reactions with specific antibodies, as discussed
above.
[0490] Preferred cells for analysis of beta-secretase activity
include primary human neuronal cells, primary transgenic animal
neuronal cells where the transgene is APP, and other cells such as
those of a stable 293 cell line expressing APP, for example,
APP-SW.
In Vivo Assays: Animal Models
[0491] Various animal models can be used to analyze beta-secretase
activity and/or processing of APP to release A-beta, as described
above. For example, transgenic animals expressing APP substrate and
beta-secretase enzyme can be used to demonstrate inhibitory
activity of the compounds of the present invention. Certain
transgenic animal models have been described, for example, in U.S.
Pat. Nos. 5,877,399, 5,612,486, 5,387,742, 5,720,936, 5,850,003,
5,877,015, and 5,811,633, and in Games et al., 1995, Nature,
373:523. Animals that exhibit characteristics associated with the
pathophysiology of Alzheimer's disease are preferred.
Administration of the compounds of the present invention to the
transgenic mice described herein provides an alternative method for
demonstrating the inhibitory activity of the compounds.
Administration of the compounds of the present invention in a
pharmaceutically effective carrier and via an administrative route
that reaches the target tissue in an appropriate therapeutic amount
is also preferred.
[0492] Inhibition of beta-secretase mediated cleavage of APP at the
beta-secretase cleavage site and of A-beta release can be analyzed
in these animals by measuring cleavage fragments in the animal's
body fluids such as cerebral fluid or tissues. Analysis of brain
tissues for A-beta deposits or plaques is preferred.
A: Enzyme Inhibition Assay
[0493] The methods of treatment and compounds of the present
invention are analyzed for inhibitory activity by use of the
MBP-C125 assay. This assay determines the relative inhibition of
beta-secretase cleavage of a model APP substrate, MBP-C125SW, by
the compounds assayed as compared with an untreated control. A
detailed description of the assay parameters can be found, for
example, in U.S. Pat. No. 5,942,400. Briefly, the substrate is a
fusion peptide formed of maltose binding protein (MBP) and the
carboxy terminal 125 amino acids of APP-SW, the Swedish mutation.
The beta-secretase enzyme is derived from human brain tissue as
described in Sinha et al., 1999, Nature, 40:537-540 or
recombinantly produced as the full-length enzyme (amino acids
1-501), and can be prepared, for example, from 293 cells expressing
the recombinant cDNA, as described in WO 00/47618.
[0494] Inhibition of the enzyme is analyzed, for example, by
immunoassay of the enzyme's cleavage products. One exemplary ELISA
uses an anti-MBP capture antibody that is deposited on precoated
and blocked 96-well high binding plates, followed by incubation
with diluted enzyme reaction supernatant, incubation with a
specific reporter antibody, for example, biotinylated anti-SW192
reporter antibody, and further incubation with
streptavidin/alkaline phosphatase. In the assay, cleavage of the
intact MBP-C125SW fusion protein results in the generation of a
truncated amino-terminal fragment, exposing a new SW-192
antibody-positive epitope at the carboxy terminus. Detection is
effected by a fluorescent substrate signal on cleavage by the
phosphatase. ELISA only detects cleavage following Leu596 at the
substrate's APP-SW 751 mutation site.
Specific Assay Procedure
[0495] Compounds of formula (I) are diluted in a 1:1 dilution
series to a six-point concentration curve (two wells per
concentration) in one row of a 96-well plate per compound tested.
Each of the test compounds is prepared in DMSO to make up a 10 mM
stock solution. The stock solution is serially diluted in DMSO to
obtain a final compound concentration of 200 .mu.M at the high
point of a 6-point dilution curve. Ten (10) .mu.L of each dilution
is added to each of two wells on row C of a corresponding V-bottom
plate to which 190 .mu.L of 52 mM NaOAc, 7.9% DMSO, pH 4.5 are
pre-added. The NaOAc diluted compound plate is spun down to pellet
precipitant and 20 .mu.L/well is transferred to a corresponding
flat-bottom plate to which 30 .mu.L of ice-cold enzyme-substrate
mixture (2.5 .mu.L MBP-C125SW substrate, 0.03 .mu.L enzyme and 24.5
.mu.L ice cold 0.09% TX100 per 30 .mu.L) is added. The final
reaction mixture of 200 .mu.M compound at the highest curve point
is in 5% DMSO, 20 .mu.M NaOAc, 0.06% TX100, at pH 4.5.
[0496] Warming the plates to 37.degree. C. starts the enzyme
reaction. After 90 min at 37.degree. C., 200 .mu.L/well cold
specimen diluent is added to stop the reaction and 20 .mu.L/well
was transferred to a corresponding anti-MBP antibody coated ELISA
plate for capture, containing 80 .mu.L/well specimen diluent. This
reaction is incubated overnight at 4.degree. C. and the ELISA is
developed the next day after a 2 hour incubation with anti-192SW
antibody, followed by Streptavidin-AP conjugate and fluorescent
substrate. The signal is read on a fluorescent plate reader.
[0497] Relative compound inhibition potency is determined by
calculating the concentration of compound that showed a 50%
reduction in detected signal (IC.sub.50) compared to the enzyme
reaction signal in the control wells with no added compound. In
this assay, preferred compounds of the present invention exhibit an
IC.sub.50 of less than 50 .mu.M.
B: FP BACE Assay: Cell Free Inhibition Assay Utilizing a Synthetic
APP Substrate
[0498] A synthetic APP substrate that can be cleaved by
beta-secretase and having N-terminal biotin and made fluorescent by
the covalent attachment of Oregon green at the Cys residue is used
to assay beta-secretase activity in the presence or absence of the
inhibitory compounds employed in the present invention. Useful
substrates include
[0499] Biotin-SEVNL-DAEFRC[oregon green]KK,
[0500] Biotin-SEVKM-DAEFRC[oregon green]KK,
[0501] Biotin-GLNIKTEEISEISY-EVEFRC[oregon green]KK,
[0502] Biotin-ADRGLTTRPGSGLTNIKTEEISEVNL-DAEFRC[oregon green]KK,
and
[0503] Biotin-FVNQHLCoxGSHLVEALY-LVCoxGERGFFYTPKAC[oregon
green]KK.
[0504] The enzyme (0.1 nM) and test compounds (0.001-100 .mu.M) are
incubated in pre-blocked, low affinity, black plates (384 well) at
37.degree. C. for 30 min. The reaction is initiated by addition of
150 mM substrate to a final volume of 30 .mu.L/well. The final
assay conditions are 0.001-100 .mu.M compound inhibitor, 0.1 molar
sodium acetate (pH 4.5), 150 nM substrate, 0.1 nM soluble
beta-secretase, 0.001% Tween 20, and 2% DMSO. The assay mixture is
incubated for 3 h at 37.degree. C., and the reaction is terminated
by the addition of a saturating concentration of immunopure
streptavidin. After incubation with streptavidin at room
temperature for 15 min, fluorescence polarization is measured, for
example, using a LJL Acqurest (Ex485 nm/Em530 nm).
[0505] The activity of the beta-secretase enzyme is detected by
changes in the fluorescence polarization that occur when the
substrate is cleaved by the enzyme. Incubation in the presence or
absence of compound inhibitor demonstrates specific inhibition of
beta-secretase enzymatic cleavage of its synthetic APP substrate.
In this assay, preferred compounds of the present invention exhibit
an IC.sub.50 of less than 50 .mu.M. More preferred compounds of the
present invention exhibit an IC.sub.50 of less than 10 .mu.M. Even
more preferred compounds of the present invention exhibit an
IC.sub.50 of less than 5 .mu.M.
C: Beta-Secretase Inhibition: P26-P4'SW Assay
[0506] Synthetic substrates containing the beta-secretase cleavage
site of APP are used to assay beta-secretase activity, using the
methods described, for example, in published PCT application WO
00/47618. The P26-P4'SW substrate is a peptide of the sequence
(biotin)CGGADRGLTTRPGSGLTNIKTEEISEVNLDAEF. The P26-P1 standard has
the sequence (biotin)CGGADRGLTTRPGSGLTNIKTEEISEVNL.
[0507] Briefly, the biotin-coupled synthetic substrates are
incubated at a concentration of from about 0 to about 200 .mu.M in
this assay. When testing inhibitory compounds, a substrate
concentration of about 1.0 .mu.M is preferred. Test compounds
diluted in DMSO are added to the reaction mixture, with a final
DMSO concentration of 5%. Controls also contain a final DMSO
concentration of 5%. The concentration of beta secretase enzyme in
the reaction is varied, yielding product concentrations with the
linear range of the ELISA assay, about 125 to 2000 pM, after
dilution.
[0508] The reaction mixture also includes 20 mM sodium acetate, pH
4.5, 0.06% Triton X100, and is incubated at 37.degree. C. for about
1 to 3 h. Samples are then diluted in assay buffer (for example,
145.4 nM sodium chloride, 9.51 mM sodium phosphate, 7.7 mM sodium
azide, 0.05% Triton X405, 6 g/L bovine serum albumin, pH 7.4) to
quench the reaction, then diluted further for immunoassay of the
cleavage products.
[0509] Cleavage products can be assayed by ELISA. Diluted samples
and standards are incubated in assay plates coated with capture
antibody, for example, SW192, for about 24 h at 4.degree. C. After
washing in TTBS buffer (150 mM sodium chloride, 25 mM Tris, 0.05%
Tween 20, pH 7.5), the samples are incubated with streptavidin-AP
according to the manufacturer's instructions. After a 1 h
incubation at room temperature, the samples are washed in TTBS and
incubated with fluorescent substrate solution A (31.2 g/L
2-amino-2-methyl-1-propanol, 30 mg/L, pH 9.5). Reaction with
streptavidin-alkaline phosphate permits detection by fluorescence.
Compounds that are effective inhibitors of beta-secretase activity
demonstrate reduced cleavage of the substrate as compared to a
control.
D: Assays Using Synthetic Oligopeptide-Substrates
[0510] Synthetic oligopeptides are prepared incorporating the known
cleavage site of beta-secretase, and optionally include detectable
tags, such as fluorescent or chromogenic moieties. Examples of such
peptides, as well as their production and detection methods, are
described in U.S. Pat. No. 5,942,400. Cleavage products can be
detected using high performance liquid chromatography, or
fluorescent or chromogenic detection methods appropriate to the
peptide to be detected, according to methods well known in the
art.
[0511] By way of example, one such peptide has the sequence
SEVNL-DAEF, and the cleavage site is between residues 5 and 6.
Another preferred substrate has the sequence
ADRGLTTRPGSGLTNIKTEEISEVNL-DAEF, and the cleavage site is between
residues 26 and 27.
[0512] These synthetic APP substrates are incubated in the presence
of beta-secretase under conditions sufficient to result in
beta-secretase mediated cleavage of the substrate. Comparison of
the cleavage results in the presence of a compound inhibitor to
control results provides a measure of the compound's inhibitory
activity.
E: Inhibition of Beta-Secretase Activity-Cellular Assay
[0513] An exemplary assay for the analysis of inhibition of
beta-secretase activity utilizes the human embryonic kidney cell
line HEKp293 (ATCC Accession No. CRL-1573) transfected with APP751
containing the naturally occurring double mutation Lys651Met652 to
Asn651Leu652 (numbered for APP751), commonly called the Swedish
mutation and shown to overproduce A-beta (Citron et al., 1992,
Nature, 360:672-674), as described in U.S. Pat. No. 5,604,102.
[0514] The cells are incubated in the presence/absence of the
inhibitory compound (diluted in DMSO) at the desired concentration,
generally up to 10 .mu.g/mL. At the end of the treatment period,
conditioned media is analyzed for beta-secretase activity, for
example, by analysis of cleavage fragments. A-beta can be analyzed
by immunoassay, using specific detection antibodies. The enzymatic
activity is measured in the presence and absence of the compounds
of formula (I) to demonstrate specific inhibition of beta-secretase
mediated cleavage of APP substrate.
F: Inhibition of Beta-Secretase in Animal Models of Alzheimer's
Disease
[0515] Various animal models can be used to screen for inhibition
of beta-secretase activity. Examples of animal models useful in the
present invention include mouse, guinea pig, dog, and the like. The
animals used can be wild type, transgenic, or knockout models. In
addition, mammalian models can express mutations in APP, such as
APP695-SW and the like as described herein. Examples of transgenic
non-human mammalian models are described in U.S. Pat. Nos.
5,604,102, 5,912,410 and 5,811,633.
[0516] PDAPP mice, prepared as described in Games et al., 1995,
Nature, 373:523-527 are useful to analyze in vivo suppression of
A-beta release in the presence of putative inhibitory compounds. As
described in U.S. Pat. No. 6,191,166,4-month-old PDAPP mice are
administered a compound of formula (I) formulated in a vehicle,
such as corn oil. The mice are dosed with the compound (1-30 mg/mL,
preferably 1-10 mg/mL). After a designated time, e.g., 3-10 h, the
brains are analyzed.
[0517] Transgenic animals are administered an amount of a compound
formulated in a carrier suitable for the chosen mode of
administration. Control animals are untreated, treated with
vehicle, or treated with an inactive compound. Administration can
be acute, (i.e. single dose or multiple doses in one day), or can
be chronic, (i.e. dosing is repeated daily for a period of days).
Beginning at time 0, brain tissue or cerebral fluid is obtained
from selected animals and analyzed for the presence of APP cleavage
peptides, including A-beta, for example, by immunoassay using
specific antibodies for A-beta detection. At the end of the test
period, animals are sacrificed and brain tissue or cerebral fluid
is analyzed for the presence of A-beta and/or beta-amyloid plaques.
The tissue is also analyzed for necrosis.
[0518] Reduction of A-beta in brain tissues or cerebral fluids and
reduction of beta-amyloid plaques in brain tissue are assessed by
administering the compounds of formula (1), or pharmaceutical
compositions comprising compounds of formula (1) to animals and
comparing the data with that from non-treated controls.
G: Inhibition of A-Beta Production in Human Patients
[0519] Patients suffering from Alzheimer's disease demonstrate an
increased amount of A-beta in the brain. Alzheimer's disease
patients are subjected to a method of treatment of the present
invention, (i.e. administration of an amount of the compound
inhibitor formulated in a carrier suitable for the chosen mode of
administration). Administration is repeated daily for the duration
of the test period. Beginning on day 0, cognitive and memory tests
are performed, for example, once per month.
[0520] Patients administered the compounds of formula (I) are
expected to demonstrate slowing or stabilization of disease
progression as analyzed by a change in at least one of the
following disease parameters: A-beta present in cerebrospinal fluid
or plasma; brain or hippocampal volume; A-beta deposits in the
brain; amyloid plaque in the brain; or scores for cognitive and
memory function, as compared with control, non-treated
patients.
H: Prevention of A-Beta Production in Patients at Risk for
Alzheimer's Disease
[0521] Patients predisposed or at risk for developing Alzheimer's
disease can be identified either by recognition of a familial
inheritance pattern, for example, presence of the Swedish Mutation,
and/or by monitoring diagnostic parameters. Patients identified as
predisposed or at risk for developing Alzheimer's disease are
administered an amount of the compound inhibitor formulated in a
carrier suitable for the chosen mode of administration.
Administration is repeated daily for the duration of the test
period. Beginning on day 0, cognitive and memory tests are
performed, for example, once per month.
[0522] Patients subjected to a method of treatment of the present
invention (i.e., administration of at least one compound of formula
(I)) are expected to demonstrate slowing or stabilization of
disease progression as analyzed by a change in at least one of the
following disease parameters: A-beta present in cerebrospinal fluid
or plasma; brain or hippocampal volume; amyloid plaque in the
brain; or scores for cognitive and memory function, as compared
with control, non-treated patients.
I: Efficacy of Compounds to Inhibit A-Beta Concentration
[0523] The invention encompasses compounds of formula (I) that are
efficacious. Efficacy is calculated as a percentage of
concentrations as follows: Efficacy=(1-(total A-beta in dose
group/total A-beta in vehicle control))*100% wherein the "total
A-beta in dose group" equals the concentration of A-beta in the
tissue, (e.g., rat brain) treated with the compound, and the "total
A-beta in vehicle control" equals the concentration of A-beta in
the tissue, yielding a % inhibition of A-beta production.
Statistical significance is determined by p-value<0.05 using the
Mann Whitney t-test. See, for example, Dovey et al., J.
Neurochemistry, 2001, 76:173-181.
[0524] Where indicated, diastereomers were separated by reverse
phase HPLC using the noted methods. The first isomer collected in
each case was designated Diastereomer A, and the second isomer
Diastereomer B. Unless otherwise indicated, specific formula (I)
compound examples represent mixtures of diastereomers.
J: Selectivity of Compounds for Inhibiting BACE Over Aspartyl
Proteases
[0525] The compounds of formula (I) can be selective for
beta-secretase versus catD. Wherein the ratio of
catD:beta-secretase is greater than 1, selectivity is calculated as
follows: Selectivity=(IC.sub.50 for catD/IC.sub.50 for
beta-secretase)*100% wherein IC.sub.50 is the concentration of
compound necessary to decrease the level of catD or beta-secretase
by 50%.
[0526] The compounds of formula (I) can be selective for
beta-secretase versus catE. Wherein the ratio of
catE:beta-secretase is greater than 1, selectivity is calculated as
follows: Selectivity=(IC.sub.50 for catE/IC.sub.50 for
beta-secretase)*100% wherein IC.sub.50 is the concentration of
compound necessary to decrease the level of catE or beta-secretase
by 50%. Selectivity is reported as the ratio of
IC.sub.50(catE):IC.sub.50(BACE).
[0527] Pharmacokinetic parameters were calculated by a
non-compartmental approach. See, for example, Gibaldi, M. and
Perrier, D., Pharmacokinetics, Second Edition, 1982, Marcel Dekker
Inc., New York, N.Y., pp 409-418.
EXAMPLE 33
EXEMPLARY FORMULA (I) COMPOUNDS EXHIBITING SELECTIVITY FOR BACE
VERSUS catD
[0528] In the following examples, each value is an average of four
experimental runs and multiple values for one compound indicate
that more than one experiment was conducted. TABLE-US-00002 Ex- am-
Selectivity ple IC.sub.50(catD)/ No. Compound IC.sub.50(BACE) 33-1
##STR105## 1.8 >2.4 1.0 1-(5-(3-tert-butylphenyl)-4,5,6,7-
tetrahydro-2H-indazol-5-ylamino)-4-
(3,5-difluorophenyl)butan-2-ol
EXAMPLE 34
EXEMPLARY FORMULA (I) COMPOUNDS EXHIBITING SELECTIVITY FOR BACE
VERSUS catE
[0529] TABLE-US-00003 Ex- am- Selectivity ple IC.sub.50(catE)/ No.
Compound IC.sub.50(BACE) 34-1 ##STR106## 1.6 1.6 0.6
1-(5-(3-tert-butylphenyl)-4,5,6,7-
tetrahydro-2H-indazol-5-ylamino)-4-
(3,5-difluorophenyl)butan-2-ol
Oral Bioavailability of Compounds for Inhibiting Amyloidosis
[0530] The invention encompasses compounds of formula (I) that are
orally bioavailable. Generally, oral bioavailability is defined as
the fraction of orally administered dose reaching systemic
circulation. Oral bioavailability can be determined following both
an intravenous (IV) and oral (PO) administration of a test
compound.
[0531] Oral bioavailability was determined in the male
Sprague-Dawley rat following both IV and PO administration of test
compound. Two month-old male rats (250-300 g) were surgically
implanted with polyethylene (PE-50) cannula in the jugular vein
while under isoflurane anesthesia the day before the in-life phase.
Animals were fasted overnight with water ad libitum, then dosed the
next day. The dosing regime consisted of either a 5 mg/kg (2.5
mL/kg) IV dose (N=3) administered to the jugular vein cannula, then
flushed with saline, or a 10 mg/kg (5 mL/kg) PO dose (N=3) by
esophageal gavage. Compounds were formulated with 10% Solutol in 5%
dextrose at 2 mg/mL. Subsequent to dosing, blood was collected at
0.016 (IV only), 0.083, 0.25, 0.5, 1, 3, 6, 9 and 24 h post
administration and heparinized plasma was recovered following
centrifugation.
[0532] Compounds were extracted from samples following
precipitation of the plasma proteins by methanol. The resulting
supernatants were evaporated to dryness and reconstituted with
chromatographic mobile phase (35% acetonitrile in 0.1% formic acid)
and injected onto a reverse phase C.sub.18 column (2.times.50 mm, 5
.mu.m, BDS Hypersil). Detection was facilitated with a
multi-reaction-monitoring experiment on a tandem triple quadrupole
mass spectrometer (LC/MS/MS) following electrospray ionization.
Experimental samples were compared to calibration curves prepared
in parallel with aged match rat plasma and quantitated with a
weighted 1/x linear regression. The lower limit of quantization
(LOQ) for the assay was typically 0.5 ng/mL.
[0533] Oral bioavailability (% F or F value) is calculated from the
dose-normalized ratio of plasma exposure following oral
administration to the intravenous plasma exposure in the rat by the
following equation %
F=(AUC.sub.po/AUC.sub.iv).times.(D.sub.iv/D.sub.po).times.100%
where D is the dose and AUC is the
area-under-the-plasma-concentration-time-curve from 0 to 24 h. AUC
is calculated from the linear trapezoidal rule by
AUC=((C.sub.2+C.sub.1)/2).times.(T.sub.2-T.sub.1) where C is
concentration and T is time.
[0534] Pharmacokinetic parameters were calculated by a
non-compartmental approach. See, for example, Gibaldi, M. and
Perrier, D., Pharmacokinetics, Second Edition, 1982, Marcel Dekker
Inc., New York, N.Y., pp 409-418.L: Brain Uptake
[0535] The invention encompasses beta-secretase inhibitors that can
readily cross the blood-brain barrier. Factors that affect a
compound's ability to cross the blood-brain barrier include a
compound's molecular weight, Total Polar Surface Area (TPSA), and
log P (lipophilicity). See, e.g., Lipinski, C. A., et al., Adv.
Drug Deliv. Reviews, 23:3-25 (1997). One of ordinary skill in the
art will be aware of methods for determining characteristics
allowing a compound to cross the blood-brain barrier. See, for
example, Murcko et al., Designing Libraries with CNS Activity, J.
Med. Chem., 42 (24), pp. 4942-51 (1999). Calculations of logP
values were performed using the Daylight clogP program (Daylight
Chemical Information Systems, Inc.). See, for example, Hansch, C.,
et al., Substituent Constants for Correlation Analysis in Chemistry
and Biology, Wiley, New York (1979); Rekker, R., The Hydrophobic
Fragmental Constant, Elsevier, Amsterdam (1977); Fujita, T., et
al., J. Am. Chem. Soc., 86, 5157 (1964). TPSA was calculated
according to the methodology outlined in Ertl, P., et al., J. Med.
Chem., 43:3714-17 (2000).
[0536] The following assay was employed to determine the brain
penetration of compounds encompassed by the present invention.
[0537] In-life phase: Test compounds were administered to CF-1
(20-30 g) mice at 10 .mu.mol/kg (4 to 7 mg/kg) following IV
administration in the tail vein. Two time-points, 5 and 60 min, are
collected post dose. Four mice are harvested for heparinized plasma
and non-perfused brains at each time-point for a total of 8 mice
per compound.
[0538] Analytical phase: Samples were extracted and evaporated to
dryness, then reconstituted and injected onto a reverse phase
chromatographic column while monitoring the effluent with a triple
quadrupole mass spectrometer. Quantitation was then performed with
a 1/x.sup.2 weighted fit of the least-squares regression from
calibration standards prepared in parallel with the in vivo
samples. The LOQ is generally 1 ng/mL and 0.5 ng/g for the plasma
and brain respectively. Data was reported in micromolar (.mu.M)
units. Brain levels were corrected for plasma volumes (16
.mu.L/g).
[0539] Results: Comparison of a compound's brain concentration
level to two marker compounds, Indinavir and Diazepam,
demonostrates the ability in which the compounds of the present
invention can cross the blood-brain barrier. Indinavir (HIV
protease inhibitor) is a poor brain penetrant marker and Diazepam
is a blood flow limited marker. The concentration levels of
Indinavir in the brain at 5 and 60 min were 0.165 .mu.M and 0.011
.mu.M, respectively. The concentration levels of Diazepam at 5 and
60 min were 5.481 .mu.M and 0.176 .mu.M, respectively.
[0540] The present invention has been described with reference to
various specific and preferred embodiments and techniques. However,
it should be understood that many variations and modifications may
be made while remaining within the spirit and scope of the present
invention.
[0541] Unless defined otherwise, all scientific and technical terms
used herein have the same meaning as commonly understood by one of
skill in the art to which this invention belongs. Although methods
and materials similar or equivalent to those described herein can
be used in the practice or testing of the present invention,
suitable methods and materials are described above. Additionally,
the materials, methods, and examples are illustrative only and not
intended to be limiting. All publications, patent applications,
patents, and other references mentioned herein are incorporated by
reference in their entirety. In case of conflict, the present
specification, including definitions, will control.
Sequence CWU 1
1
11 1 4 PRT Artificial Sequence Description of Artificial Sequence
Synthetic peptide 1 Lys Met Asp Ala 1 2 4 PRT Artificial Sequence
Description of Artificial Sequence Synthetic peptide 2 Asn Leu Asp
Ala 1 3 13 PRT Artificial Sequence Description of Artificial
Sequence Synthetic peptide MOD_RES (11) Covalent attachment of
Oregon green at Cys residue 3 Ser Glu Val Asn Leu Asp Ala Glu Phe
Arg Cys Lys Lys 1 5 10 4 13 PRT Artificial Sequence Description of
Artificial Sequence Synthetic peptide MOD_RES (11) Covalent
attachment of Oregon green at Cys residue 4 Ser Glu Val Lys Met Asp
Ala Glu Phe Arg Cys Lys Lys 1 5 10 5 22 PRT Artificial Sequence
Description of Artificial Sequence Synthetic peptide MOD_RES (20)
Covalent attachment of Oregon green at Cys residue 5 Gly Leu Asn
Ile Lys Thr Glu Glu Ile Ser Glu Ile Ser Tyr Glu Val 1 5 10 15 Glu
Phe Arg Cys Lys Lys 20 6 34 PRT Artificial Sequence Description of
Artificial Sequence Synthetic peptide MOD_RES (32) Covalent
attachment of Oregon green at Cys residue 6 Ala Asp Arg Gly Leu Thr
Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile 1 5 10 15 Lys Thr Glu Glu
Ile Ser Glu Val Asn Leu Asp Ala Glu Phe Arg Cys 20 25 30 Lys Lys 7
33 PRT Artificial Sequence Description of Artificial Sequence
Synthetic peptide MOD_RES (7) Oxidized Cys MOD_RES (19) Oxidized
Cys MOD_RES (31) Covalent attachment of Oregon green at Cys residue
7 Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr 1
5 10 15 Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ala Cys
Lys 20 25 30 Lys 8 33 PRT Artificial Sequence Description of
Artificial Sequence Synthetic peptide 8 Cys Gly Gly Ala Asp Arg Gly
Leu Thr Thr Arg Pro Gly Ser Gly Leu 1 5 10 15 Thr Asn Ile Lys Thr
Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu 20 25 30 Phe 9 29 PRT
Artificial Sequence Description of Artificial Sequence Synthetic
peptide 9 Cys Gly Gly Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
Gly Leu 1 5 10 15 Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Asn
Leu 20 25 10 9 PRT Artificial Sequence Description of Artificial
Sequence Synthetic peptide 10 Ser Glu Val Asn Leu Asp Ala Glu Phe 1
5 11 30 PRT Artificial Sequence Description of Artificial Sequence
Synthetic peptide 11 Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
Gly Leu Thr Asn Ile 1 5 10 15 Lys Thr Glu Glu Ile Ser Glu Val Asn
Leu Asp Ala Glu Phe 20 25 30
* * * * *